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Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the retina in preterm infants and
an important cause of childhood blindness. The incidence of ROP has varied over time and across the
world as a result of changes in clinical neonatal practice. ROP is a multifactorial disease with low
birth weight, low gestational age and exposure to supplemental oxygen being key risk factors.
Prenatal and postnatal body growth together with availability of growth factors may also be involved
in the pathogenesis. Premature infants undergo eye screening using binocular indirect
ophthalmoscopy (BIO) or wide-field digital retinal imaging (WFDRI) in order to identify those infants
with sight-threatening disease that require treatment with laser photocoagulation. Eye screening is a
painful and distressing procedure for infants.
AIMS
(i) To report the trends in incidence of ROP within Lothian, Scotland
(ii) To report the incidence of ROP in small-for-gestational (SGA) infants
(iii) To study retinal vascular development in growth-restricted rat pups
(iv) To carry out a prospective randomised study comparing the diagnostic accuracy of WFDRI with
BIO for ROP eye examinations
(v) To compare the pain experienced by infants undergoing WFDRI and BIO
METHODS
Data from eye screening examinations within Lothian between 1990 and 2004 were analysed and
epidemiological data were obtained from the Scottish Health Service. Dams of rat pups were fed
either a 'normal' (18%) or 'low' (9%) protein diet. Dams and pups were exposed to either room air or
a fluctuating oxygen profile for 14 days. Retinas were dissected and blood vessels were stained using
immunohistochemistry. The extent of vascular development was measured and compared between
animal groups. Serum was collected from pups and levels of insulin-like growth factor-1 (IGF-1) were
measured using an enzyme-linked immunosorbent assay. Infants from Edinburgh Neonatal Unit
undergoing routine ROP screening were recruited and screened by both WFDRI and BIO in random
order. The sensitivity and specificity of WFDRI compared to BIO was calculated. The pain
experienced by infants was scored using the Premature Infant Pain Profile (PIPP) and compared
between the two techniques.
RESULTS
There has been an increase in survival of preterm infants, a reduction in the incidence of any degree of
ROP, severe ROP and a marked reduction in treatment for ROP in Lothian from 1990-2004. The
prevalence of ROP and severe ROP were higher in SGA infants than their appropriately sized peers.
Pups of dams fed the 9% protein diet were born growth restricted. The growth restricted rat pups had
significantly larger retinal avascular areas and lower serum IGF-1 levels than 'normal' sized pups.
The sensitivity of WFDRI in detecting any ROP, stage 3 ROP and plus disease was 60%, 57% and
80% respectively with a specificity of 91%, 98% and 98% respectively. ROP screening using WFDRI
and BIO was painful but the pain experienced by infants was similar for both techniques (WFDRI
PIPP score 15.0, BIO PIPP score 15.2).
CONCLUSIONS
Advances in obstetric and neonatal care within the developed world over the last two decades are
likely responsible for the increased survival of premature infants and the overall decreasing incidence
of ROP seen in Lothian. Body growth and IGF-1 are important in the pathogenesis of ROP. Further
work is required to identify a mechanism for this association and clinical trials of nutritional therapies
are needed. WFDRI is a useful examination technique for ROP eye screening but has some technical
limitations which need to be improved. Further work is required to implement adequate analgesia
regimes for ROP screening.
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7.1 Summary of findings










ANOVA analysis of variance
BIO binocular indirect ophthalmoscopy
BOOST Benefits of oxygen saturation targeting
BW birth weight
CGA corrected gestational age
CI confidence interval
Cryo-ROP cryotherapy for ROP
ELISA enzyme-linked immunosorbent assay
ETROP early treatment for ROP
GA gestational age
HIF-1 hypoxia-inducible factor 1
HIF-la Hypoxia-Inducible Factor-la
IGF-1 insulin-like growth factor 1
IGF-1R IGF-1 receptor
IGFBP IGF binding protein
IGFBP-3 insulin-like growth factor binding protein-3
IMR infant mortality rate
ISD Information services division
IUGR intrauterine growth restriction
LB live births
LREC Lothian research ethics committee
MAPK mitogen-activated protein kinases
NICU neonatal intensive care unit




PIPP premature infant pain profile
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ROP retinopathy of prematurity
SD standard deviation
SGA small-for-gestational age
SMR Scottish morbidity record
SUNDROP Stanford university network for diagnosis of ROP
VEGF vascular endothelial growth factor
VLBW very low birth weight
WFDRI wide-field digital retinal imaging
WINROP Weight IGF-1 Neonatal ROP
X2 Chi-square test
X2 trend Chi-square test for trend
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Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the retina in
preterm infants. ROP can cause a range of visual deficits and is an important cause of
childhood blindness worldwide.
1.1 Normal retinal blood vessel development (Figures 1.1-1.3)
There are two sources of blood supply to the retina:-the central retinal artery and the
choroidal blood vessels. Both sources are derived from the ophthalmic artery. The
choroidal blood vessels supply the uvea and outer and middle layers of the retina
while the central retinal artery enters via the optic nerve head to nourish the inner
retinal layer. Branches of the central retinal artery are first seen emerging from the
centre of the optic disc when the fetus is approximately 16 weeks gestation. The
blood vessels grow radially outwards towards the ora serrata and vascularisation is
complete when the fetus is approximately 36 weeks gestation [Hughes et al, 2000].
Normal human retinal vascular development occurs as a result of vasculogenesis and
angiogenesis [Hughes et al, 2000]. Vasculogenesis occurs first and involves the
formation of blood vessels from endothelial precursor cells known as 'spindle' cells.
Spindle cells are first seen emerging from the optic head and growing out towards
the periphery across the superficial layer of the retina when the fetus is 14-15 weeks
gestation. Spindle cells arrange to form cords which further develop into primitive
vascular tubes. These tubes become associated with vascular smooth muscle cells
and supporting pericytes [Hughes et al, 2000; Zhang and Stone, 1997], Spindle cells
do not reach the retinal periphery or the fovea and vasculogenesis is complete by the
time the fetus is 21 weeks gestation.
Angiogenesis refers to the development of additional new blood vessels by budding
from the existing primary vascular network. It is first seen when the fetus is 17-18
weeks gestation. Angiogenesis leads to the development of capillary networks within
the existing vascular framework in the superficial layer of the retina. Angiogenesis
also occurs from the leading vascular edge and forms the peripheral capillary
network in the superficial layer. Some angiogenic 'buds' from the superficial layer
grow downwards and vascularise the deep retinal layer [Gariano et al, 1994; Provis,
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2001]. Glial astrocytes support and provide a framework for capillary development.
Astrocyte invasion precedes retinal vascular development and also migrates radially
[Ling and Stone, 1988; Provis et al, 1997; Chu et al, 2001], Over time, the primary
vascular plexus is remodelled and matures into a hierarchical vascular tree [Fruttiger,
2007],
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Figure 1.1 Intricate association between astrocytes (red) and blood vessels (green) in central area of rat pup
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Figure 1.2 Astrocytes (red) precede developing blood vessels (green) to ora serrata (green
superior edge), [picture taken by C.Dhaliwal and T.Gillespie]
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Figure 1.3 Angiogenesis-filopodia budding from existing vascular network into supportive
astrocyte framework, [picture taken by C.Dhaliwal and T.Gillespie]
Vascular endothelial growth factor (VEGF) plays a key role in both normal
angiogenesis and abnormal retinal blood vessel development. VEGF was initially
identified as a 'permeability factor' in 1983 and in 1989 was identified as an
endothelial cell mitogen and important in angiogenesis [Senger et al, 1983; Leung et
al, 1989], Six isoforms of VEGF exist (VEGF 121, 145, 165, 183, 189, 206),
produced by alternative splicing of VEGF mRNA. Hypoxia inducible factor-1 (HIF-
1) is a nuclear protein and transcription factor for VEGF. VEGF mRNA expression
is increased in hypoxic conditions [Plate and Wamke, 1997].
Normal retinal angiogenesis on the superficial layer is driven by a zone of
'physiological hypoxia' in the region anterior to the developing vascular front [Chan-
Ling et al, 1995]. Astrocytes and Muller cells secrete VEGF165 in response to this
local hypoxia resulting in endothelial cell proliferation and blood vessel development
[Dorrell et al, 2002; Forsythe et al, 1996; Stone et al, 1995]. The new blood vessels
in turn supply oxygen to the local tissue and this 'normoxia' negatively feedbacks to
reduce VEGF165 production [Stone et al, 1995], The wave of physiological hypoxia
then moves more peripherally and the cycle repeats until the ora serrata is reached.
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1.2 Abnormal retinal blood vessel development
Infants born prematurely have an incompletely vascularised retina with a peripheral
avascular zone. The more premature the baby is, the larger the avascular zone. ROP
is recognised by specific morphological changes seen at the junction between the
vascular and avascular retina.
ROP is described in terms of severity (stages 1-5), location (zones 1-3), extent of
disease (1-12 clock hours) and presence or absence of 'plus' disease [The Committee
for the Classification of Retinopathy of Prematurity, 1984, 2005]. In stage 1 ROP
there is a demarcation line present between the central vascular and peripheral
vascular retina. This develops into a ridge in stage 2 ROP. This ridge is associated
with extra-retinal neovascularistion in stage 3 ROP. Stage 4 is partial retinal
detachment and stage 5 is total retinal detachment and blindness. Stages 1 and 2 are
considered to be 'mild' and mostly regress spontaneously. Stage 3 may regress or
progress to stage 4 or 5. The zones are centred on the optic nerve. Zone 1 is the most
posterior and is a circle of radius twice the optic nerve-to-macula distance. Zone 2 is
an annulus with the inner border defined by zone 1 and the outer border defined as
the distance from the optic nerve to the nasal ora serrata. Zone 3 is the residual
temporal crescent of the retina (figure 1.4). Disease in zone 1 is high risk disease.
The extent of ROP is defined in a circumferential pattern by clock hours of
involvement with 12 o'clock being superior. 'Plus' disease refers to the appearance
of the posterior blood vessels. It is said to be present when the posterior arterioles are
tortuous and the posterior venules are dilated. It can progress to include iris vascular








Figure 1.4 Scheme of retina of right eye (RE) and left eye (LE) showing zone borders and clock
hours used to describe the location and extent of ROP (ICROP Revisited Arch
Ophthalmol.2005:l23:992)
The clinical histopathology of ROP is poorly understood. The demarcation line/ridge
in stages 1-3 ROP originates from mesenchymal tissue and is composed of immature
astrocytes [Fleck and Mcintosh, 2008]. It is possible that these astrocytes lose their
supportive function and allow extraretinal vascular growth into the vitreous which
instead supports the immature vessels. The ridge also contains arteriovenous shunt
vessels and posterior to the ridge are areas of capillary non-perfusion [Schulenburg
and Tsanaktsidid, 2004], Plus disease is thought to occur as a result of increased
retinal blood flow to these arteriovenous shunts and could be caused by a direct
effect of VEGF [Saunders et al, 1995; Schaffer et al, 1993],
One theory that is widely accepted to explain the development of ROP is that it is a
two-phase disease [Smith, 2004]. Impaired growth of retinal vessels in phase 1 is
followed by hypoxia-driven uncontrolled vessel growth in phase 2. VEGF is well
accepted as playing a crucial role in both phases of the pathogenesis of ROP.
In phase 1, the 'physiological hypoxia' which drives normal fetal retinal
vascularisation is suddenly arrested following preterm birth. The preterm infant is
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exposed to breathing room air and often requires supplemental oxygen. In utero
retinal development occurs at oxygen tensions of 2-3kPa and after birth the preterm
infant will have circulating oxygen tensions of 6-10kPa [Fleck and Mcintosh, 2008].
This relative 'hyperoxia' of the extrauterine environment suppresses VEGF
expression and leads to cessation and subsequent regression of retinal vascular
growth [Smith, 2004]. In the weeks following birth the preterm infant grows and
matures and the peripheral avascular retina becomes increasingly metabolically
active. Local tissue hypoxia in this region occurs as the vascular supply is
insufficient for the needs of the developing retinal tissue. VEGF secretion is
increased in response to local hypoxia and in turn triggers pathological
neovascularisation which is the hallmark of phase 2 ROP and occurs when the infant
is 32-24 weeks corrected gestational age (CGA) [Pierce et al, 1995].
This theory is however not universally accepted as some clinician scientists feel it is
too simplistic and does not relate adequately to the clinical situation where there is a
gradual progression from mild-moderate-severe ROP rather than a sudden 'phase 2'
of neovascularisation and it does not explain why regression of ROP which is often
seen clinically occurs.
1.2.1 VEGF
Animal studies have shown that VEGF plays a central role in ocular
neovascularisation [Aiello et al, 1995; Robinson et al, 1996; Adamis et al, 1996,
Donahue et al, 1996; Miller et al, 1994; Stone et al, 1996; Young et al, 1997],
Intravitreal injection of a VEGF inhibitor in mice (either VEGF antisense
oligonucleotide or VEGF binding molecule) during phase 2 has been shown to
significantly reduce retinal neovascularisation [Aiello et al, 1995; Robinson et al,
1996],
Clinical studies also support the importance of VEGF in retinal neovascularisation
and elevated levels of VEGF have been measured in the vitreous from patients with
diabetic proliferative retinopathy [Aiello et al, 1994; Adamis et al, 1994], VEGF has
also been isolated from the retina of a patient with ROP [Young et al, 1997].
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The importance of VEGF and oxygen in ROP pathogenesis is accepted but other
important molecules and pathways must also be involved as neovascularisation is
still seen despite inhibition of VEGF and ROP is still seen clinically despite rigorous
control of supplemental oxygen.
1.3 ROP screening
The purpose of screening is to identify those infants who will need therapy to prevent
disease progression. Screening protocols differ geographically. In the UK, current
guidelines recommend that all infants with birth weight (BW) <1501 g and/or
gestational age (GA) <31 weeks undergo screening for ROP [Royal College of
Paediatrics and Child Health, 2008], Fewer than 10% of infants screened will
develop severe ROP warranting treatment [Dhaliwal et al, 2008].
Screening is carried out using binocular indirect ophthalmoscopy (BIO) with eyelid
speculum and scleral indentation performed by an experienced ophthalmologist
commencing when the infant is approximately 34 weeks CGA (or 4-5 weeks
postnatal age) and continued weekly or fortnightly until complete retinal blood vessel
development has occurred. It is recognised as being a painful and distressing
procedure for infants [Dhillon et al, 1993].Wide-field digital retinal imaging
(WFDRI) is another screening method. This is an attractive screening tool as trained
staff can capture retinal images which can be interpreted by a remote
ophthalmologist. There is still much controversy over which examination method is
best.
ROP screening is a significant work-load for ophthalmologists and is a stressful
examination for infants although remains vital to detect and treat disease. There is
scope for further refinement of screening programmes.
1.4 ROP treatment
Destruction of the avascular retina with laser photocoagulation or cryotherapy causes
involution of pathological vessels and regression of ROP. The multicentred trial of
cryotherapy for ROP (cryo-ROP) found that treatment of the peripheral avascular
19
retina in infants with severe disease decreased the chance of retinal
traction/detachment by 41% [Cryotherapy for ROP cooperative group, 1988].
Cryotherapy has been largely replaced by laser photocoagulation as the preferred
treatment modality. Laser photocoagulation is better for treating posterior disease,
better tolerated than cryotherapy and is associated with a better visual outcome [Ng
et al, 2002; Connolly et al, 2002], Treatment prevents blindness but
ophthalmological status is not normalised as treatment is nonselective and destroys
all retinal cell types [Cryotherapy for ROP cooperative group, 1988]. Children with
previous ROP commonly have reduced visual acuity, visual fields and contrast
sensitivity, refractive errors and strabismus [Larsson et al, 2003; Larsson et al, 2004;
Larsson et al, 2005; Larsson and Holmstrom, 2006; O'Connor et al, 2002], They are
also at increased risk of retinal detachment in later life [Park et al, 2004],
Treatment was previously directed at infants with 'threshold' disease which refers to
stage 3 ROP present in either zone 1 or zone 2, with at least 5 contiguous or 8
continuous clock hours of disease with the presence of plus disease [Cryotherapy for
ROP cooperative group, 1988]. The Early Treatment for ROP (ETROP) study
showed that earlier laser treatment for infants with type 1 disease further reduced the
risk of severe visual morbidity [Early Treatment for ROP Cooperative Group, 2003].
Type 1 disease was defined as zone 1 ROP (any stage) with plus disease; zone 1,
stage 3 disease with/without plus disease and zone 2 ROP (stage2/3) with plus
disease [Early Treatment for ROP Cooperative Group, 2003]]. A reduction from
19.5% to 14.5% in an unfavourable grating visual acuity measurement and from
15.6% to 9.1% in an unfavourable structural outcome at 9 months was seen in infants
treated with type 1 disease compared with the control group that was not treated until
threshold ROP was reached [Early Treatment for ROP Cooperative Group, 2003],
Treatment is now recommended for all infants with type 1 disease [Royal College of
Paediatrics and Child Health, 2008]. The presence of 'plus' disease is now the
primary indication for laser therapy. Scleral buckling and or vitrectomy surgery may
be performed for infants with stage 4/5 ROP but the outcome is generally poor [Shah
et al, 2009],
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An anti-VEGF aptamer and anti-VEGF antibody have been developed
(bevacizumab) and are currently used for treating neovascularisation associated with
age-related macular degeneration. They are administered by injection into the
vitreous of the eye. Bevacizumab has been used with positive effect in some infants
to treat ROP and clinical trials are planned to evaluate and formalise their use
[Mintz-Hittner et al, 2008; Chung et al, 2007; Kusaka et al, 2008; Lalwani et al,
2008; Quiroz-Mercado et al, 2008].
Visual morbidity post ROP treatment would be reduced if a preventive therapy was
available. Children with spontaneously regressed ROP also suffer visual morbidity
and would therefore also benefit from a preventative therapy. Vitamin A is required
by the retina for both low-light and colour vision. It is also essential for growth and
development. Preterm infants have low levels of vitamin A and some studies have
related this to an increased risk of developing ROP [Mactier and Weaver, 2005],
Vitamin A supplementation may therefore play a role in the prevention of ROP.
Antioxidant factors have been investigated as possible preventative strategies.
Metanalyses of clinical trials using antioxidant vitamin E therapy suggest this
strategy is beneficial [Raju et al, 1997] but use of this therapy is not widespread
mainly because one clinical trial showed an increase in sepsis and mortality
following high-dose vitamin E therapy [Johnson et al, 1985],
1.5 Epidemiology of ROP
ROP, as it is known today, was first described by Terry in 1942 as a 'fibroblastic
overgrowth of persistent vascular sheath behind each crystalline lens' [Terry, 1942].
Since this first description, the incidence of ROP has varied over time and across the
world as a result of changes in clinical neonatal practice. Within the developed world
there have been two notable epidemics [Campbell, 1951; Gibson et al, 1989; Gibson
et al, 1990; Valentine et al, 1989].
The first epidemic was seen in the early 1950s and was associated with exposure to
high oxygen concentrations for prolonged periods of time [Campbell, 1951]. Oxygen
therapy became available in clinical practice just before and during the Second
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World War. The first randomised controlled trial of oxygen therapy was published in
1956 and found that 'retrolental fibroplasia' was more commonly seen in infants
exposed to liberal oxygen therapy compared to those exposed to oxygen therapy
which was restricted to the lowest concentration necessary to avoid clinical cyanosis
[Kinsey, 1956]. The epidemic ceased following controlled oxygen therapy and the
incidence of childhood blindness due to 'retrolental fibroplasia' fell dramatically
[Hatfield, 1972], Unfortunately, this decline was accompanied by an increase in
mortality of very low birth weight (VLBW) infants from respiratory distress
syndrome [Avery, 1960] and an increase in morbidity from brain injury, [McDonald,
1963]. Subsequently, oxygen therapy remained controlled but was tailored to an
infant's needs according to blood gas measurements.
The second epidemic developed in the late 1970s and early 1980s and was related to
an increased survival of VLBW infants associated with advances in neonatal
medicine [Gibson et al, 1989; Gibson et al, 1990; Valentine et al, 1989; Schalij-
Delfos and Cats, 1997], These advances included the introduction of antenatal
corticosteroids, surfactant therapy, new methods of neonatal mechanical ventilation
and continuous oxygen monitoring with intravascular and transcutaneous electrodes
[Horbar et al, 1993; Vento et al, 2005; Richardson et al, 1998; Cooke, 2006]. Very
premature infants were surviving but their inherent immaturity was making them at
increased risk of developing ROP.
There is a marked variation in the incidence of ROP worldwide. Globally,
approximately 50,000 children are blind as a result of ROP [Gilbert et al, 2005]. In
industrialised countries with infant mortality rates (IMR) of <10 per 1000 live births,
ROP accounts for between 6-20% of childhood blindness [Steinkuller et al, 1999;
Gilbert et al, 1997; Fleck and Dangata, 1994; Goggin and O'Keefe, 1991], In these
countries, sight threatening ROP is predominantly seen in infants weighing <750g at
birth and is uncommon in infants weighing >1000g [Lad et al, 2008]. The CRYO-
ROP multicentre study found that 18% of infants weighing <1251 g at birth
developed stage 3 ROP and only 6% required treatment [Cryotherapy for ROP
cooperative group, 1988], In the United Kingdom, 5-8% of childhood vision
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impairment in 1985-1990 resulted from ROP-induced partial or complete blindness
and this incidence had decreased to 3% in 2000[Rahi and Cable, 2003; Rahi and
Dezateux, 1998], At least 17/233 (7%) preterm babies with stage 3 ROP identified in
the UK over a 14 month period from 1997-1999 were blind in one or both eyes as a
result of the disease [Haines et al, 2005].
ROP remains an important cause of childhood blindness in countries with IMRs of
10-60 per 1000 live births [Gilbert, 2008]. These 'middle-income' countries include
the Former Socialist Economies, Latin America and the emerging powerful
economic countries of China and India [Chaudhari et al, 2009]. This has been
referred to as the 'third epidemic' of ROP [Gilbert et al, 1997]. In these countries
there is a wide range of BWs and GAs of infants developing severe ROP suggesting
that this epidemic combines features of both the first and second epidemics [Gilbert,
2008]. The 'third epidemic' is thought to result from higher rates of preterm birth,
improved access to neonatal intensive care, increased neonatal exposure to ROP risk
factors and lack of screening and treatment programs in these 'middle-income'
countries.
1.6 Aetiology of ROP
ROP is a multifactorial disease. Risk factors for ROP have been identified
predominantly from numerous case-control studies and cohort studies.
1.6.1 Main risk factors: low birth-weight, immaturity, oxygen exposure
Low birth weight, low gestational age and exposure to supplemental oxygen are the
most widely and consistently reported risk factors for ROP. In most epidemiological
studies, the association between birth weight and ROP is stronger than the
association between GA and ROP [Cryotherapy for ROP cooperative group, 1988;
Schaffer et al, 1993; Seiberth and Linderkamp, 2000],
As mentioned above, ROP was associated with excessive high concentration oxygen
therapy shortly after the condition was first described. Since this link was
established, there has been a lot of research focused on the role of oxygen in the
pathogenesis of ROP. Neonatal units now administer controlled supplemental
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oxygen to premature infants. Oxygen levels are monitored by intermittent blood gas
sampling and by assessing arterial oxygen saturation by continuous pulse oximetry.
Prolonged respiratory support and exposure of infants to relatively high pulse
oximetry oxygen saturations have been associated with increased risk of ROP [Tin et
al, 2001; Anderson et al, 2004; Chow et al, 2003]. In addition, infants exposed to
greater variations in oxygen levels during the first 2 weeks of life have also been
shown to be at risk of developing ROP [Cunningham et al, 1995]. Recent case series
where infants were exposed to stable, tightly controlled, relatively low oxygen
saturations on pulse oximetry have consistently reported low incidences of severe
ROP [Chow et al, 2003], Importantly though, a large randomized trial comparing
target oxygen saturations of 85-89% or 91-95% in preterm infants from 24 to 28
weeks gestation yielded a worrying result. There was an increase in mortality (death
before discharge) in the lower-oxygen-saturation group [Carlo et al, 2010]. A large
multi-centre randomised controlled trial is currently underway in the United
Kingdom to try and determine the optimal oxygen saturation range for preterm
infants (www.npeu.ox.ac.uk/boost). There is an urgent need to clarify the appropriate
oxygen saturation range in order to minimize ROP but without increasing adverse
outcomes.
1.6.2 Body growth and growth factors
Premature infants are born with incompletely vascularised retinas which must
complete development postnatally. Low BW and low GA have been most
consistently and directly reported as key risk factors for ROP. Taken together, it is
therefore conceivable that nutritional status and availability of growth factors may
influence postnatal retinal vascularisation.
Premature infants who are born small-for-gestational age (SGA, BW<10lh percentile)
are at increased risk of neonatal morbidity and mortality [Bardin et al, 1997; Beeby,
1998; Tyson et al, 1995; Kok et al, 1998; Bernstein et al, 2000; Regev and
Reichman, 2004; Ley et al, 1997]. They comprise a heterogeneous group of infants.
The majority of infants in the western world born SGA are as a result of placental
insufficiency causing intrauterine growth restriction (IUGR). Other SGA infants may
have a fetal or maternal reason for being small such as a congenital or genetic defect,
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infectious disease, multiple birth or they may be constitutionally small due to short
parental height. Several studies have reported that SGA infants are at increased risk
of developing ROP [Darlow et al, 2005; Allegaert et al, 2003; Regev et al, 2003;
Bardinefa/, 1997].
Postnatal growth retardation is inevitable in preterm infants [Cooke et al, 2004;
Embleton et al, 2001]. Recent research has highlighted that poor postnatal weight
gain of VLBW infants is an independent risk factor for ROP [Wallace et al, 2000;
Lofqvist et al, 2006; Hellstrom et al, 2009; Hall et al, 1995]. In addition, a low
weight at 32 weeks corrected gestational age and low weight at school age has been
shown to be related to poor childhood visual acuity and poor visual perception [Hok-
Wikstrand et al, 2010]. This highlights that rate of neonatal body growth has an
important impact on childhood visual development.
1.6.2.1 Insulin-like growth factor 1 (IGF-1)
With the emergence of the importance of body growth and rate of growth on the
development of ROP, research has recently been directed at finding a mechanism to
explain this clinical association. IGF-1 has been earmarked as a key molecule. IGF-1
is a peptide and is essential for body growth. It was originally discovered as a
mediator of growth hormone actions but it is also an important regulator of cell
metabolism, differentiation and survival. IGF-1 is secreted by most fetal tissues and
after birth is produced predominantly by the liver [Holly and Perks, 2006]. Nutrition
together with pituitary growth hormone regulates the IGF system. Serum IGF-1
concentration rises with increasing gestational age and increasing fetal size. Fevels
increase significantly during the third trimester [Arosio et al, 1995; Pirazzoli et al,
1997; Holmes et al, 1997; Langford et al, 1998; Reece et al, 1994], The effects of
IGF-1 are mediated by the IGF-1 receptor (IGF-1 R). This is a classical
transmembrane tyrosine kinase cell surface receptor. There are six different IGF
binding proteins (IGFBPs) and the principal carrier and regulator of the
bioavailability of IGF-1 is IGF binding protein 3 (IGFBP-3).
Animal studies have shown that IGF-1 is important for normal retinal vascular
growth as IGF-1 knockout mice show slower retinal vascular development than wild-
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type controls. IGF-1 has also been shown to control maximum VEGF activation of
the Akt endothelial cell survival pathway [Hellstrom et al, 2001], In the proliferative
phase (phase 2), administration of an IGF-1 receptor antagonist in mice was found to
reduce retinal neovascularisation without influencing VEGF levels [Smith et al,
1999], Transgenic mice with vascular endothelial cell specific knockout of the IGF-1
receptor showed suppression of retinal neovascularisation compared to controls
following exposure to a high oxygen profile known to induce proliferative retinal
changes [Kondo et al, 2003],
Clinically, serum IGF-1 levels in preterm infants of the same gestational age were
significantly lower in infants who went on to develop ROP [Hellstrom et al, 2003].
Weekly postnatal weight gain measurements together with serum IGF-1 levels have
been used to predict infants at risk of severe ROP [Lofqvist et al, 2006; Hellstrom et
al, 2009]. Young adults who were born SGA as a result of IUGR (with abnormal
fetal blood flow) have reduced retinal vascularisation with fewer branching points on
blood vessels [Hellstrom et al, 2004],
Thus both animal and human studies have highlighted that IGF-1 plays a role in
normal retinal blood vessel development and in abnormal neovascularisation seen in
severe ROP. It has been suggested that one of the ways that IGF-1 may regulate
retinal neovascularisation is through control of VEGF activation of p44/42 mitogen-
activated protein kinases (MAPK) [Hellstrom et al, 2001; Smith et al, 1999]. It has
been proposed that sufficient serum levels of IGF-1 are required for appropriate
VEGF-induced vessel growth in normal retinal vascular development. The following
theory has been developed to explain the roles of IGF-1 and VEGF in ROP. After
preterm birth, the supply of nutrients and growth factors from the placenta is
suddenly lost and serum IGF-1 levels decrease and remain low until the neonatal
liver takes over production [Langford et al, 1998; Hikino et al, 2001]. Low IGF-1
together with low VEGF (due to relative 'hyperoxia' of extrauterine environment)
cause suppression of normal vessel growth in phase 1. Over time, as the infant grows
and matures, IGF-1 levels slowly rise and local retinal hypoxia leads to increased
expression of VEGF. It is thought that phase 2 occurs when IGF-1 levels reach a
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certain 'threshold' concentration that is required to permit VEGF to work maximally
and stimulate the abnormal blood vessel growth which is the hallmark of phase 2
ROP [Chen and Smith, 2007],
1.6.3 Other risk factors
Male infants are at increased risk of developing severe ROP [Darlow et al, 2005;
Nodgaard et al, 1996; Todd et al, 1990]. Infants who have had blood transfusions or
erythropoietin therapy are at increased risk of ROP [Cooke et al, 1993; Hesse et al,
1997], Genetic factors may play a role in a subset of infants with mutations in the
Norrie disease gene [Shastry et al, 1997; Hiraoka et al, 2001]. Other reported
contributing factors include hyperglycaemia [Ertl et al, 2006], sepsis [Liu et al, 2005;
Bharwani and Dhanireddy, 2008], parenteral nutrition [Shohat et al, 1983],
hypo/hypercarbia [Ben et al, 1988], patent ductus arteriosus, necrotising enterocolitis
and intraventricular haemorrhage [Arroe and Peitersen, 1994], With many of these
factors, it is unclear if they are true independent risk factors for ROP or simply
indicators of the compromised health of the neonate.
Studies on light reduction have concluded that reduction of light exposure does not
reduce the progression of ROP [Reynolds et al, 1998]. Maternal smoking may have
an inhibitory effect against developing severe ROP, perhaps relating to nitric oxide
exposure, but further research is required [Hirabayashi et al, 2010].
1.7 Experimental models of ROP
Models of ROP have yielded much of what is currently known on the molecular and
cellular mechanisms underlying the disease. Rodents such as mice and rats are
predominantly used to study the pathogenesis of ROP. Murine systems are popular
due to the possible genetic manipulations available in mice. Rodent pups are born
with no retinal blood vessels (and are therefore at an equivalent stage of development
as a 16 week human fetus) and vascularisation occurs during the first 2 weeks of life
[Henkind, 1967; Cairns, 1959], The pattern of vascularisation has some similarities
to that of the human. Exposure to oxygen following birth is used to induce abnormal
retinal vascularisation akin to human ROP in rodent pups [Patz, 1954], There are
many different oxygen profiles used [Ricci and Caolgero, 1988; Ventresca et al,
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1990; Penn et al, 1994], Popular protocols used in the mouse include exposure to
high oxygen levels (75%) from postnatal day 7 until day 12 then return to room air
until day 17-21 [Smith et al, 1994], Penn et al developed many of the rat models
using alternating daily exposure to 40/80% and 50/10% oxygen for the first 14 days
of life [Penn et al, 1994; Penn and Johnson, 1993]. The 50/10% oxygen exposure
regimen has become a widely accepted model of ROP. Retinal neovascularisation
has also been induced in rodents secondary to early acidosis [Holmes and Duffner,
1999],
These models although effective at inducing abnormal retinal vascularisation are
very unphysiological and are not a true representation of a preterm infant's oxygen
exposure. This led the Edinburgh group to develop 'the Edinburgh rat model of
ROP' [McColm et al, 2000]. The fluctuating oxygen profile over the first 14 days of
life from a preterm infant who developed threshold ROP was taken. The oxygen
profile was recorded on a minute-minute basis via a transcutaneous oxygen probe
and staff aimed to keep the infant's oxygen levels between 6-10kPa (mean 8kPa).
This profile was converted into an equivalent inspired oxygen profile for a rat. Pups
were exposed to this computer-controlled profile over the first 14 days of life. At 14
days, the pup retinas showed significantly larger avascular areas than room air
controls. No neovascularisation was observed. The strength of this model is that it is
very physiological and a more true representation of the oxygen exposure of a
preterm infant.
Several animal models have been developed to study the relationship between body
growth and retinal vascularisation. Rat pups can be 'cross-fostered' after birth so one
dam can raise pups from two originally separate litters. These pups grow more
slowly in the postnatal period than those raised in 'normal-sized' litters. On exposure
to high levels of oxygen the growth retarded pups from the larger litters have shown
more severe abnormal retinal neovascularisation [Holmes and Duffner, 1996; Zhang
et al, 2001]. These animal models have been created by manipulating postnatal
growth as weight at birth of the rat pups was not different.
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1.8 Summary
The World Health Organisation's Vision 2020 programme identifies ROP as an
'avoidable disease' [Gilbert and Foster, 2001]. Significant visual impairment as a
result of ROP affects the motor, language, conceptual and social development of a
child and their quality of life [Mets, 1999; Quinn et al, 2004; Halsey et al, 1993;
Tamai and Majima, 1996; Msall et al, 2004. It also carries a high financial cost for
society. Early detection and treatment to prevent blindness is vital. This is a
worldwide challenge as the disease is now becoming more prevalent in developing
countries.
The role of body growth and growth factors in the pathogenesis of ROP remains
poorly understood but is an exciting area as there is potential to develop preventative
strategies based on nutrition. This is the overall theme of my work. I start my thesis
with an epidemiological study reporting on the incidence of ROP in Lothian (Chapter
2). As I am interested in the effect of growth on ROP development, I compared the
incidence of ROP in SGA and appropriate-for-gestational age (AGA) infants within
the Lothian population and I report these findings in Chapter 3. I manipulated the
'Edinburgh rat model of ROP' in order to study the effect of nutrition on retinal
vascular development within this animal model. Chapter 4 reports on my findings
related to rat growth, serum IGF-1 and retinal vascularisation. Alongside this work, I
carried out a randomised clinical trial to validate the use of WFDRI as a screening
modality for ROP detection. Chapters 5 and 6 report the trial findings. This work
links into my theme of 'nutrition' as WFDRI techniques are being developed to
measure human retinal vascular development in SGA and poor postnatal weight-gain
infants. Chapter 7 summarises all my findings and outlines scope for future work.
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CHAPTER 2
THE INCIDENCE OF RETINOPATHY OF PREMATURITY IN LOTHIAN,
SCOTLAND
Dhaliwal C, Fleck B, Wright E, Graham C, Mcintosh N.
Incidence of retinopathy of prematurity in Lothian, Scotland, from 1990 to 2004.
Arch Dis Child Fetal Neonatal Ed. 2008 Nov;93(6):F422-6.
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2.1 Introduction
Since retinopathy of prematurity (ROP) was first described in 1942 [Terry, 1942],
there have been two notable epidemics within the developed world [Campbell, 1951;
Gibson et al, 1989; Gibson et al, 1990; Valentine et al, 1989]. The first was seen in
the early 1950s and was associated with unmonitored supplemental oxygen for
preterm infants [Campbell, 1951]. The second epidemic developed in the 1980s and
was related to increased survival of very low birth weight (VLBW) infants associated
with advances in neonatal medicine [Gibson et al, 1989; Gibson et al, 1990;
Valentine et al, 1989; Schalij-Delfos and Cats, 1997]. The subsequent trends in
incidence of ROP have been the subject of much debate. There is widespread
variability in the reported incidence of ROP in hospital cohorts and population-based
studies. Some centres in the developed world reported a decline in the incidence of
ROP in the 1990s and early 2000s [Hussain et al, 1999; Bullard et al, 1999;
Rowlands et al, 2001; Keith and Doyle, 1995] but other centres in the developed
world also reported an increase in the incidence of ROP [Valentine et al, 1989;
Gibson et al, 1990; Schalij-Delfos and Cats, 1997]. This variability in incidence and
severity of ROP reflects differences in case demographics, selection variability,
observer bias and outcome measures together with differences in neonatal care
provided. Large-scale population-based studies on ROP have been limited and these
report the longer term trends in incidence most accurately [Darlow et al, 2003; Ng et
al, 1988; Darlow, 1988; Todd et al, 2007; Chiang et al, 2004; Hameed et al, 2004],
2.2 Aim
To report the trends in incidence of ROP within the Lothian region of South East
Scotland over a 15-year period from 1990-2004.
2.3 Methods
2.3.1 Subjects
This was a prospective observational cohort study. The study population consisted of
all infants eligible for eye screening who were born to mothers resident within the
Lothian region of South East Scotland during the study period of January 1st 1990-
December 31st 2004. All infants born with gestational age (GA)<32 weeks and/or
31
birth weight (BW)<1500 grams who survived until eye screening commenced were
eligible. Eligible Lothian babies born outside Lothian and transferred back into
Lothian during eye screening were included.
During the study period infants were born at one of three hospitals:
The Simpson Memorial Maternity Pavilion / The New Royal Infirmary, Edinburgh
This is the level 3 South East Scotland Regional Neonatal Unit with over 6000 live
births per year. Approximately 520 infants are admitted to the neonatal unit each
year. The hospital moved to the site of the New Royal Infirmary, Edinburgh in
summer 2002.
The Eastern General Hospital, Edinburgh
This hospital closed in 1998 but before then had a level 2 neonatal unit with
approximately 2200 live births and 250 babies admitted to the neonatal unit each
year. After closure, babies were delivered at the Simpson's or New Royal Infirmary,
Edinburgh.
St. Johns Hospital, Livingston
This hospital has a level 2 neonatal unit with approximately 2400 live births 170
admissions to the neonatal unit each year.
Nursing staff in these hospitals referred all eligible babies to the ophthalmology
team. Ophthalmologists recorded the date of birth, sex, gestational age, birth weight
and maximum severity of ROP reached in any one eye for every baby examined.
This information was prospectively stored on a database. Neonatal protocols were
similar in the 3 units.
2.3.2 Lothian population epidemiological data
Epidemiological data were obtained from the Information Services Division (ISD) of
the Scottish Health Service who accessed the Scottish Morbidity Record (SMR02).
The ISD figures differ from our Lothian hospital data and our results are based on
both sources. Unfortunately we were unable to cross-check our data with ISD due to
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patient confidentiality and data protection legislation, thus a small discrepancy
remains. For the purposes of our study, survival was defined as survival to 42 weeks
corrected gestational age.
2.3.3 Eye examination schedule
Screening and treatment (if required) was carried out by 2 dedicated paediatric
ophthalmologists (Dr Brian W. Fleck and Dr Elizabeth Wright). Eligible infants were
first examined at 4-6 weeks chronological age, or 34 weeks corrected age, whichever
was earlier. Screening was continued fortnightly until full retinal vascularisation.
Examinations were performed weekly if 'prethreshold' disease was found (see below
for definition).
2.3.4 Eye examination technique
Pupils were dilated with topical phenylephrine 2.5% and tropicamide 0.5% applied
60 minutes and 30 minutes prior to eye examination. Indirect ophthalmoscopy was
performed using a binocular indirect ophthalmoscope and 28-dioptre lens. A lid
speculum and scleral indenter were routinely used. The entire retina was examined,
including the periphery throughout 360 degrees. Retinopathy was graded according
to The International Classification of ROP [The Committee for the Classification of
Retinopathy of Prematurity, 1984]. The stage of ROP (1-5), zone of vascularisation,
number of clock hours of ROP and presence or absence of 'plus' disease was
documented in both the eye logbook and patient medical notes. 'Plus' disease
represented significant dilatation and tortuosity of posterior pole blood vessels
[Cryotherapy for ROP cooperative group, 1988]. 'Threshold' ROP referred to 5 or
more contiguous or 8 or more cumulative clock hours of stage 3 ROP in zones 1 or 2
in the presence of 'plus' disease [Cryotherapy for ROP cooperative group, 1988].
'Prethreshold' disease consisted of any stage 3 disease less extensive than threshold,
or stage 2 disease in the presence of 'plus' [Cryotherapy for ROP cooperative group,
1988]. All eyes examined with 'threshold' ROP were treated with cryotherapy in
1990-1991 and with diode laser therapy from 1992 onwards. From January 2005 new
treatment criteria were used following the publication of the ETROP study [Early
Treatment For Retinopathy Of Prematurity Cooperative Group, 2003]. The study
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period therefore terminated at the end of 2004. Each hospital throughout the period
of study used oxygen saturation monitor thresholds of 86-94%.
2.3.5 Statistical Analysis
The maximum severity of ROP in either eye for an individual infant was recorded.
The 15-year study period was divided into three 5-year epochs: 1990-1994, 1995-
1999, and 2000-2004. Statistical analysis was performed using the GraphPad InStat
programme (GraphPad Software, California, USA). Contingency tables were
analyzed using the chi-square test (X2) and chi-square test for trend (X2 trend). As
birth weights and gestational ages did not to follow a normal distribution, Mann-
Whitney tests were used to compare the missing eligible babies with those of the
study population. The Kruskal-Wallis test was used to compare the birth weights and
gestational ages of the study population in each of the three epochs. In all cases a p-
value <0.05 was taken to indicate statistical significance.
The Lothian Research Ethics Committee was contacted and declared that no ethical
approval was required for this research.
2.4 Results
2.4.1 Lothian population epidemiological data (Table 2.1)
The total population of Lothian increased steadily from approximately 745,000 in
1990 to 790,000 in 2004. There were approximately 9800 live births in 1990 which
decreased over the years to 8300 in 2004.
The proportion of babies born with BW<1500g and/or GA<32 weeks that survive to
42 weeks corrected gestational age (CGA) has increased from 1990-2004 (p<0.001
using chi-square test for trend). This increase in survival is evident despite the
proportion of these babies being born remaining unchanged (p=0.271 using chi-
square test).
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Table 2.1: Lothian population epidemiological data (supplied by ISD Scotland)






LB BW<1500g and/or GA<32wks
surviving to CGA 42wks
(% of LB BW<1500g and/or
GA<32wks)*
1990-1994 47,937 701 (1.5%) 637 586 (84%)
1995-1999 44,410 596(1.3%) 547 518 (87%)
2000-2004 40,833 587 (1.4%) 564 532 (91%)
Total 133,180 1,884(1.4%) 1,748 1,636 (87%)
LB=live births
* X2 trend shows evidence towards increased survival 1990-2004 (p<0.001)
2.4.2 Study population-from Lothian hospitals data
During the study period, there were 1450 eligible babies registered for eye screening.
77 (5%) were discharged home prior to eye screening, or failed to attend outpatient
eye screening, and there were insufficient medical records from 10 (0.7%) babies.
Thus complete data was available from 1363 infants (1363/1450, 94% of eligible
population). ISD report a total of 1636 babies from 1990-2004 with BW<1500g
and/or GA<32wks where the baby survived to CGA 42wks or more (table 1).
Therefore, a discrepancy of 186 babies remains between our hospital data and ISD
data. We were unable to access details on these babies due to patient confidentiality
and data protection legislation and therefore could not crosscheck our hospital
records with ISD. We feel that our numbers are likely to be more accurate than ISD
figures as ISD obtain their data from medical coding whereas our figures are based
on raw data obtained from babies' eye examinations.
The median gestational age for the Lothian hospitals study population (1363) was 29
weeks, (interquartile range 28-31) and median birth weight was 1240g, (interquartile
range 965-1490). The study population comprised 54% males. The median
gestational age of the missing eligible babies (enough data only from 77 discharged
babies) was 31 weeks, (interquartile range 30-32) and median birth weight was
1467g, (interquartile range 1340-1675). Using a Mann-Whitney test we found that
the 77 babies had a significantly higher gestational age [p<0.001] and also a higher
birth weight [p<0.001]. These baseline characteristics of the missing eligible babies
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were expected as only the more mature and heavier babies would have been able to
be discharged prior to commencement of eye screening.
The baseline characteristics of infants in the three time epochs: 1990-1994, 1995-
1999 and 2000-2004 were also calculated. There was no evidence of statistically
significant differences in birth weight (Kruskal-Wallis p=0.48) or gestational age at
birth (Kruskal-Wallis p=0.09) between the three cohorts.
2.4.3 Incidence and severity of ROP in Lothian hospitals study
population (Table 2.2)
One baby in 1999 developed stage 4 ROP after laser treatment. No babies developed
stage 5 ROP during the study period. The heaviest baby treated weighed 1190g at
birth and the most mature baby treated was 30 weeks gestation at birth.

















1990-1994 442 96 (22%) 53 (12%) 41 (9%)
1995-1999 447 94 (21%) 39 (9%) 21 (5%)
2000-2004 474 81 (17%) 45 (9%) 24 (5%)
Severe ROP=stage 3 or greater ROP
*no evidence of a statistically significant difference (X2=3.628, p=0.16; X2trend=3.13, p=0.08)
$ no evidence of a statistically significant difference (X2=2.872, p=0.24; X2trend=1.52, p=0.22)
# evidence of a statistically significant difference (X2=9.789, p<0.01; X2trend=6.686, p<0.01)
2.4.4 Incidence and severity of ROP in Lothian hospitals study
population for birth weight categories (Tables 2.3, 2.4)
From Lothian hospitals study population data, the total number of babies with
BW<1500g who underwent eye screening was 1032 from 1990-2004. The remaining
331 babies had gestational ages <32 weeks but birth weights >1500g and were not
included in this analysis. A trend towards a greater proportion of babies with
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BW<750g having no ROP (p=0.03) was observed and a reduced proportion of these
babies required treatment (p<0.01). The incidence of severe ROP in babies with BW
1000-1249g and 1250-1499g was consistently low and there was a trend towards
fewer 1250-1499g birth weight babies having any ROP (p=0.04). No statistically
significant trends from 1990-2004 were observed for babies with BW 750-999g and
1000-1249g.
Table 2.3: Incidence of ROP in Lothian hospitals study population in babies with BW<750g and
BW 750-999g.
Total babies Babies with no Babies with Babies with Babies with stage 3
screened in ROP stages 1,2 ROP stage 3 ROP- ROP-treated
Lothian (% of babies (% of babies untreated (% of babies screened)
screened) screened) (% of babies
screened)
BW BW BW BW BW BW BW BW BW BW 750-
<750g 750- <750gA 750- <750g 750- <750g 750- <750g# 999g
999g 999g 999g 999g
1990- 35 92 6 50 6 16 4 7 19 19
1994 (17%) (54%) (17%) (17%) (11%) (8%) (54%) (21%)
1995- 50 61 9 37 15 15 11 4 15 5
1999 (18%) (61%) (30%) (25%) (22%) (7%) (30%) (8%)
2000- 48 83 18 51 7 16 11 6 12 10
2004 (38%) (61%) (15%) (19%) (23%) (7%) (25%) (12%)
Alinear trend towards increased proportion of babies with no ROP
(X2=6.489, p=0.04; X2trend=5.050, p=0.03)
#linear trend towards reduced proportion of babies treated
(X2=8.418, p=0.01; X2trend=7.148, p<0.01)
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Table 2.4: Incidence of ROP in Lothian hospitals study population in babies with BW 1000-
1249g and BW 1250-1499g.
Total babies Babies with no Babies with Babies with Babies with stage 3
screened in ROP stages 1 ,2 ROP stage 3 ROP- ROP-treated
Lothian (% of babies (% of babies untreated (% of babies screened)
screened) screened) (% of babies
screened)
BW BW BW BW BW BW BW BW BW BW 1250-
1000- 1250- 1000- 1250- 1000- 1250- 1000- 1250- 1000- 1499g
1249g 1499g 1249g 1499gA 1249g 1499g 1249g 1499g 1249g
1990- 97 101 81 95 13 5 0 1 3 0
1994 (84%) (94%) (13%) (5%) (0%) (1%) (3%) (0%)
1995- 104 126 83 121 17 5 3 0 1 0
1999 (80%) (96%) (16%) (4%) (3%) (0%) (1%) (0%)
2000- 118 117 106 116 7 0 3 1 2 0
2004 (90%) (99%) (6%) (0%) (3%) (1%) (2%) (0%)
A linear trend towards increased proportion of babies with no ROP
(X2=4.301, p=0.12; X2trend=4.224, p=0.04)
2.4.5 Incidence and severity of ROP in Lothian hospitals study
population for gestational age categories (Tables 2.5, 2.6)
From Lothian hospitals population data, the total number of babies with GA<32wks
who underwent eye screening was 1218 from 1990-2004. Similar trends were
observed when considering the babies in GA categories (tables 2.5, 2.6)
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Table 2.5: Incidence of ROP in Lothian hospitals study population in babies with GA</=24wks
and GA 25-26wks.
Total babies Babies with no ROP Babies with stages Babies with stage Babies with stage 3
screened in (% of babies 1,2 ROP 3 ROP (untreated) ROP (treated)
Lothian screened) (% of babies (% of babies (% of babies
screened) screened) screened)
GA GA GA GA 25- GA GA GA GA GA GA 25-
</=24wks 25- </=24wksA 26wks* </=24wks 25- </=24wks 25- </=24wks 26wks#
26wks 26wks 26wks
1990- 13 57 0 23 2 8 1 6 10 20
1994 (40) (15) (14) (8) (11) (78) (35)
1995- 18 43 0 7 5 18 6 7 7 11
1999 (16) (28) (42) (33) (16) (39) (26)
2000- 21 64 5 28 4 15 2 10 10 11
2004 (24) (44) (19) (23) (10) (16) (48) (17)
Alinear trend towards increased proportion of babies with no ROP out of babies screened 1990-2004
(X2-8.166, p=0.02; X2trend=6.285, p=0.01)
*evidence of a statistically significant change in proportion of babies with no ROP out of babies
screened 1990-2004 but no evidence of a linear trend (X2=9.441, p<0.01; X2trend=0.231, p=0.63)
#linear trend towards reduced proportion of babies treated out of babies screened 1990-2004
(X2=5.071, p=0.08; X2trend=5.066, p=0.02)
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Table 2.6: Incidence of ROP in Lothian hospitals study population in babies with GA 27-28wks
and GA 29-3Iwks.
Total babies Babies with no Babies with stages Babies with stage Babies with stage
screened in ROP 1,2 ROP 3 ROP (untreated) 3 ROP (treated)
Lothian (% of babies (% of babies (% of babies (% of babies
screened) screened) screened) screened)
GA 27- GA 29- GA 27- GA 29- GA 27- GA 29- GA 27- GA 29- GA 27- GA 29-
28wks 31 wks 28wksA 31 wks 28wks 31 wks 28wks 31 wks 28wks# 31wks
1990- 97 230 64 215 19 13 3 2 11 0
1994 (66) (94) (20) (6) (3) (1) (11)
1995- 75 264 55 245 14 18 4 0 2 1
1999 (73) (93) (19) (7) (5) (3) (<D
2000- 90 246 74 233 7 10 6 3 3 0
2004 (82) (95) (8) (4) (7) (1) (3)
Alinear trend towards increased proportion of babies with no ROP out of babies screened 1990-2004
(X2=6.355, p=0.04; X2trend=6.338, p=0.01)
#linear trend towards decreased proportion of babies treated out of babies screened 1990-2004
(X2=7.389, p=0.04 using a Fishers exact test due to small expected counts; X2trend=5.353, p=0.02
2.5 Discussion
The trends in the incidence of ROP within the developed world since the early 1990s
have been the cause of much debate. Some centres have reported an increase in the
incidence of ROP (thought to be a reflection of improved survival rates for premature
infants), whilst other centres have reported a decrease in incidence (thought to be due
to improved neonatal care) [Valentine et al, 1989; O'Connor et al, 2003; Hussain et
al, 1999; Chow et al, 2003; Wallace et al, 2007; Wright et al, 2006; Arroe and
Peitersen, 1994; Keith et al, 1995]. Population studies over a long period of time
provide the most robust evidence of epidemiological changes. Our prospective
population based study has found a significant reduction in the number of babies
treated for ROP from 1990-2004. A reduction in the overall incidence of any degree
of ROP and severe ROP was also observed. We have also seen an increase in overall
survival in babies with BW<1500g or GA<32wks.
Our observed changes are based on a complete population rather than single hospital
data and therefore referral and inclusion bias should be eliminated. One of the key
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strengths of this study is that inter observer variation should be minimal for detection
of severe ROP as only 2 examiners examined the population over the 15-year period
and both were experienced paediatric ophthalmologists. Observer bias has been
shown to be one of the key causes of inter-centre variation in the incidence of ROP
[Darlow et al, 2008], The methods of ophthalmoscopic examination for ROP and the
classification system used were the same for the whole study period. Oxygen
saturation monitors were introduced in the late 1990s and the target limits have
always been 86-94%. Arterial catheters were infrequently used throughout the study
period with the target partial pressure of oxygen being 6-10kpa. We have not
separately analysed mild stages (stage 1 or 2) of ROP, as this data is less robust due
to likely inherent observer error in scoring these lesser grades. There may have been
an under-reporting of 'any degree of ROP' and a related over-reporting of 'no ROP'
as a consequence of failure to detect minor degrees of ROP. The context of this
prospective data acquisition was as a clinical service rather than a precisely defined
epidemiological project as in other studies [Ng et al, 1988]. We did not formally
record ethnicity but results from the 2001 census in Scotland report the Scottish
population as being 98% Caucasian, 1.4% Asian and 0.6% Afro-Caribbean and other
ethnic background [The General Register Office for Scotland, 2007]. There was
minimal movement of babies between different centres.
Recent population studies report differing trends in the incidence of ROP. I shall
discuss studies that report on the incidence of severe ROP in the developed world as
this data is likely to be more clinically relevant to our study population. I shall also
only discuss studies pre-2005 as many centres in the developed world changed their
clinical practice following the publication of the ET-ROP trial and this will likely
affect the incidence of treated ROP reported [Early Treatment For Retinopathy Of
Prematurity Cooperative Group, 2003].
Lee et al reported an 11% incidence of severe ROP and 3% incidence of treated ROP
in Canada during 1996-1997 [Lee et al, 2000]. These incidences are very similar to
our reported ones during 1995-1999 and probably reflect similar neonatal practices.
Larsson et al compared ROP rates during 1988-1990 (260 infants) and 1998-2000
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(253 infants) in Sweden and found no change in the incidence of severe ROP in
infants with BW<1500g [Larsson et al, 2002]. Similarly, Lundqvist et al studied a
population in southern Sweden from 1995-2004 and despite an increase in survival
of premature infants <32 wks there were no changes in the incidence of severe ROP
[Lundqvist et al, 2009], Todd et al studied the incidence and treatment of severe
ROP in New South Wales and the Australian Capital Territory from 1992-2002
[Todd et al, 2007], They found a significant increase in severe ROP in infants
</=24wks gestation (42% to 54%) together with an increase in treatment for severe
ROP (19% to 24%). In infants of 25-26wks gestation there was a significant decrease
in severe ROP (26% to 19%) and there was no change in 27-29 wks gestation
infants. Hameed et al reported on severe ROP in 505 infants in Leicestershire, UK
from 1990-1999 in infants with BW</=1250g [Hameed et al, 2004]. They found an
increase in severe ROP from 4% in 1990-1994 to 12% in 1995-1999. This increase
in severe ROP was also observed in infants with BW<750g. This is very different to
our findings as we observed a reduction in the incidence of severe ROP in babies
<750g. The reason for the different outcomes is unknown but the incidence of severe
ROP may be influenced by variations in population ethnicity and relatively minor
changes in neonatal care policies and practice.
The papers discussed above are all population studies and provide the most
epidemiologically robust information on large numbers of infants. The main
limitation of population studies is due to the fact that they often involve multiple
observers reporting ROP. This can lead to difficulties of consistent diagnosis and
classification.
Most papers published on the incidence of ROP have observed the trends in either a
single hospital or a group of hospitals. These findings can be difficult to relate to the
population as a whole due to local regional differences in survival rates, neonatal
management and ethnicity [Darlow et al, 2005; Simpson et al, 2003; Vohr et al,
2004; Vyas et al, 2000]. Darlow et al reported the incidence of ROP from 25 NICUs
in Australia and New Zealand and found considerable variation in the rates of severe
ROP (0-25%) and this remained despite adjustment for case mix and sampling
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variability [Darlow et al, 2005], Vohr et al found striking differences in neonatal
outcomes in America which remained after adjustment for demographics and
antenatal interventions, thus suggesting that differences in neonatal care between
centres strongly influences outcome neonatal outcome [Vohr et al, 2004].
Despite this however, large hospital based cohort studies still provide useful
information. Rowlands et al found a significant reduction in the incidence of severe
ROP in screened infants (BW<1500g or GA<31wks) from 5.7% in 1989 to 1.5% in
1997 in a level 2 neonatal unit in London [Rowlands et al, 2001]. Hussain et al
reported on a similar time period (1989-1997) from a level 3 neonatal unit in the
USA and found an incidence of 5% for severe ROP [Hussain et al, 1999]. O'Connor
et al found no significant trend in the incidence of threshold ROP (2-5%) in a single
American centre between 1994 and 2000 [O'Connor et al, 2003] as did Larsson et al
in Sweden (severe ROP 18.2% versus 20%) when comparing the incidence of severe
ROP in 1988-1990 with 1998-2000 [Larsson et al, 2002], Following adjustment for
case mix and sampling variability, Darlow et al reported a <5.9% incidence of severe
ROP in 20% of NICUs within the Australian and New Zealand Neonatal Network in
1998 and 1999 [Darlow et al, 2005], These incidences of severe ROP are similar to
our findings and may reflect similar neonatal practices. However, other centres report
increases in incidence of severe ROP. Schiariti et al reported a marked increase in
severe ROP from 7% in 1992-1996 to 14% in 1997-2001 in a tertiary referral
hospital in Vancouver, Canada [Schiariti et al, 2008], Vyas et al found a significantly
higher incidence of severe ROP in one of five English cities studied in 1994 [Vyas et
al, 2000]. This city also had a lower death rate and so the authors propose that
improved survival and development of severe ROP are associated. This study was
carried out in very multicultural cities in the Midlands and ethnicity was not
accounted for. This may have influenced these results.
In the last decade there have been a number of publications highlighting the role of
oxygen free radicals in several neonatal disease processes, as well as ROP [Sola et
al, 2007; Deulofeut et al, 2006; Tin et al, 2001], As a result, many neonatal units
have implemented new oxygen saturation policies to reduce the amount of
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supplemental oxygen given to premature babies. Several large centres have reported
a significant decrease in the incidence of severe ROP following introduction of lower
oxygen saturation targets [Vanderveen et al, 2006; Wallace et al, 2007; Wright et al,
2006; Cole et al, 2003; Silverman, 2004; Askie et al, 2003; Tokuhiro et al, 2009;
Sears et al, 2009]. We did not change our oxygen saturation policy throughout the
period of the study. Importantly though, a large randomized trial comparing target
oxygen saturations of 85-89% or 91-95% in preterm infants from 24 to 28 weeks
gestation yielded a worrying result. There was an increase in mortality (death before
discharge) in the lower-oxygen-saturation group [Carlo et al, 2010]. The Benefits Of
Oxygen Saturation Targeting (BOOST-II) UK trial will provide valuable results on
target oxygen saturations and incidence of ROP that should help guide evidence-
based neonatal care and help lower the incidence of severe ROP [National Perinatal
Epidemiology Unit, 2009],
2.6 Summary
In summary, we have seen an increase in survival of preterm infants, a reduction in
the incidence of any degree of ROP, severe ROP and a marked reduction in treatment
for ROP in Lothian from 1990-2004. The last 20 years in the developed world have
seen dramatic advances in obstetric and neonatal care with routine administration of
antenatal corticosteroids for premature labour, use of surfactant therapy, new
methods of neonatal mechanical ventilation, introduction of continuous pulse
oximetry, use of computerized monitoring systems and advances in neonatal
nutritional support. There has also been an increase in centralisation of neonatal care.
It is highly probable that these advances are responsible for the increased survival of
premature infants and the overall decreasing incidence of ROP seen.
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CHAPTER 3
RETINOPATHY OF PREMATURITY IN SMALL-FOR-GESTATIONAL AGE
INFANTS
Dhaliwal CA, Fleck BW, Wright E, Graham C, Mcintosh N.
Retinopathy of prematurity in small-for-gestational age infants compared with those
of appropriate size for gestational age.
Arch Dis Child Fetal Neonatal Ed. 2009;94(3):FI93-5.
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3.1 Introduction
The aetiology of retinopathy of prematurity (ROP) is multifactorial [Romagnoli,
2009]. There is an increasing body of evidence highlighting the importance of rate of
body growth both in utero and postnatally in the pathogenesis of ROP [Allegaert et
al, 2003; Wallace et al, 2000; Hellstrom et al, 2009]. In early pregnancy, fetal
growth is due primarily to an increase in cell number and most fetal weight gain
occurs during the second and third trimesters [Yu and Upadhyay, 2004], There are
many reasons why infants are born small-for-gestational age (SGA) but in the
western world the majority have been exposed to placental insufficiency during the
third trimester leading to growth failure. Premature infants who are born SGA are a
vulnerable population for the duration of their life. SGA infants have a greater than
average risk of morbidity and mortality from many neonatal disorders [Bardin et al,
1997; Regev and Reichman, 2003; Gortner et al, 1999], They are also more likely to
exhibit neurodevelopmental deficits in childhood and are at increased risk of
developing cardiovascular disease and type 2 diabetes in later life [Sung et al, 1993;
Low et al, 1992; Barker, 1990; Hales et al, 1991], Several studies have indicated that
SGA infants are at greater risk of developing ROP and one study has shown that
IUGR infants had abnormal retinal vascular morphology in adult life [Bardin et al,
1997; Wallace et al, 2000; Hellstrom et al, 2004].
3.2 Aim
To compare the incidence of ROP in SGA and appropriate-for-gestational age
(AGA) infants who underwent eye screening within the Lothian region of South East
Scotland over a 15-year period from 1990-2004.
3.3 Methods
3.3.1 Study population
This was a prospective observational cohort study. The study population consisted of
all infants who underwent eye screening in Lothian hospitals from January 1st 1990-
December 31st 2004. These were infants with GA <32 weeks and/or BW <1500
grams who were screened at one of three hospitals (The Simpsons Memorial
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Maternity Pavilion, Edinburgh Royal Infirmary; The Eastern General Hospital,
Edinburgh; St. John's Hospital, Livingston).
3.3.2 Eye examination schedule
During the study period, two dedicated paediatric ophthalmologists (Dr Brian W.
Fleck and Dr Elizabeth Wright) carried out all the eye screening in Lothian. The eye
examination schedule is the same as that detailed in Chapter 2 (2.3.3 Eye
Examination Schedule).
3.3.3 Eye examination technique
The eye examination technique is the same as that detailed in Chapter 2 (2.3.4 Eye
Examination Technique).
3.3.4 Data collection
Information on all babies whose eyes were screened in Lothian during the study
period was stored on a database. For every baby, the date of birth, sex, GA, BW and
maximum severity of ROP (stage 1-5) in either eye was stored.
3.3.5 Data analysis
The database was accessed and for every baby the BW was plotted on a sex-specific
growth chart {Cooney, K. Growth and developmental record (boys: preterm-12
months; girls: preterm-12 months). 1995. Castlemead Publications}. If the BW was
below the 10th percentile for gestational age, the infant was defined as being SGA. If
the BW was equal to or greater than the 10th percentile for gestational age, the infant
was defined as being AGA. The incidence of ROP in SGA babies was compared to
the incidence of ROP in AGA babies in gestational age categories. Statistical
analysis was performed using SPSS and the GraphPad Instat programme (GraphPad
Software, California, USA). As birth weights and gestational ages did not follow a
normal distribution, Mann Whitney tests were used to compare the baseline
characteristics of the SGA and AGA babies. Contingency tables were analysed in
gestational age categories using Chi-square test with Yate's continuity correction.
Fishers Exact test was used where numbers were small (<5 infants). In all cases, a




1668 infants were registered for eye screening during the study period. 168/1668
(10%) were transferred to a neonatal unit outwith Lothian prior to eye screening,
77/1668 (5%) were discharged home prior to eye screening or failed to attend
outpatient eye screening and there were insufficient medical records from 10 (<1%).
Thus complete data was available from 1413 infants. 329/1413 (23%) of the study
population were SGA. The baseline characteristics are shown in table 3.1.












AGA infants 1084 (617:438)* 890 (585-1170) 27 (26-31) 25
SGA infants 329 (130:194)# 1035 (825-1235) 31 (29-32) 125
* sex not recorded for 29 babies
# sex not recorded for 5 babies
The SGA infants had a higher median birth weight and gestational age than the AGA
infants (Mann Whitney p<0.0001 for both).
3.4.2 Prevalence and severity of ROP.
The maximum severity of ROP recorded for every study baby is presented in Table
3.2. One AGA baby (GA 24 weeks) in 1999 developed stage 4 ROP after laser
treatment. No babies developed stage 5 ROP during the study period. The numbers
of AGA and SGA infants with any stage of ROP (1-5), severe (stage 3 or greater)
ROP and treated ROP were compared using Chi-square test or Fishers exact test
where cell numbers were small. The findings are displayed in table 3.2. SGA infants
born at gestational ages 26-31 weeks were more likely to develop any stage of ROP
(p<0.01) than their AGA peers. They were also more likely to develop severe ROP
(GA 26-27wks p<0.01, GA 28-29wks p=0.01, GA 30-31wks p=0.01).
48
Table 3.2: Maximum severity of ROP (stages 1-5) in AGA and SGA infants.
</=25 wks 26-27 wks 28-29 wks 30-31 wks >/=32 wks
n-Without ROP (AGA:SGA) 27:0 112:6 265:51 429:83 25:123
[%AGA;%SGA]
[2:0] [10:2] [24:16] [40:25] [2:37]
n-Stages 1,2 ROP (AGA:SGA) 31:3 39:10 25:10 15:11 0:1
[%AGA;%SGA]
[3:1] [4:3] [2:3] [1:3] [0:<1]
n-Stage 3 untreated (AGA:SGA) 19:0 12:11 4:5 0:1 0:1
[%AGA;%SGA]
[2:0] [1:3] [<1:2] [0:< 1 ] [0:<1]
n-Stage 3 treated (AGA:SGA) 51:3 28:8 2:1 0:1 0:0
[%AGA;%SGA]
[5:1] [3:2] [<1:<1] [0:< 1 ] [0:0]
p value* of difference: 0.46 <0.01 <0.01 <0.01 1.00A
any stage of ROP
p value* of difference: 1.00A <0.01 0.01 0.03A 1.00A
severe (stage 3-5) ROP
p value* of difference: 1.00A 0.59 1.00A 0.46A
treated ROP
*
p values relate to comparison of AGA and SGA infants using chi square test;
p values not corrected for the multiple comparisons
A-Fishers exact test used due to small numbers
3.5 Discussion
In our study population, SGA infants born at gestational ages 26-31 weeks were
more likely to develop any stage of ROP and severe ROP than their AGA peers. We
did not find this association to be statistically significant in infants with GA</=25
weeks. This may have been because of our small numbers at this gestation but also
because these infants are at a high risk of ROP irrespective of whether they are SGA
or AGA. We also did not find a statistically significant difference in ROP prevalence
in SGA and AGA infants born with GA>32wks and this is almost certainly due to
the low risk of developing ROP at this gestational age. When comparing the numbers
of SGA and AGA infants requiring treatment for severe ROP, SGA infants were not
more likely to require laser therapy. This finding is again most likely to be explained
by our small numbers with treated ROP. Interestingly, 23% of our study population
were SGA and by the terminology definition, this ought to have been 10%. This high
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incidence was observed as we had disproportionately large numbers of more mature
babies (GA>32 weeks) but whose birth weights were less than the 10th percentile.
The main strength of our study is that our findings are based on a large cohort of
babies over a long period of time with two consistent observers and methodical
documentation of eye examination findings. The methods of ophthalmoscopic
examination for ROP and the classification system used were the same over the
whole study period. The two specialised ophthalmologists have worked together
using BIO to perform all the ROP eye screening examinations in the Lothian region
since 1990. In 2007, for the purpose of another study, the examiners undertook inter-
observer agreement studies by independently and blindly grading 80 clinical ROP
screening RetCam images. They demonstrated 95% agreement on the presence or
absence of 'plus' disease, 94% agreement on stage of ROP and 97% agreement on
zone of ROP. We are therefore confident that inter-observer variation should be
minimal. There may have been some minor variation in neonatal care between the
three Lothian hospitals. However, there were no changes in target oxygen saturation
policies during the study period. Ethnicity was not formally recorded but the 2001
census in Scotland reported the population as being 98% Caucasian, 1.4% Asian and
0.6% Afro-Caribbean and other ethnic background.
SGA infants are a vulnerable population at higher risk of perinatal morbidity and
mortality than their appropriately sized peers. Other studies have also reported on the
incidence of ROP in SGA and AGA infants with similar findings to ours. Gortner et
al reported the incidence of ROP in SGA infants to be more than double that in AGA
infants (37% vs. 15%) although there was no difference in prevalence of stage 3
disease between the two groups [Gortner et al, 1999]. Bardin et al compared two
historical cohorts of SGA and AGA infants born between 24-26 weeks gestation.
Like us, they found SGA infants to be at increased risk of developing any stage of
ROP (90% vs. 58%) and severe ROP (65% vs. 12%) [Bardin et al, 1997], Allegaert
et al demonstrated that SGA infants were 3.7 times more likely to develop threshold
ROP than their AGA peers [Allegaert et al, 2003], They went on to document
perinatal growth and found that even when growth restricted (birth weight<25th
50
percentile) infants displayed normal postnatal growth (i.e. same g/kg/d as AGA
infants) they still have a higher risk of developing threshold ROP. Misra et al report
that SGA infants in their cohort were at increased risk of developing severe ROP
earlier than their AGA counterparts [Misra et al, 2008],
There are many possible explanations for why SGA infants have an increased
incidence of ROP. The majority of SGA infants are small as a result of IUGR. IUGR
infants are exposed to changes in organ development due to fetal hypoxaemia,
antioxidant deficiency, free oxygen radicals, nutrient restriction and an altered
endocrine environment [Regev and Reichman, 2004; Kelly, 1993; Saugstad, 2001].
These developmental changes may be linked to the increase in ROP. SGA infants are
often sicker infants than their AGA peers, requiring more intensive and more
prolonged hospital care [Yu and Upadhyay, 2004], Thus their comorbidities may be
linked to the increase in incidence seen. SGA infants have lower serum levels of
insulin-like growth factor-1 (IGF-1) and there is evidence for the role of this growth
factor and vascular endothelial growth factor (VEGF) in the pathogenesis of ROP
[Smith, 2005]. Certainly there is scope to study prenatal and postnatal growth rates in
premature infants in relation to later development of ROP as there is great potential
to modify nutrition which may ameliorate ROP development.
Early nutrition has a 'programming' effect on health in early adulthood, notably on
cardiovascular disease risk, bone health and cognitive function [Lucas, 2005]. It is
possible that a stimulus such as placental insufficiency during the third trimester may
'program' the fetus to develop vascular disease in the neonatal period such as ROP.
3.6 Summary
In our study population we found that the prevalence of ROP was higher in SGA
infants than AGA infants. In addition, the prevalence of severe (stages 3-5) disease
was greater in SGA infants. There are many possible explanations for this observed
association and I was keen to explore the role of nutrition and growth further. This
led me to adapt the 'Edinburgh rat model of ROP' in order to study the association
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THE INFLUENCE OF GROWTH, INSULIN-LIKE GROWTH FACTOR-1
AND OXYGEN ON RETINAL VASCULAR DEVELOPMENT-
DEVELOPMENT OF AN ANIMAL MODEL
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4.1 Introduction
Normal fetal growth is a complex process dependent on the genetic profile of the
embryo, adequate nutrient and oxygen supply via the placenta and the fetal-maternal
hormonal and growth factor milieu. Insulin-like growth factors are key growth
factors in fetal growth and development [van Kleffens et al, 1998]. This process is
interrupted following preterm birth and premature infants are therefore born with
incompletely vascularised retinas which must complete development in the postnatal
period. Retinopathy of prematurity (ROP) develops as a result of abnormal postnatal
retinal vascular development.
Premature infants who are born small-for-gestational age (SGA) are at increased risk
of developing retinopathy of prematurity (ROP) [Dhaliwal et al, 2008; Bardin et al,
1997; Darlow et al, 2005], Premature infants who suffer from postnatal growth
retardation are also at increased risk of developing ROP [Wallace et al, 2000;
Lofqvist et al, 2006; Hellstrom et al, 2009]. These facts suggest that the nutritional
status of the fetus and premature neonate may influence retinal vascular
development.
Animal models are useful tools to try and understand the mechanisms behind
observed clinical associations. The rat is a suitable model in which to study retinal
vascularisation as this occurs in the first 14 days after birth [Henkind, 1967], The
Edinburgh Rat Model of ROP exposes rat pups to a fluctuating oxygen profile from
birth to day 14 of life [Cunningham et al, 2000], This model induces rat retinal
changes similar to those observed in clinical ROP.
We adapted the Edinburgh Rat Model of ROP in order to study the effect of growth
restriction on rat retinal development. We also wanted to study insulin-like growth
factor-1 (IGF-1) in this model as there is evidence to suggest that it may play a key
role in the observed association between growth restriction and ROP [Smith, 2005],
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4.2 Methods
This study was approved by the UK Home Office and all animals were cared for in
accordance with UK Home Office legislation.
4.2.1 The Edinburgh Retinopathy of Prematurity oxygen chamber
(figure 4.1)
This animal model of ROP was developed in Edinburgh [Cunningham et al, 2000],
Edinburgh Neonatal Intensive Care Unit has stored computerized data on arterial
oxygen concentrations of infants. Arterial oxygen concentrations were measured
transcutaneously and a mean of data points for every minute were stored. The
minute-to-minute oxygen profile over the first 14 days of life from one infant who
developed threshold ROP was taken. The infant's arterial oxygen profile was
converted into an equivalent oxygen profile for the rat. A computer-controlled
system delivered this oxygen profile to the rat litters by releasing oxygen and
nitrogen gases on a minute-by-minute basis into a closed animal chamber
(BioSpherix Ltd, New York). Changes in retinal vascularisation on the rat retina
were seen that were similar to those observed in human infants with ROP. Rat pups
raised in this variable oxygen profile around a hyperoxic mean inspired oxygen
concentration have been shown to have more severe retinal vascular abnormalities
[McColm et al, 2004], For this work, rats were exposed to the mildly hyperoxic
variable oxygen profde about a mean inspired oxygen concentration of 14.9kPa
(24.7% Fi02) (equivalent to neonatal arterial oxygen concentration of lOkpa).
4.2.2 Animals
Pregnant Sprague-Dawley rats were used. From day 15 gestation, they were fed
either an isocaloric low protein (9% casein) diet (to induce growth restriction) or a
'normal protein' (18% casein) diet (see appendix section 1.3). The same diet was
continued following the birth of pups. Water was available ad libitum. Dam and pups
were weighed on the day of pup birth. Litter size was standardised to 10-12 pups.
Two experimental groups and two control groups of animals were studied (figure
4.2).
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Figure 4.1: The Edinburgh Rat Model of ROP





On the day of birth, some litters were placed in the oxygen chamber and the variable
oxygen profile commenced whilst other litters remained in cages in room air. Soda
lime was placed in the enclosed oxygen chamber in order to maintain the carbon
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dioxide concentration at normal atmospheric levels. Light was cycled on a 12 hour
on, 12 hour off schedule and the room temperature was maintained at approximately
21 degrees centigrade. The variable oxygen profile was paused briefly on day 7 in
order to change bedding. Bedding was also changed for room air litters on day 7.
Experiments were terminated on day 14.
4.2.3 Tissue collection
On day 14, dam and pups were weighed. Pups were anaesthetised by intraperitoneal
injection of ketamine (2.5mg/kg) and xylazine (lmg/kg). The thoracic cavity was
opened. A blood sample was taken from the left ventricle using 25 gauge needle and
lml syringe. A cut was then made in the liver (to permit exsanguination) and lOmls
of phosphate-buffered saline (PBS-see appendix section 1.2) pH 7.4, followed by
5mls of 0.5% paraformaldehyde (PFA, Sigma-Aldrich) was injected into the left
ventricle of the heart. These fluids flushed blood out and initiated tissue fixation.
Pups were then killed by intracardiac injection of pentobarbitone (80mg/kg). Both
eyes were enucleated.
4.2.4 Tissue processing-retinas (Figure 4.3)
Enucleated eyes were immediately fixed in 4% PFA for one hour and then washed in
PBS. The cornea, lens and vitreous of the eyes were surgically removed and the
retinas were dissected using the method described by Chan-Ling [Chan-Ling, 1997],
Four incisions were made in the 'cup-shaped' retinas and they were wholemounted
on TESPA (3'-aminopropyltriethoxysilane) coated microscope slides (figure 4.3). A
rectangle was drawn on the slide around each retina using a Dako pen [Dako UK
Ltd] in order to contain the solutions applied during processing.
Figure 4.3: Tissue processing-retina
retina cup retina flatmounted on slide
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The immunohistochemical staining regime described below was designed in order to
label both the retinal astrocyte cells and retinal endothelial cells. My colleague (JW)
studied the astrocytes (which I shall not discuss) and I studied the endothelial cells.
The retinas were fixed in 70% ethanol (stored at -20°C) for 20 minutes with gentle
shaking and then washed three times in PX (see appendix section 1.2) for 5 minutes
each time. Blocking buffer (see appendix section 1.2) was applied for 2 hours at
room temperature. The primary antibody for astrocyte staining (rabbit anti-cow
GFAP, diluted 1 in 1000 in blocking buffer [Dako UK Ltd]) was applied and retinas
were incubated overnight at 4°C. Retinas were washed three times in PX (5 minutes
per wash). The secondary antibody for astrocyte staining (swine anti-rabbit IgG
biotinylated, diluted 1 in 200 in PX [Dako UK Ltd]) was added for 2 hours at room
temperature with gentle shaking. Retinas were again washed three times in PX (5
minutes per wash). The fluorescent label for astrocyte staining (streptavidin alexa
fluor 568, red, diluted 1 in 200 in PX [Invitrogen Ltd UK]) was applied and retinas
incubated for 2 hours at room temperature with gentle shaking in the dark. The
retinas remained in the dark for the subsequent immunohistochemical stages.
Retinas were then washed three times in PX (5 minutes per wash). In order to block
non-specific binding during the endothelial cell staining, the retinas were first
incubated with avidin for 20 minutes and then biotin for 20 minutes at room
temperature [avidin/biotin blocking kit, Vector Laboratories Ltd, UK]. Retinas were
incubated with biotinylated lectin (Griffonia simplicifolia Bandeiraea isolectin IB4,
diluted 1 in 40 in PX [ICN Pharmaceuticals Ltd, UK]) overnight at 4°C to label the
endothelial cells. The retinas were washed three times in PX (5 minutes per wash)
before incubating with the endothelial cell fluorescent label (fluorescein streptavidin,
green, diluted 1 in 100 in PX [Sigma-Aldrich, UK]) for 2 hours at room temperature
with gentle shaking. Slides were washed three times in PX (5 minutes per wash) and
once in PBS for 5 minutes and mounted using mowiol (see appendix section 1.2).
4.2.5 Imaging, image analysis and statistics
Images of the stained flatmounted retinas were taken using an argon krypton laser
confocal microscope (Leica TCS-NT, Leica Microsystems, Bucks, UK). Digitalised
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whole retina images were reconstructed using Adobe Photoshop (Adobe Systems
Incorporated) and stored as jpeg files (figures 4.4, 4.5).
Figure 4.4: sample retina from 14 day rat pup (room air, 18% diet)
Figure 4.5: sample retina from 14 day rat pup (room air, 9% diet)
For every retina, the avascular retinal area and total retinal area was measured using
Image J Software. The analyser (CD) was blind to the experimental conditions. The
avascular area was expressed as a proportion of the total retinal area. A one-way
analysis of variance (ANOVA) was carried out to study the effect of independent
variables (pup birthweight, pup weight gain, 9% diet, 18% diet, room air, variable
oxygen) on the dependent variable (the avascular area). The computer package SPSS
was used.
Mean pup birth weights and day 14 weights were calculated and compared using an
unpaired t test and Mann Whitney test respectively. Statistical analysis was
performed using the GraphPad Instat programme (GraphPad Software, California,
USA). In all cases, a p-value of <0.05 was taken to indicate statistical significance.
4.2.6 Serum IGF-1 analysis and statistics
Blood was taken from day 14 rat pups as described above. Blood was also taken
from day 7 rat pups which were being used for different research work within our
group. These pups were reared under identical experimental conditions. Blood
samples were allowed to clot for 2 hours at room temperature. They were then
centrifuged for 20 minutes at 1000 x g. Serum was removed and stored at -70°C until
assayed.
A quantikine mouse IGF-1 immunoassay kit [R&D Systems Europe Ltd, UK] was
used to quantify serum IGF-1. This was an enzyme-linked immunosorbent assay
(ELISA) which had also been validated for rat IGF-1. Rat serum samples were
diluted 1000-fold for the assay. The kit contained a monoclonal antibody specific for
IGF-1 pre-coated onto a microplate. Standards, controls and samples were pipetted
into the microplate wells. These were all assayed in duplicate. The immobilised
antibody bound to any IGF-1 and any unbound substances were washed away. An
enzyme-linked polyclonal antibody specific for IGF-1 was then added to the wells.
The wells were washed to remove any unbound substances before a substrate
solution was added. The enzyme reaction yielded a colour change that was
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terminated by addition of the stop solution. The intensity of the colour was measured
using a microplate reader and was in proportion to the amount of rat IGF-1 bound in
the first step. The standard, control and sample duplicate readings were averaged and
the average zero standard optical density was subtracted. A standard curve was
constructed using GraphPad Prism computer software and sample values were read
off the standard curve. The values were then multiplied by the dilution factor of 1000
to give serum concentrations measured in ng/ml.
One-way ANOVAs were carried out to study the effect of independent variables
(pup weight gain, 9% diet, 18% diet, room air, variable oxygen) on the dependent
variable (serum IGF-1) on results from both day 7 and 14 pups. The computer
package SPSS was used.
4.3 Results
4.3.1 Pup weights (Figure 4.6)
The mean birth weight of pups from dams fed the 18% normal protein diet was 5.73g
(SD 0.70) and mean birth weight of pups from dams fed the 9% low protein diet was
5.46g (SD 0.68){unpaired t test comparing mean birth weights p<0.0001}. The pups
from dams fed the low protein diet weighed on average 5% lighter at birth.
The mean day 14 weight of pups in the four experimental and control groups is
shown in figure 10 {Mann Whitney tests: comparing room air 18% diet with room
air 9% diet mean weights p<0.000!, comparing variable oxygen 18% diet with
variable oxygen 9% diet mean weights p<0.0001}. Pups from dams fed the low
protein diet weighed on average 36% lighter than those from dams on the normal
protein diet at day 14.
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Figure 4.6: Day 14 rat pup mean weights {bars=standard deviation}
4.3.2 Retinal avascular areas
The results are shown in table 4.1. Growth restricted (9% protein diet) pups had
smaller total retinal areas than 'normal size (18% protein diet) pups as they had
smaller eyes.
Table 4.1: Mean retinal areas in four animal groups
Mean retinal Mean total Mean [avascular
avascular area mm2 retinal area mm2 area/total retinal
area] mm2
(SD) (SD) (SD)
Normal (18%) protein diet 0.602 36.271 0.017
Room Air
(n=31 pups from 6 litters) (0.154) (2.661) (0.004)
Normal (18%) protein diet 0.682 37.330 0.018
Variable Oxygen
(n=23 pups from 4 litters) (0.252) (1.461) (0.007)
Low (9%) protein diet 0.784 33.743 0.023
Room Air
(n=29 pups from 5 litters) (0.267) (3.409) (0.007)
Low (9%) protein diet 1.051 34.965 0.038
Variable Oxygen
(n=27 pups from 4 litters) (0.299) (3.056) (0.041)
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A credible ANOVA requires that the variances within each group are the same. This
was tested for using Levene's test. The initial test showed that the variances were not
equal and so the data was transformed using a square root transformation. A repeat
Levene's test showed equality of variance (p=0.060) so an ANOVA was done on the
transformed data [square root of (avascular area/total retinal area)]. The results are
shown in table 4.2.
Table 4.2: ANOVA Tests of Between-Subjects Effects [dependent variable: square root
(avascular area/total retinal area)]




Mean square F Significance
Corrected Model 0.33 5 0.007 13.431 0.000*
Pup birth weight 0.001 1 0.001 2.291 0.133
Pup weight gain$ 2.087E-5 1 2.087E-5 0.042 0.838
Oxygen concentration 0.006 1 0.006 12.271 0.001*
Diet (9% or 18%) 0.004 1 0.004 7.324 0.008*
Gas/diet interaction 0.000 1 0.000 0.409 0.524
Error 0.051 104 0.000
Total 2.441 110
Corrected Total 0.085 109
$ pup weight gain=(day 14 weight-birth weight)/birth weight
The ANOVA (table 4.2) shows a significant main effect for oxygen concentration
(air or oxygen) and diet (9% or 18%). The effect of oxygen concentration (air or
oxygen) is more significant than the effect of diet (9% or 18%). These findings are
illustrated graphically in figure 4.7. There is no significant interaction effect between
gas and diet (see table 4.2).
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The ANOVA shows no significant independent effect of birth weight or pup weight
gain.
4.3.3 Serum IGF-1
The number of serum IGF-1 samples measured for each of the four groups of
animals is shown in table 4.3.











26 28 29 25
Day 7 serum
Number of litters
3 3 3 3
Day 14 serum
Number of pups
30 32 29 20
Day 14 serum
Number of litters
3 3 3 3
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All control samples were within the recommended kit concentration range. Levene's
test for homogeneity at both 7 and 14 days was significant and this could not be
corrected by a transformation. Results from the one-way ANOVAs at day 7 and 14
are tabulated in tables 4.4 and 4.5 with the Levene p value reported. There are
limitations of using ANOVA in this situation but figures 4.8 and 4.9 illustrate clearly
why the variances were not equal.
Table 4.4: Day 7 results:-ANOVA Tests of Between-Subject Effects [dependent variable: serum
IGF-1] Levene p=0.000




Mean Square F Significance
Corrected Model 361967.785 4 90491.946 25.203 0.000*
Pup weight gain$ 37210.331 1 37210.331 10.364 0.002*
Oxygen concentration 8327.473 1 8327.473 2.310 0.131
Diet (9% or 18%) 50499.016 1 50499.016 14.065 0.000*
Gas/diet interaction 1203.821 1 1203.821 0.335 0.564
Error 369819.116 103 3590.477
Total 3914826.570 108
Corrected Total 731786.901 107
$ pup weight gain=(day 14 weight-birth weight)/birth weight
Table 4.5: Day 14 results:-ANOVA Tests of Between-Subject Effects [dependent variable:
serum IGF-1] Levene p=0.000




Mean Square F Significance
Corrected Model 472185.242 4 11 40.393 0.000*
Pup weight gain$ 114993.901 1 114993.901 39.349 0.000*
Oxygen concentration 1201.671 1 1201.671 0.411 0.523
Diet (9% or 18%) 18420.913 1 18420.913 6.303 0.014*
Gas/diet interaction 310.572 1 310.572 0.106 0.745
Error 309776.906 106 2922.424
Total 4053709.091 111
Corrected Total 781962.147 110
$ pup weight gain=(day 14 weight-birth weight)/birth weight
66
The ANOVAs (tables 4.4, 4.5) show a significant main effect for diet (9% or 18%)
and pup weight gain at both time points. The effect of oxygen concentration (air or
oxygen) is not significant. These findings are illustrated graphically in figures 4,8
and 4.9.
Figure 4.8: Effect of diet and gas on serum IGF-1 at pup day 7 of life
9% diet 18% diet
Variable Oz Room Air Variable 02 Room Air
Figure 4.9: Effect of diet and gas on serum IGF-1 at pup day 14 of life
9% diet 18% diet
Variable O, Room Air
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Non-parametric (Mann-Whitney) tests were carried out in order to confirm the
differences for the ANOVAs reported in tables 5 and 6 and to help explain why the
variances could not be made homogeneous. At both day 7 and day 14, oxygen
concentration did not have an effect on serum IGF-1 (p=0.45, p=0.848 respectively)
and diet had a significant effect on serum IGF-1 (p=0.000 for both).
4.4 Discussion
We have shown that a 9% low protein diet caused prenatal and postnatal growth
restriction in rat pups. Growth restricted rat pups had significantly larger retinal
avascular areas than normally grown rat pups (p=0.008) following exposure to both
room air and variable oxygen. This means that the area of the retina covered by
blood vessels was smaller in growth restricted pups and indicates that retinal
vascularisation was delayed. In addition, rat pups exposed to variable oxygen had
significantly larger avascular areas than rat pups exposed to room air (p=0.001) on
both diets. Growth restricted rat pups had significantly lower serum IGF-1 levels at
postnatal days 7 and 14 than normally grown pups (ANOVA test effect of diet on
IGF-1 p=0.000 day 7, p=0.014 day 14). Serum IGF-1 levels were associated with
pup weight gain (p=0.002 day7, p=0.000 day 14) meaning that pups gaining weight
more slowly had lower serum IGF-1 levels. Exposure to air or variable oxygen did
not influence serum IGF-1 levels.
The main advantage of the Edinburgh rat model of ROP is that it is physiological.
We did not observe neovascularisation in our model but we did observe significant
changes in the size of the avascular retinal areas. This is an important early stage in
retinal vascularisation because the longer the retina remains avascular, the more it is
at risk of abnormal neovascularistion. We therefore believe our model to be an
important model in which to study early retinal vascular changes that precede frank
neovascularistion characteristic of severe ROP. The model has previously shown that
pups exposed to the variable oxygen profile have larger retinal avascular areas and
our findings support this but demonstrate further that the largest avascular areas are
seen in growth restricted rat pups raised in variable oxygen. Growth restriction
together with variable oxygen hinders retinal vascularisation. The main disadvantage
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of our in vivo model is that it does not cause frank neovascularisation that is seen in
humans and other animal models of ROP [Smith et al, 1994; Penn et al, 1994],
Cunningham et al reported that the Edinburgh model caused development of
'neovascular tufts' but we were not able to visualise these in our experiments
[Cunningham et al, 2000]. One possible explanation for why frank
neovascularisation was not observed is due to rat strain differences. The incidence of
neovascularisation in oxygen exposed rats has been shown to be much higher in
Brown Norway rather than Sprague Dawley strains [Floyd et al, 2005].
Several animal models of intrauterine growth restriction (IUGR) have been
developed. These include nutritional manipulation, surgical uterine artery ligation,
hypoxia and drug induced methods [Holemans et al, 1998; Snoeck et al, 1990;
Barker, 1990; Woodall et al, 1996; Wigglesworth, 1964; de Grauw et al, 1986;
Benediktsson et al, 1993; Langley-Evans et al, 1994; Hohmann et al, 1992]. We
chose to give the low protein diet from day 15 gestation as this has been shown to
cause late gestation impairment of truncal growth with little effect on brain growth
[Langley-Evans and Nwagwu, 1998]. IUGR in humans is most commonly
asymmetrical, occurring in the last trimester as a result of a failing placenta.
Premature infants have an increased metabolic rate and have a high protein loss in
the early couple of days of life [Denne, 2001]. The diet of preterm infants in
intensive care is also high in fat and carbohydrate and low in protein [Vasu and
Modi, 2007], We therefore felt that this model most closely mimicked the human
clinical situation. The rat low protein nutritional model causes reduced substrate
delivery to the fetoplacental unit, decreased uteroplacental blood flow and reduction
in total milk volume during lactation. These all hamper neonatal rat pup growth
[Holemans et al, 1998].
We have shown that growth restricted rat pups had larger avascular areas following
exposure to both room air and variable oxygen than normally grown pups. We have
also shown that growth restricted rat pups had significantly lower levels of serum
IGF-1 at postnatal days 7 and 14. These associations reflect the clinical observations
in human preterm infants that slow postnatal growth is associated with low serum
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IGF-1 levels and an increased risk of developing ROP [Lofqvist et al, 2006; Wallace
et al, 2000; Allegaert et al, 2003], Unfortunately we were not able to relate
individual rat pup retinas to the corresponding pup serum IGF-1. This was due to
technical difficulties in retinal dissection, staining and in some cases low volume of
serum obtained. Nutrition is a key regulator of IGF-1 production in both pre- and
postnatal life [Davenport et al, 1990]. It has previously been shown that restriction in
protein intake in humans and animals leads to a significant reduction in serum
concentration of IGF-1 and IUGR [Woodall et al, 1996]. Our findings support this
and we postulate that serum IGF-1 concentration may have a direct effect on retinal
vascularisation with a low serum IGF-1 being associated with slower retinal vascular
development.
Vanhaesebrouck et al carried out a very similar set of experiments to ours except
they studied the effect of postnatal rat pup growth restriction [Vanhaesebrouck et al,
2009], They raised pups in small or large litters and measured body weight, serum
IGF-1, retinal avascular area and number of neovascular nuclei. They found that in
smaller litters, mice were heavier with higher serum IGF-1 levels and less
neovascularisation. Like us they found that body weight influenced serum IGF-1.
They did however also find that IGF-1 strongly correlated with the percentage
avascular area (r=0.53; p<0.0001) and with the number of neovascular nuclei
(r=0.53; p<0.0001). This supports our theory that serum IGF-1 levels have a direct
effect on normal retinal blood vessel development. Vanhaesebrouck et al also gave
the mice a single dose of exogenous IGF-1 and this had a profound effect by
improving body weight, increasing endogenous IGF-1 levels and reducing
neovascularisation (p=0.00001) [Vanhaesebrouck et al, 2009]. Holmes et al also
studied the effect of postnatal growth restriction (induced by raising pups in large
litters) on retinal vascularisation and found that growth retarded pups developed
more severe abnormal retinal neovascularisation [Holmes et al, 1996].
There is now a wealth of data supporting the importance of IGF-1 in normal and
abnormal retinal vascularisation but the mechanisms behind how IGF-1 affects
retinal vascularisation are still being described [Hellstrom et al, 2003; Hellstrom et
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al, 2001; Hellstrom et al, 2004; Lofqvist et al, 2006]. Hypoxia-inducible factor-la
(HIF-la) is a key oxygen dependent transcription factor but can also be activated in
an oxygen-independent way. IGF-1 has been shown to act though a
posttranscriptional mechanism to cause HIF-la accumulation, nuclear translocation
and increased activity [Treins et al, 2005]. IGF-1 stimulates HIF-la activity through
signalling pathways that lead to vascular endothelial growth factor (VEGF) mRNA
expression. It appears likely that hypoxia and IGF-1 lead to HIF-la activation and
downstream VEGF expression by independent signalling pathways which act
together to cause the neovascularisation seen in ROP [Treins et al, 2005], IGF-1 has
also been shown to have a direct effect on VEGF. A low level of IGF-1 has been
shown to prevent the in vitro activation of VEGF-induced protein kinase B (Akt),
which is a critical kinase involved in endothelial cell survival [Hellstrom et al, 2001].
It remains likely however that the fine balance of normal retinal blood vessel
development versus frank neovascularisation is a sophisticated interplay of multiple
components and pathways although the effects of IGF-1 on HIF-la and VEGF
appear to be key interactions.
Although unlikely, it also remains possible that our observed larger avascular areas
in the growth restricted pups may not be related to serum IGF-1 levels at all. It is
possible that the serum IGF-1 levels are just a reflection of body weight and have no
interaction with retinal blood vessel development. Other possible mediators for the
observed association between growth restriction and blood vessel development are
the glucocorticoids. Feeding of a low protein diet during pregnancy in the rat is
associated with increased fetal glucocorticoid exposure and effects on the structure
and function of the endocrine pancreas in the pups [Holemans et al, 1998; Snoeck et
al, 1990; Langley-Evans and Nwagwu, 1998]. Glucocorticoids are powerful
biological molecules and have been implicated in the prenatal programming of
hypertension and impaired glucose tolerance in later life [Langley-Evans and
Nwagwu, 1998], Their receptors are highly expressed in most fetal tissues and
therefore they may also be involved in retinal vascular development [Holemans et al,
1998], Whether they play a role in the pathogenesis of ROP remains poorly
understood.
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Our animal model has been a useful tool in trying to further understand and describe
the association between growth restriction, IGF-1 and ROP. However, necessary
caution is required when extrapolating our findings to the clinical situation. It is very
likely that rat dam hormonal milieu, placental function and fetal response to growth
restriction is different to human response.
4.5 Summary
We have demonstrated that growth restricted rat pups have larger retinal avascular
areas than normally grown pups. Rat pups exposed to a variable oxygen profile also
have larger retinal avascular areas than pups exposed to room air. Larger retinal
avascular areas infer less retinal blood vessel coverage. These findings have
important clinical implications and are consistent with our clinical observation that
small-for-gestational age infants are more likely to develop severe ROP. In the
premature infant, the longer the retina takes to vascularise, the more at risk the infant
is of developing ROP.
We also demonstrated that growth restricted rat pups had significantly lower serum
IGF-1 levels at postnatal days 7 and 14 than normally grown pups. Serum IGF-1
levels were influenced by pup weight gain. We hypothesise that serum IGF-1
concentration may have a direct effect on retinal vascularisation in our rat model of
ROP, with a low serum IGF-1 being associated with slower retinal vascular
development.
Further research is required into nutritional therapies which may improve retinal
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5.1 Introduction
The purpose of retinopathy of prematurity (ROP) eye screening examinations is to
identify premature infants with potentially sight-threatening disease. Early detection
and treatment of these infants with laser photocoagulation has been shown to
significantly reduce the incidence of severe visual loss [Early Treatment For
Retinopathy Of Prematurity Cooperative Group, 2003]. Current UK guidelines
recommend that all infants with birth weight (BW)<1501g and/or gestational age
(GA)<32 weeks are screened for ROP [Royal College of Paediatrics and Child
Health, 2008],
The conventional gold standard screening technique is binocular indirect
ophthalmoscopy (BIO) with eyelid speculum and scleral indentation. This is a
technically difficult procedure and must be performed by an experienced
ophthalmologist. In the developed world, adequate ophthalmic expertise is often
confined to larger regional neonatal units. It is therefore difficult to provide adequate
ROP screening to infants at remote centres. Screening with BIO is even more
difficult to implement in 'middle income' countries, where there is currently an
epidemic of ROP, which is due in part to the paucity of adequately trained specialists
to deliver the service [Gilbert, 2008].
Wide field digital retinal imaging (WFDRI) with eyelid speculum is an alternative
screening technique. The digital camera system (RetCam II, Clarity Medical
Systems, Pleasanton, California) captures images of the retina which are stored for
interpretation. With the advent of 'store and forward' telemedicine, this is an
attractive screening tool as trained staff can capture retinal images which can be
interpreted by a remote ophthalmologist [Chiang et al, 2007; Ells et al, 2003; Lorenz
et al, 1999; Roth et al, 2001], The remote ophthalmologist may be based at a
regional or national or even international centre. WFDRI is being developed as a tool
for future clinical trials and there is therefore a need to validate WFDRI against BIO.
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We have carried out a masked, double-observer prospective randomised comparison
of WFDRI and BIO in a consecutive series of ROP screening examinations in our
neonatal unit.
5.2 Aim
To compare the diagnostic accuracy of WFDRI with the current 'gold standard' of
BIO for ROP screening examinations.
5.3 Methods
This was a prospective, randomised, comparative study. The Lothian Research Ethics
Committee (LREC) approved the study. All parents gave informed consent.
5.3.1 Study population
Consecutive infants undergoing routine ROP screening at Edinburgh Royal Infirmary
Neonatal Unit were eligible for inclusion in the study. At this centre, all infants born
with GA<32 weeks and/or BW <1500g have their eyes screened for ROP. Patients
were recruited from June 2004 to May 2007.
5.3.2 Examination Schedule
Screening was carried out by two experienced paediatric ophthalmologists (Dr Brian
Fleck and Dr Elizabeth Wright). Infants were first examined at a chronological age
of 4-6 weeks or corrected age of 34 weeks, whichever was earlier. Screening was
continued fortnightly if no ROP was present and weekly if any ROP was seen.
Screening continued until the retina was normally vascularised into zone 3, the infant
required treatment or until the infant was transferred to an outlying hospital. On each
screening occasion, study infants had both eyes examined by both BIO and WFDRI.
The study coordinator (Dr Catharine Dhaliwal) randomised both examiners to
screening using either BIO or WFDRI and also randomised the order in which the
examinations were to be carried out. Randomisation was carried out for each
examination using sealed envelopes.
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5.3.3 Examination Technique
Pupils were dilated with topical phenylephrine 2.5% and tropicamide 0.5% applied
60 minutes and 30 minutes prior to the eye examination. One drop of oxybuprocaine
0.4% was applied to each eye immediately prior to examination. BIO was performed
using a 28 dioptre lens. A lid speculum and scleral indenter were used. WFDRI
images were recorded with the RetCam II Digital Retinal Camera (Clarity Medical
Systems) with the neonatal nose cone. A lid speculum was used and polyacrylic acid
gel (viscotears) was applied to the anaesthetised cornea before capturing the images.
The study coordinator timed how long each eye examination took from the insertion
of the eyelid speculum to its removal at the end of the examination. All examinations
were performed with cardiac and oxygen saturation monitoring. The examinations
were interrupted if an infant's heart rate or oxygen saturation decreased to an
unacceptably low level and recommenced once these had stabilised.
5.3.4 Clinical Findings
Both examiners graded retinopathy according to The International Classification of
ROP [The International Classification of ROP revisited, 2005]. The stage of ROP,
zone of vascularisation, number of clock hours of ROP and presence or absence of
'plus' disease was documented. 'Plus' disease represented significant dilatation and
tortuosity of posterior pole blood vessels meeting or exceeding that of a standard
photograph [The International Classification of ROP revisited, 2005]. 'Threshold'
ROP, as defined in the CRYO-ROP trial referred to stage 3 ROP in zone 1 or 2 of 5
or more contiguous or 8 or more cumulative clock hours in the presence of 'plus'
disease [Cryotherapy for ROP cooperative group, 1988], All eyes with 'threshold'
ROP were treated with diode laser therapy from June 2004-December 2004. From
January 2005, new treatment criteria were used following the publication of the
ETROP study [Early Treatment For Retinopathy Of Prematurity Cooperative Group,
2003], Eyes with type 1 ROP were treated and both eyes were treated.
5.3.5 Examination documentation and management plans
Each examiner documented their findings in separate books and remained masked to
the other examiner's findings and to their own findings from previous weeks. Based
on their findings, each examiner documented a management plan, which was to
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discharge the infant, treat the infant or examine the infant again in either 1 or 2
weeks time. The study coordinator read each examiners management plans. If there
was any difference in management plan then the infant was seen again the following
week. This continued until both management plans were the same. If a decision to
treat was reached using BIO but not using WFDRI then the infant was seen the
following week. If the infant still warranted treatment the following week as judged
by BIO then the infant was treated even if a discrepancy remained with the WFDRI
management plan. The study coordinator was present at all examinations to ensure
that examiners remained masked to each other's findings.
5.3.6 Standardisation of examiners
The two specialised paediatric ophthalmologists have worked together using BIO to
perform all ROP eye screening examinations in the Lothian region since 1990. In
order to measure interobserver agreement, the examiners independently analysed
RetCam images from 81 clinical ROP screening examinations from the study. The
stage of ROP seen, the presence or absence of plus disease and the location of the
disease were documented.
5.3.7 Data interpretation and statistical method
For each eye examined by BIO and WFDRI, the highest stage of ROP, the presence
or absence of plus disease and the management plan were recorded and used for
analysis. The WFDRI findings were compared to those of the current 'gold standard'
of BIO and the sensitivity and specificity, together with 95% confidence intervals,
were calculated. The WFDRI management plan reached for each infant after both
eyes were examined was compared with the plan from the 'gold standard' BIO by
calculating the kappa value as a marker of technique agreement.
5.4 Results
5.4.1 Patients and study examinations
A total of 81 babies were recruited from May 2004 to June 2007. The median
gestational age at birth of study infants was 29 weeks (interquartile range 27 to 31)
and median birth weight was 1225 grams (interquartile range 878 to 1492). A total of
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123 eye examinations on both eyes were carried out (246 eyes examined in total). On
one occasion it was not possible to obtain adequate quality images from one eye
using WFDRI. Findings from 245 eyes were therefore analysed. 54 infants
contributed one examination, 20 infants contributed two examinations, 3 infants
contributed three examinations, 2 infants contributed four examinations, 1 infant
contributed five examinations and 1 infant contributed seven examinations on both
eyes. Not every examination of every infant was included as study examinations
could not be performed when one examiner was unavailable. In this cohort, BIO
detected 24 infants who developed ROP (24/81, 30%) and 5 infants (5/81, 6%) that
required treatment. On 63/123 examinations BWF used WFDRI and EW used BIO.
5.4.2 Standardisation of examiners
The two examiners demonstrated 95% agreement (95% CI 91 to 98) on the presence
or absence of plus disease, 94% agreement on stage of ROP (95% CI 91 to 98) and
97% agreement (95% CI 95 to 99) on the zone of ROP following the independent,
masked scoring of 81 RetCam images. In addition, the study data were analysed for
systematic bias between the two examiners in each diagnostic category, for BIO and
for WFDRI. There were no significant systematic differences in any diagnostic
category, using the Fisher exact test (table 5.1).











5 5 7 4
Stage 3 ROP
(number of eyes)
7 7 6 7
Any ROP
(number of eyes)
26 19 25 21
Treat
(number of infants)
3 3 4 3
Discharge
(number of infants)
35 34 31 31
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5.4.3 Detection of disease
The detection of any stage of ROP, stage 3 disease and plus disease is shown in
tables 5.2-5.4.
Table 5.2: Detection of any stage of ROP
BIO ROP present BIO no ROP
WFDRI ROP present 27 19
WFDRI no ROP 18 181
Sensitivity=60% (44-74%). Specificity=91% (86-94%)
Table 5.3: Detection of stage 3 disease
BIO stage 3 present BIO no stage 3 disease
WFDRI stage 3 present 8 5
WFDRI no stage 3 disease 6 226
Sensitivity=57% (29-82%). Specificity=98% (95-99%)
Table 5.4: Detection of plus disease
BIO plus present BIO no plus
WFDRI plus present 8 5
WFDRI no plus 2 230
Sensitivity=80% (44-97%). Specificity=98% (95-99%)
5.4.4 Proportional agreement
The proportional agreement of the two examination methods is shown in table 5.5.
Table 5.5: Proportional agreement of WFDRI and BIO
Outcome Proportional agreement
Detection of any stage of ROP 0.85
Detection of stage 3 disease 0.96
Detection of 'plus' disease 0.97
The proportional agreement is represented by the number of times that BIO and WFDRI
concur divided by the total number of examinations.
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5.4.5 Patient management decisions
Following the eye examination, each examiner decided a management plan for the
infant choosing one out of three possible outcomes- treat the infant, discharge the
infant or review the infant in 1 or 2 weeks time. The kappa value for agreement on
management decisions between the WFDRI and BIO was 0.85 which is very good
agreement. Details of decisions to treat and discharge are given in tables 5.6 and 5.7.
Table 5.6: Decision to treat an infant
BIO treated BIO not treated
WFDRI treat 5 2
WFDRI not treat 1 115
Table 5.7: Decision to discharge an infant
BIO discharged BIO not discharged
WFDRI discharge 56 5
WFDRI not discharge 14 48
On two occasions the WFDRI management decision was to treat the infant while the
BIO decision was not to treat. One infant was re-examined the following week and
both WFDRI and BIO agreed that treatment was required. The second infant was re¬
examined the following week using BIO only (one examiner was absent) and was not
treated.
On one occasion the BIO decision was to treat the infant while the WFDRI decision
was not to treat. The documented clinical findings for this individual case showed
that the infant was borderline for treatment. When this infant was re-examined one
week later both BIO and WFDRI agreed that treatment was required.
On five occasions the WFDRI decision was to discharge the baby and the BIO was to
perform a further examination. On re-examination the following week there was
agreement between WFDRI and BIO in two cases. The remaining three infants had
left the study due to transfer back to local hospitals and detailed retinal examination
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findings were unknown. However it was known that no infant subsequently required
treatment. On fourteen occasions the BIO decision was to discharge the infant and
WFDRI disagreed. There was agreement on management plan within one week in
seven cases and two weeks in one case. We do not have information on five infants
who left the study due to transfer back to local hospitals. It was known that none of
these infants subsequently required treatment.
5.4.6 Time taken to complete an examination
The median time taken for WFDRI examination of both eyes was 110 seconds
(interquartile range 80 to 133). The median time taken for BIO of both eyes was 90
seconds (interquartile range 65 to 120). Examinations using BIO were significantly
quicker (Mann Whitney p=0.005).
5.5 Discussion
We compared the ability of WFDRI to detect ROP and guide patient management
decisions compared to the current gold standard of BIO. We found the sensitivity of
WFDRI in detecting any ROP, stage 3 ROP and plus disease to be 60%, 57% and
80% respectively with a specificity of 91%, 98% and 98% respectively. There was
excellent proportional agreement between the two screening modalities for detecting
stage 3 ROP and plus disease (0.96 and 0.97) and very good agreement on
management decisions (kappa value 0.85).
There have been a number of other studies comparing the performance of WFDRI
and BIO for ROP screening. These studies have used similar methodology whereby
the same or different examiners perform WFDRI and BIO imaging on an infant on
the same or different screening occasions. The stored WFDRI images are then
anonymised and interpreted by either the study examiner or another specialist. One
of the key strengths of our study lies in the methodology as we present, to our
knowledge, the first masked, double-observer prospective randomised comparison of
WFDRI and BIO for ROP examinations.
Previous studies have, like us, reported lower sensitivities and higher specificities for
disease detection. Roth et al found 82% sensitivity and 94% specificity of WFDRI
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compared with BIO for detecting any stage of ROP [Roth et al, 20011. Shah et al
found 86% sensitivity and 92% specificity of WFDRI compared with BIO in
detecting any stage of ROP and no case of threshold ROP was missed with WFDRI
[Shah et al, 2006]. Yen et al used WFDRI to attempt to predict which eyes would
develop threshold disease by evaluating WFDRI images at two distinct gestational
time points [Yen et al, 2002], Low sensitivities and high specificities were recorded
for detecting various stages of ROP. The authors of these three studies thought their
lower sensitivities were due in part to the technical difficulties encountered using a
standard child lens attachment for the screening examinations. A specialised smaller
neonatal nose cone has now been developed which we used in our study.
Despite using the neonatal nose cone, our ophthalmologists still reported technical
difficulties in imaging the peripheral retina using WFDRI. Both ophthalmologists
agreed that visualisation of the peripheral retina was easier and more complete using
BIO rather than WFDRI. The stages of ROP are predominantly present in zones 2
and 3 which are more peripheral than posterior zone 1. This may explain our low
sensitivities of WFDRI for detection of any stage of ROP and stage 3 ROP (60%,
57%) as this disease is likely to be located peripherally and therefore technically
more difficult to capture using WFDRI. However, other studies using the neonatal
nose cone have reported higher sensitivities for WFDRI detection of any stage of
ROP.
The results from the ETROP study have led to changes in clinical ophthalmology
practice worldwide [Early Treatment For Retinopathy Of Prematurity Cooperative
Group, 2003]. This study identified plus disease as the new driver for ROP treatment.
All eyes in which 'plus' disease is present (type 1 disease) should be treated for
optimal visual outcomes. Therefore, any potential screening modality must be good
at detecting 'plus' disease. 'Plus' disease is located in the posterior retina and
WFDRI is particularly effective at imaging this region. We found that WFDRI was
better at detecting plus disease (sensitivity 80%) than detecting stages of ROP. Other
studies have reported much higher sensitivities for detecting 'plus' disease using
WFDRI. Ells et al and Wu et al reported a sensitivity of 100% using WFDRI to
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detect 'referral warranted' ROP (any zone 1 disease, 'plus' disease or stage 3
disease) [Ells et al, 2003; Wu et al, 2006]. Lorenz et al also reported a sensitivity of
100% for detecting suspected treatment ROP (type 1 ROP according to ETROP)
using WFDRI in a large cohort of 913 infants [Lorenz et al, 2009]. The Stanford
University Network for Diagnosis of ROP (SUNDROP) study also found a
sensitivity of 100% for WFDRI detection of ROP that required treatment [Murakami
et al, 2009].
Our calculated specificities for using WFDRI to detect ROP were very high and our
calculated sensitivities were lower. We studied a consecutive series of infants and
stage 3 ROP and plus disease were uncommon in our study population. This meant
that a discrepancy in detection of disease between WFDRI and BIO in just one case
led to a marked reduction in sensitivity with minimal change in specificity.
Although the sensitivity and specificity ofWFDRI in detecting ROP is important, the
management decisions made in light of viewing the images are critical. In our study,
all cases judged to require treatment following BIO examination were identified with
WFDRI. One infant, with borderline findings, was thought to require treatment
following BIO but not following WFDRI. However, one week later a decision to
treat was made by both observers. In our study the sensitivity of WFDRI in making
treatment decisions was therefore 100%, allowing for a repeat examination after one
week. Interestingly, following WFDRI a management decision on two occasions was
to treat the infant a week before BIO examination resulted in a management decision
to treat. Ells et al found that severe ROP was diagnosed by WFDRI at least 1 week
before BIO in 43% of eye examinations [Ells et al, 2003].
In our study there were 14 occasions when the management plan to discharge an
infant was reached using BIO but not reached using WFDRI. This was likely due to
better visualisation of the peripheral retina and hence better visualisation of normal
vascularisation into zone 3 using BIO than WFDRI. This suggests that BIO is
superior to WFDRI in making decisions to discharge infants from ROP screening.
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The quality of the images obtained and technical usability of WFDRI has been
reported to be variable. Wu et al failed to interpret 21% of screening examinations
due to poor image quality, necessitating referral for BIO [Wu et al, 2006]. Ells et al
failed to perform WFDRI on 4% of infants due to technical difficulties [Ells et al,
2003]. Motion artefact is also a well documented problem when using WFDRI. In
the multi-centre Photo-ROP study, 8% of image sets were uninterpretable [The
photographic screening for ROP study, 2008]. We encountered minimal problems
with our ophthalmologists failing to obtain only one adequate quality WFDRI eye
examination (1/246 eyes: 0.4%).
We found that WFDRI took longer to perform than BIO (median time WFDRI 110s
vs. BIO 90s). This may change as examiners become more experienced and familiar
with WFDRI. Some centres have developed a protocol for WFDRI for ROP and this
again may help reduce WFDRI examination time.
5.6 Summary
We have carried out a masked, double-observer prospective randomised comparison
to determine the sensitivity and specificity of WFDRI in detecting and making ROP
management decisions, compared to the current gold standard of BIO. WFDRI
showed relatively poor sensitivity for detecting mild forms of ROP located in the
peripheral retina but was more effective at detecting 'plus' disease in the posterior
retina. WFDRI correctly identified all infants that required laser therapy for ROP.
BIO was superior to WFDRI in making decisions to discharge infants from the
screening programme. As a result of our study, our ROP screening practice has
changed in our neonatal unit. WFDRI is currently used for ROP screening
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6.1 Introduction
Extremely preterm infants need regular screening for the early detection of
retinopathy of prematurity (ROP) and the successful prevention of its blinding end
stage [Royal College of Paediatrics and Child Health, 2008], The mainstay of
screening is binocular indirect ophthalmoscopy (BIO) with eyelid speculum and
scleral indentation which improves examination of the peripheral retina [Dhillon et
al, 1993]. It is recognised as being an uncomfortable and distressing procedure and
topical anaesthesia should be applied immediately prior to screening [Royal College
of Paediatrics and Child Health, 2008]. Comfort care (using pacifiers, sucrose or
nesting) is used more variably, although evidence suggests that this can ameliorate
the pain [Kleberg et al, 2008; Gal et al, 2005; Mitchell et al, 2004], Systemic
analgesia is not normally given.
The use of the digital retinal camera for wide-field digital retinal imaging (WFDRI)
has been suggested as a replacement for BIO. WFDRI can be carried out by less
specialist staff with the help of experts for interpretation using telemedicine. It has
been suggested that WFDRI may be less painful than BIO [Mukheijee et al, 2006].
Chapter 5 reports on our randomised comparison of the diagnostic accuracy of
WFDRI with BIO. We designed, as part of our investigation, a study to compare the
pain effects of both BIO and WFDRI screening processes and this chapter describes
the findings.
6.2 Aim
To compare the pain experienced by premature infants undergoing WFDRI and BIO
for ROP screening.
6.3 Methods
This was a prospective, randomized, comparative study. Ethical approval was
granted by the Lothian Research Ethics Committee and all parents gave written
consent.
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6.3.1 Subjects and study design
All infants recruited required routine ROP screening at Edinburgh Royal Infirmary
Neonatal Intensive Care Unit between June 2004 and May 2007. Infants were
excluded if they were requiring mechanical ventilation or analgesic medication or if
they had moderate/severe neurological impairment (grade3/4 intraventricular
haemorrhage or periventricular leukomalacia) as it was felt that these infants would
respond differently to painful stimuli. Infants were examined by two experienced
paediatric ophthalmologists (BF and EW). Only the first screening examination for
each baby was included in this study. Infants had both eyes examined by both
WFDRI and BIO. The study coordinator (CD) randomised both examiners to
screening using either WFDRI or BIO and also randomised the order in which the
examinations were to be carried out. The right eye was always examined first.
6.3.2 Eye examinations
Infants had their pupils dilated with topical phenylephrine 2.5% and tropicamide
0.5% applied 60 minutes and 30 minutes prior to eye examination. Infants were then
handled minimally and were not exposed to painful procedures unless medically
indicated. One drop of oxybuprocaine 0.4% was applied to each eye immediately
prior to each eye examination. Infants were examined on a cot blanket. They were
unswaddled and non-nested. The study coordinator held the infants arms gently
across their chests and steadied their heads during both examinations. Pacifiers were
not used and oral sucrose was not given. A lid speculum (Barraquer Oosterhuis child
speculum) and scleral indenter (Schokett style paediatric scleral depressor) were
routinely used during BIO. WFDRI images were taken using the digital retinal
camera (RetCam II, Clarity Medical Systems) with the neonatal nose-cone. The same
type of lid speculum was used but scleral indentation was not routinely performed.
After the first examination by the first examiner, the infant was handled minimally
and allowed to recover for at least 30 minutes, to allow physiological variables to
return to baseline prior to undergoing the second eye examination. All infants had
constant cardiac and oxygen saturation monitoring.
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6.3.3 Pain Monitoring and data interpretation
The Premature Infant Pain Profile (PIPP) scoring system (table 6.1) was used
[Stevens et al, 1996]. Infants were observed for 15 seconds immediately prior to each
eye examination (before insertion of oxybuprocaine eyedrops) and their baseline
heart rate, oxygen saturation and behavioural state was noted. During the first minute
of the right eye examination the maximum and minimum heart rate and minimum
oxygen saturation of the infants were documented. The facial features of every infant
were video-recorded and videotapes were later reviewed by an independent observer
(KD) who scored the facial features during the first minute of BIO and WFDRI
according to the PIPP. KD could not be blinded to the type of examination. The PIPP
scores, heart rates and oxygen saturations for WFDRI and BIO were compared using
paired t tests generated from the GraphPad InStat program. Fisher's Exact Test was
used to compare the occurrence of marked bradycardias and desaturations. A p-value
<0.05 was taken to indicate statistical significance.
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Table 6.1:PIPP scoring system [Stevens etal, 1996].
Indicator Finding Points
Gestational age >/=36 weeks 0
32 weeks-35 weeks 6 days 1
28 weeks-31 weeks 6 days 2
<28 weeks 3
Behavioural state active/awake eyes open facial movements 0
quiet/awake eyes open no facial movements 1
active/sleep eyes closed facial movements 2
quiet/sleep eyes closed no facial movements 3
Heart rate maximum 0-4 beats per minute increase 0
5-14 beats per minute increase 1
15-24 beats per minute increase 2
>/= 25 beats per minute increase 3
02 saturation minimum 0-2.4% decrease 0
2.5-4.9% decrease 1
5.0-7.4% decrease 2
7.5% decrease or more 3
Brow bulge none {<1=9% time) 0
minimum (10-39% time) 1
moderate (40-69% time) 2
maximum {>1=10% time) 3
Eye squeeze none {<1=9% time) 0
minimum (10-39% time) 1
moderate (40-69% time) 2
maximum {>1=10% time) 3
Nasolabial furrow none {<1=9% time) 0
minimum (10-39% time) 1
moderate (40-69% time) 2
maximum {>1=10% time) 3
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6.4 Results
A total of 81 infants were recruited to our WFDRI/BIO diagnostic comparative trial.
Inadequate quality video-recordings were obtained from four infants and one infant
was excluded as he had periventricular leukomalacia. Therefore, a total of 76 infants
were included in this study of whom 39 received BIO first and 37 WFDRI first. The
baseline characteristics of the study population are shown in table 6.2. There were 40
male infants and 36 females. A total of 50 infants were breathing room air, 13 infants
had nasal prong oxygen and 13 infants were having nasal continuous positive airway
pressure with oxygen.
Table 6.2: Baseline characteristics of the study population
Mean (range)
Gestational age (weeks) 28.6 (24-35)
Corrected gestational age at ROP examination (weeks) 34.1 (30-40)
Birth weight (grams) 1208 (610-1970)
Number of days intubated and ventilated 4.6 (0-45)
Number of days of morphine 0.2 (0-5)
Table 6.3 shows details of infants' heart rates and oxygen saturation levels before
and during both eye examinations. There were no differences in baseline levels
between the two groups. The mean PIPP score for WFDRI was 15.0 (SD 2.1) and
mean PIPP score for BIO was 15.2 (SD 2.4). There was no statistically significant
difference in PIPP scores (paired t test p=0.47).





Baseline heart rate (bpm) 148 (13) 147 (14)
Minimum heart rate during examination (bpm) 134 (25) 133 (28)
Maximum heart rate during examination (bpm) 168 (18)* 172 (17)*
Baseline oxygen saturation (%) 96 (4) 96 (4)
Minimum oxygen saturation during examination (%) 87 (12) 88 (10)
* Statistically significant difference comparing BIO and WFDRI maximum heart rates
(paired t test p=0.03)
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We observed a significantly greater increase in heart rate during WFDRI than during
BIO (p=0.03). During WFDRI, 8 infants had a marked bradycardia (HRclOObpm)
and 11 infants had a marked desaturation (min 02 sat <80%). During BIO, 9 infants
had a marked bradycardia and 15 infants had a marked desaturation. There was no
statistically significant difference in occurrence of marked bradycardias (Fisher's
Exact Test p=l.00) or marked desaturations (Fisher's Exact Test p=0.52) during the
two examination techniques.
6.5 Discussion
This study, where infants received BIO and WFDRI, demonstrates that ROP eye
screening is painful but the pain experienced is similar for both techniques.
The PIPP was chosen as it is a well validated method for measuring procedural pain
in preterm infants and uses contextual indicators (gestational age and behavioural
state), physiological indicators (heart rate and oxygen saturation) and behavioural
indicators (brow bulge, eye squeeze and nasolabial furrow) in its calculation [Stevens
et al, 1996], The major drawback of using the PIPP score in this setting is that it only
takes into account an increase in heart rate but bradycardia during eye screening can
occur due to the oculocardiac reflex [Clarke et al, 1985]. We therefore additionally
recorded the minimum heart rates during all examinations but there was no
significant difference between the two screening methods.
Several studies have investigated the systemic effects of ROP screening using BIO
by measuring physiological markers (heart rate, oxygen saturation and blood
pressure) [Belda et al, 2004; Rush et al, 2004; Laws et al, 1996]. Laws et al report a
median drop in oxygen saturation of 3% with a rise in heart rate of 7 beats per minute
during BIO [Laws et al, 1996], Rush et al also recorded a significant increase in
heart rate and fall in oxygen saturation levels during the procedure [Rush et al,
2004]. Our results too show a reduction in oxygen saturation and increase in heart
rate during both screening methods. In addition to studying physiological and
behavioural parameters, Kleberg et al measured a biochemical parameter (salivary
Cortisol) during and after ROP eye screening using BIO [Kleberg et al, 2008]. Infants
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were randomly assigned to receiving either Newborn Individualized Developmental
Care and Assessment Program (NIDCAP) care or standard care during ROP
screening examinations. They found no difference in physiological parameters or
PIPP scores between the two care strategies during eye examination but lower
salivary Cortisol levels 60 minutes after examination in the infants receiving
NIDCAP care, thus implying a faster recovery for these infants. It would be
interesting to compare Cortisol levels in infants undergoing BIO with infants
undergoing WFDRI.
Mukherjee et al compared only cardiorespiratory parameters as a measure of distress
during ROP screening using both BIO and WFDRI [Mukherjee et al, 2006]. In
contrast to our study, they found a significantly higher increase in heart rate and
respiratory rate in the group undergoing BIO than those undergoing WFDRI. This
finding may be related to differences in our study populations and examination
techniques and lack of randomisation in their study could have led to significant
baseline variations and selection bias. Mehta et al carried out a pilot crossover study
in a small cohort of twelve infants comparing WFDRI, BIO with speculum and BIO
without speculum [Mehta et al, 2005]. They studied both physiological and
behavioural parameters and although the cohort was too small to draw absolute
conclusions, infants undergoing WFDRI and BIO with speculum had more
pronounced changes than with BIO without speculum. Kirchner et al compared pain
scores and heart rates in a cohort of 92 infants who underwent either BIO with
speculum and scleral indentation or BIO with no speculum and no scleral
indentation. They also found that BIO without speculum and without scleral
indentation was less stressful for the infants [Kirchner et al, 2009].
While carrying out this study we observed that infants immediately started crying
with corresponding physiological changes as soon as the eyelid speculum was
inserted and crying stopped on speculum removal. As both WFDRI and BIO require
speculum use to obtain optimal retinal views we propose that the speculum, rather
than the examination method may contribute most to the pain experienced. As
discussed, other groups have also reported marked physiological responses
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associated with speculum insertion [Mehta et al, 2005; Kirchner et al, 2009] and
Slevin et al report marked neurobehavioral changes associated with speculum
withdrawal [Slevin et al, 1997], Perhaps more investigation should be directed to
examination techniques that do not require the use of a speculum, or to improved
speculum design and insertion technique. We are currently investigating the use of a
small, relatively malleable Barraquer-style single-use neonatal speculum that can be
slightly bent prior to use in order to set the blades closer together or wider apart in
order to accommodate differing palpebral aperture sizes (Malosa Medical 7.00 mm
closed blade, 0.8 mm wire; Malosa, Sowerby Bridge, UK).
Observations of infants undergoing eye screening by both WFDRI and BIO indicate
that, despite use of topical anaesthesia and comfort care, these procedures remain
painful and distressing for neonates [Sun et al, 2010]. Many extremely preterm
infants need to be screened over a number of weeks. Exposure to repeated painful
procedures has been shown to have long-term detrimental consequences [American
Academy of Pediatrics, 2000]. These include neuroanatomical abnormalities, altered
pain sensitivity, emotional, behavioural and learning disabilities [Oberlander et al,
2000; Ruda et al, 2000; Anand et al, 1999; Porter et al, 1999; Anand and Scalzo,
2000; Fitzgerald and Beggs, 2001; Maroney, 2003], Effective analgesia can reduce
altered pain sensitivity [Grunau et al, 2001; Peters et al, 2003]. Neonatal staff have
an ethical obligation to minimize pain in neonates. There is an urgent need for
studies to evaluate the use of different systemic analgesia regimes in order to
optimise pain control during ROP screening.
6.6 Summary
This study demonstrates that ROP eye screening using both WFDRI and BIO with
eyelid speculum and topical anaesthesia is painful for infants but the pain
experienced is of a similar severity for both techniques. Further work is required to





7.1 Summary of findings
7.1.1 Incidence of retinopathy of prematurity in Lothian, Scotland
Lothian population data showed a steady decline in the number of live births from
1990-2004. The proportion of babies born with birth weight (BW) <1500g and/or
gestational age (GA) <32 weeks remained constant (p=0.271 using chi-square test),
though the proportion of these babies surviving to 42 weeks corrected gestation
increased from 1990-2004 (p<0.001 using chi-square test for trend). There was a
statistically significant linear trend towards a reduction in the number of babies
undergoing treatment for retinopathy of prematurity (ROP) throughout the study
period (p<0.01 using chi-square test for trend). A reduction in the incidence of any
degree of ROP and severe (stage 3 or greater) ROP was also observed although this
did not reach statistical significance.
In summary, there was a significant increase in survival of infants with BW<1500g
and/or GA<32weeks together with a significant reduction in the number of infants
treated for ROP in the Lothian region of South East Scotland from 1990-2004.
7.1.2 ROP in small-for-gestational age infants
A total of 1413 babies with birth weights <1500g and/or gestational age <32 weeks
underwent eye screening in the Lothian hospitals from 1990-2004. 329/1413 (23%)
of the study population was small-for-gestational age (SGA). SGA infants born at
gestational ages 26-31 weeks were more likely to develop any stage of ROP (p<0.01)
than their appropriate-for-gestational age (AGA) peers. SGA infants were also more
likely to develop severe ROP (GA 26-27wks p<0.01, GA 28-29wks p=0.01, GA 30-
31wks p=0.01).
In summary, SGA infants who underwent eye screening in the Lothian region of
South East Scotland from 1990-2004 were significantly more likely to develop ROP
and more severe disease than AGA infants.
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7.1.3 The influence of growth, insulin-like growth factor-1 and
oxygen on retinal vascular development
This was a laboratory based animal study. Rat pups were growth restricted in the
prenatal and postnatal periods. This was carried out by feeding the dams a low
protein (9%) diet. Litters of growth restricted pups and litters of normal sized pups
were exposed to either room air or to a variable oxygen profile (minute-minute
fluctuations around a mean inspired oxygen concentration of 24%), known to induce
retinal changes similar to clinical ROP.
In summary, retinal blood vessel development in growth restricted pups was slower
than in normal sized pups. Retinal blood vessel development in pups exposed to
variable oxygen was slower than in pups exposed to room air. Growth restricted pups
had lower serum insulin-like growth factor-1 (IGF-1) levels than normal sized pups
and pups that were slower to gain weight had lower serum IGF-1 concentrations.
We suggest that serum IGF-1 concentration may have a direct effect on retinal
vascularisation in our rat model of ROP, with a low serum IGF-1 being associated
with slower retinal vascular development. Our work demonstrates that prenatal and
postnatal nutrition is important to promote optimal retinal blood vessel development
and supports our clinical finding that small-for-gestational age infants have more
severe ROP than appropriately sized peers.
7.1.4 Wide-field digital retinal imaging versus binocular indirect
ophthalmoscopy for ROP screening
This was a prospective, randomised, comparative study. A total of 81 infants were
enrolled and results from 245 eyes were analysed. The sensitivity of wide-field
digital retinal imaging (WFDRI) in detecting any ROP, stage 3 ROP and plus disease
was 60%, 57% and 80% respectively with a specificity of 91%, 98% and 98%
respectively. There was excellent proportional agreement between WFDRI and
binocular indirect ophthalmoscopy (BIO) for detecting stage 3 ROP and plus disease
(0.96, 0.97). There was very good agreement between the two screening methods on
management decisions (kappa value 0.85).
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In summary, WFDRI was good at detecting plus disease located at the posterior pole.
BIO was better than WFDRI at detecting stages of ROP which are predominantly
found in the more peripheral retina. WFDRI identified all infants that required
treatment for ROP. WFDRI is a useful examination technique for ROP screening.
7.1.5 Pain in neonates undergoing ROP screening
A total of 76 infants were recruited in this prospective, randomised, comparative
study. The mean Premature Infant Pain Profile (PIPP) score for WFDRI was 15.0
(SD 2.1) and for BIO was 15.2 (SD 2.4). There was no statistically significant
difference in occurrence of marked bradycardias or marked desaturations (Fisher's
exact test p=1.00, p=0.52 respectively) during the two screening techniques. We
observed that infants started crying with corresponding physiological changes as
soon as the eyelid speculum was inserted and crying stopped on speculum removal.
In summary, despite application of topical anaesthesia, WFDRI and BIO with eyelid
speculum are painful procedures. The pain experienced is of similar severity for both
techniques. We propose that the eyelid speculum, rather than the examination
technique, contributed most to the pain experienced.
7.2 Limitations of data
7.2.1 Incidence of ROP in Lothian, Scotland
The main limitation of this work was the discrepancy found between the Information
Services Division (ISD), Scotland epidemiological data and our own hospital data
(186 babies). We were unable to cross-check our records with ISD due to patient
confidentiality and data protection legislation. It is likely that these 186 babies were
either transferred back to their local hospitals or were discharged home and failed to
attend outpatient eye screening. Ethnicity is a well documented risk factor for ROP
with Asian and Afro-Carribean infants being at greater risk of severe ROP [Aralikatti
et al, 2009]. We did not formally collect ethnicity data and this information would
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have been useful to allow readers of our paper to compare the baseline characteristics
of our population with their own.
7.2.2 ROP in SGA infants
We studied the incidence of ROP in SGA infants which we defined as infants with a
birth weight less than the 10lh percentile for gestational age. By definition, SGA
refers only to size at birth and does not give us any information about fetal growth
velocity. Within our SGA babies there will be infants with many different patterns of
growth. Some will be constitutionally small with 'normal' patterns of growth while
others will have been following a larger growth percentile until exposure to placental
insufficiency in the third trimester resulting in growth failure. Our main limitation
therefore refers to the terminology 'SGA' which is really a 'blanket term' referring to
small babies as a result of many diverse underlying mechanisms. In order to address
this issue and identify only the infants with growth failure, other researchers have
used absent or reversed end diastolic flow in the umbilical artery as a marker of
growth restricted babies. Another limitation of our study was we only looked at size
at birth (SGA/AGA) and association with ROP and did not study rate of fetal growth
or postnatal growth of SGA/AGA babies.
7.2.3 The influence of growth, IGF-1 and oxygen on retinal
vascular development
Our animal model is a useful tool to study the pathogenesis of ROP but caution is
required when relating findings to the human premature infant. Our rat model,
although unique and very physiological, has some limitations. Mainly, the model
does not cause frank neovascularisation. Most other animal models developed cause
retinal neovascularisation and retinal grading systems have been developed to score
the degree of neovascularisation together with specific processing and staining
techniques used to quantify this [Zhang et al, 2000; Penn and Thum, 1989], We were
unable to use these and therefore unable to directly compare our findings with others.
Unfortunately we were not able to relate individual rat pup retinas to the
corresponding pup serum IGF-1 and pup weight. This was due to technical
difficulties in retinal dissection, staining and in some cases low volume of serum
obtained.
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7.2.4 Wide-field digital retinal imaging versus binocular indirect
ophthalmoscopy for ROP screening
The strength of our study lay in the study design. By using two expert
ophthalmologists using the two screening techniques we reduced intraobserver bias
which was a major flaw in previously reported studies [Roth et al, 2001; Shah et al,
2006; Chiang et al, 2007; Ells et al, 2003], In order to check interobserver agreement
between our two ophthalmologists they independently analysed WFDRI images and
we reported good agreement. We did not however check interobserver agreement
between our ophthalmologists using BIO. This is a limitation of our study. In order
to do this we would have had to allow both ophthalmologists to perform BIO on the
same infant on the same screening occasion and compare their findings. We would
have required separate ethical approval for this and we felt that this was not
necessary as both ophthalmologists had worked together using BIO for ROP
screening for over ten years and had shown good interobserver agreement on
WFDRI images. We felt that subjecting infants to an additional stressful examination
could not be justified ethically.
A key strength of our study was that we recruited consecutive infants. However we
included all infants eligible for eye screening and by doing so had a high proportion
of more mature infants with mild disease and fewer lower gestational age infants
with more severe disease. BIO detected stage 3 ROP in 14/245 (6%) eyes and plus
disease in 10/245 (4%) eyes. As a result, any discrepancies between WFDRI and
BIO in disease detection in just one case had a large influence on sensitivity and
negligible influence on specificity. The prevalence of ROP increases with decreasing
gestational age. Perhaps future comparative studies should recruit consecutive infants
with lower gestational ages, for example those <28 weeks gestation.
7.2.5 Pain in neonates undergoing ROP screening
We chose to use the PIPP score as it is a well validated method of scoring procedural
pain in premature infants [Stevens et al, 1996]. The one limitation of this score for
ROP screening is due to the fact that neonates often experience bradycardias during
screening caused by the oculocardiac reflex [Clarke et al, 1985]. The PIPP score
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does not take this into account. We tried to overcome this limitation by documenting
the lowest heart rates recorded on all infants. I think the study could have been
improved by performing sequential PIPP scores, perhaps every minute during eye
examination and during the recovery. This would have given us more information on
the time required to re-attain baseline PIPP scores as perhaps the pain of one method
may be more prolonged than the other. In order to prove our theory that the eyelid
speculum is the cause of most pain, a PIPP score immediately prior to speculum
insertion and immediately post speculum removal would have been beneficial.
Ideally this study should have had one ophthalmologist performing all the eye
examinations, in order to eliminate inter-examiner variability in examination
handling and technique, but this was not possible as this data collection was
integrated into our WFDRI versus BIO comparative study.
7.3 Future directions
7.3.1 Epidemiology of Retinopathy of Prematurity
The Early Treatment for ROP (ETROP) study has been one of the key publications
on ROP in the last decade and has led to widespread change in clinical practice
[Early Treatment for ROP Cooperative Group, 2003]. Infants with ROP less severe
than threshold are now being treated. This especially applies to infants with stage 2
disease in zone 2 with plus disease. In addition, the severity of disease in zone 1 that
requires treatment has been better defined. The presence or absence of 'plus' disease
is now the key factor in determining if an infant requires treatment. There is a need to
report on the incidence and severity of ROP since the introduction of these new
treatment indications and changes in practice, as the natural history of the disease is
now interrupted by treatment at an earlier stage in some infants.
The incidence of ROP is closely associated to neonatal oxygen exposure
[Vanderveen et al, 2006; Wallace et al, 2007; Wright et al, 2006; Carlo et al, 2010],
Despite decades of research on this association, optimal neonatal oxygen saturation
targets have yet to be established. A recent large randomized trial comparing target
oxygen saturations of 85-89% or 91-95% in preterm infants identified an increase in
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mortality in the lower-oxygen-saturation group [Carlo et al, 2010]. If confirmed, we
have hit a barrier to further reduction of ROP by oxygen management. The BOOST-
II UK is a double blind randomised controlled trial comparing the effects of targeting
oxygen saturation levels of 85-89% versus 91-99% in infants <28 weeks gestation
and will help to clarify the situation [National Perinatal Epidemiology Unit, 2009],
There is an urgent need to define appropriate oxygen saturation ranges in order to
minimize ROP but without increasing adverse outcomes. There is now even more
incentive to find other ways of reducing the incidence of ROP, for example, by
improving nutrition.
Population based longitudinal studies provide valuable information on changes in
disease and clinical practice over time. This enables objective auditing of care
leading to improvements in clinical effectiveness. It would be advantageous to
develop both a Scottish and British national Neonatal Intensive Care Units database
as this would provide important information for planning future research, allocating
resources and designing public health policies relating to ROP and all other neonatal
diseases.
Screening programmes for ROP are well established in industrialised countries and
provide vital information on the population of babies requiring treatment and the
changes in this population over time. This information is used to refine screening and
treatment criteria. There is now an urgent need to collect data on the population of
babies developing ROP in 'middle-income' countries. This data will enable the
implementation of relevant screening programmes in these countries where ROP
blindness is increasingly prevalent.
7.3.2 Growth, nutrition and Retinopathy of Prematurity
Survival rates of premature infants have improved and more infants are at risk of
developing ROP. There is therefore a need to develop effective strategies to reduce
the morbidity following preterm birth.
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Many ROP therapies aim to inhibit pathological neovascularisation, the late stage of
the disease, rather than trying to improve normal vascular development. There is a
window of opportunity in the early weeks following birth before ROP develops in
which to a preventative therapy could be administered. Many infants treated by laser
photocoagulation do not develop optimal visual acuity. Development of a
pharmacological therapy that would improve normal retinal vascular development
and thereby prevent neovascularisation and associated visual morbidity is highly
desirable. The insulin-like growth factor system has potential to be manipulated as a
preventative therapy.
IGF-1 and IGFBP-3 play critical roles in vascular development and administration of
recombinant human IGF-1 or combined IGF-l/IGFBP-3 remains a potential
preventative therapy. IGFBP-3 may be a novel agent to improve vascular
development. As well as serving as a transporter protein for IGF-1, it has also been
shown to be important in cell signalling affecting cell mobility and survival [Granata
et al, 2004; Lofqvist et al, 2007], Evidence is mounting in support of IGFBP-3 as an
important regulator of both physiological and pathological angiogenesis and further
research is required in order to identify the optimal preventative agent in the IGF
system to target.
Early restoration of IGF-1 levels may be achieved through improving nutrition (in
particular protein intake) or by exogenous administration [Smith et al, 1997],
Although nutrition with breast and formula milk will increase circulating IGF-1
levels, enteral nutrition in preterm infants may not be tolerated due to gut immaturity
and concern about the risk of necrotising enterocolitis [Neu, 2007; Smith et al,
1997], Exogenous administration may therefore be preferable. Animal studies are
evaluating their use but further work is required to decipher optimal dosing, timing
and route of administration regimens [Liechty et al, 1999].
Timing of any potential preventative therapy is crucial. Early administration of IGF-
1 may improve normal retinal vascular development and thus prevent ROP but if
administered too late, when the retina is hypoxic, it may potentiate
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neovascularisation. Care must also be taken to minimize adverse effects on other
organ systems [Mathews et al, 1988],
Poor weight gain during the early postnatal weeks is now being recognised as one of
the strongest predictors for ROP [Lofqvist et al, 2006; Hellstrom et al, 2009], Rate of
postnatal weight gain together with serum IGF-1 levels have been used to predict
which babies will develop ROP [Lofqvist et al, 2006; Hellstrom et al, 2009; Lofqvist
et al, 2009]. The algorithm 'Weight IGF-1 Neonatal ROP' (WINROP) has been
validated retrospectively, using just serial weight measurements, in Sweden and
America with promising results [Hellstrom et al, 2009; Wu et al, 2010], We are
currently involved in validating the WINROP algorithm in Edinburgh using a ten
year cohort of infants screened. This is exciting as it has potential to reduce the
number of infants exposed to stressful eye examinations and suggests that improved
nutrition in the early postnatal weeks, leading to improved weight gain, may reduce
the risk of ROP from developing. We have found however, that very premature
infants are often not weighed for several weeks due to the difficulties and risks
involved in transferring a very sick ventilated infant from the incubator to the
weighing scales. A better measure of linear growth is obtained using knemometry
and this is an easier measurement to obtain in sick premature neonates [Gibson et al,
2003], Further studies to look weekly knemometry readings and development of
ROP are required.
Premature infants lack the long chain polyunsaturated fatty acids-omega-3 and
omega-6 [Crawford et al, 2003]. Research suggests that lack of omega-3 may be
associated with poor weight gain and ROP [Fierro et al, 2002; Kermorvant-
Duchemin et al, 2005], There is therefore potential to supplement these either in the
diet or in intravenous fat emulsions but further research is required to check neonatal
tolerance and safety.
There is a real need to define optimal growth rates in preterm infants, and in
particular small-for-gestational-age preterm infants and this will require further
research. Impaired fetal and postnatal growth in term infants have been related to a
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higher risk of ischaemic heart disease, impaired glucose tolerance, type II diabetes
mellitus, obesity and hypertension [Barker, 1990; Barker et al, 2002; Eriksson et al,
2007; Eriksson et al, 2006; Eriksson et al, 2003; Eriksson et al, 2001; Salonen et al,
2009; Osmond et al, 2007]. Evidence suggests that growth restricted infants with a
fast catch-up growth are most at risk of developing these diseases [Lucas, 2005],
These observations have critical implications for preterm infants. Evidence suggests
that a faster postnatal growth rate in preterm infants may reduce the incidence of
ROP but there is no data yet available on the effect this may have on the incidence of
vascular diseases in later life.
7.3.3 Screening for Retinopathy of Prematurity
WFDRI is an attractive screening method but it is not yet universally accepted
[Kemper et al, 2008], There are some technical difficulties regarding its use. Studies
have reported greater accuracy when using WFDRI on more mature infants with
higher corrected gestational age. This has been attributed to improved image capture
and improved image quality because more mature infants have larger palpebral
fissures, larger eyes and less corneal and vitreous haze [Chiang et al, 2007; Wu et al,
2006; Yen et al, 2002], There is scope for the manufacturers to refine the camera lens
and head in order to improve image capture and image quality in premature infants.
This may lead to improvements in reported sensitivities for ROP detection which
may result in more widespread use and acceptance ofWFDRI in ROP screening.
WFDRI does have some distinct technological advantages over BIO. Firstly, WFDRI
may be superior at detecting plus disease. Publications by the International
Classification of ROP have been produced to provide an international standard and
reference for detection of ROP [The Committee for the Classification of Retinopathy
of Prematurity, 1984, 2005]. In particular, the articles contain images of 'plus' and
'pre-plus' disease to help examiners interpret the level of dilation and tortuousity
sufficient for diagnosing plus disease. The ability of an ophthalmologist to correctly
identify pre-plus and plus disease is crucial as it is now the primary indication for
laser treatment in ROP [Early Treatment For Retinopathy Of Prematurity
Cooperative Group, 2003], Despite the attempts to standardise and clarify severity of
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ROP, interobserver agreement remains very variable, even among experts in the field
[Darlow et al, 2008; Chiang et al, 2007; Wallace et al, 2008]. With increasing use of
WFDRI, image libraries can be developed for educational and research purposes
with potential to improve the uniformity of ROP diagnosis. In order to reduce
subjectivity and increase objectivity in diagnosis of plus disease, computer-based
tools have been developed. These take quantitative measurements from blood vessels
captured by WFDRI and have the potential to augment clinical assessment and
improve inter-observer consistency [Johnson et al, 2007; Chiang et al, 2008; Aslam
et al, 2009], These are distinct advantages ofWFDRI over BIO.
Secondly, WFDRI with store-and-forward telemedicine has potential to improve the
accessibility and quality of care and may be particularly useful in 'middle-income'
countries where the incidence of ROP is rising and where ROP screening is not yet
routinely performed [Field, 1997; Gilbert, 2008], One of the greatest barriers to
implementing this screening method is initial cost of equipment. Two studies have
compared the cost-effectiveness of telemedicine WFDRI versus BIO for ROP
screening and both studies found several telemedicine strategies to be more cost
effective than current BIO practice [Castillo-Riquelme et al, 2004; Jackson et al,
2008]. These results are encouraging and likely to change in the next decade with
advances in information technology and increasing use of large-scale store-and-
forward applications in healthcare driving down costs [Grigsby and Sanders, 1998;
Krupinski et al, 2002],
In summary, WFDRI has many distinct technological advantages over BIO but has
some technical limitations which need to be improved [Lorenz et al, 2009; Wu et al,
2006]. It remains unresolved what is 'adequate' accuracy for WFDRI to be accepted
as a screening method and whether BIO is a true 'gold standard' against which
WFDRI should been compared [Scott et al, 2008]. There is a need for more
objective and accurate methods for assessing vascular abnormalities in order to treat
infants at the optimal time.
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7.3.4 Neonatal pain management during ROP screening
ROP screening examinations remain vital in order to identify infants with sight-
threatening disease but are painful and distressing procedures for neonates. Neonatal
exposure to repetitive painful procedures can have long-term negative effects [Anand
et al, 1999; Anand and Scalzo, 2000]. Adequate analgesic regimes are not currently
being performed. So far the mainstay of analgesia has been topical anaesthesia and
comfort care. Although routinely given, there is little evidence in the literature to
suggest that topical anaesthesia reduces pain [Marsh et al, 2005; Saunders et al,
1993]. The drops numb the cornea and conjunctiva but will have no effect on the
discomfort caused from the traction on the orbicularis orbis muscle and lateral
canthal skin by the eyelid speculum. Studies reporting on comfort care methods
including pacifier use, sucrose and swaddling have variable findings [Gal et al, 2005;
Mitchell et al, 2004; Boyle et al, 2006]. Certainly there is most evidence to suggest
that sucrose and swaddling does ameliorate the pain experienced during eye
screening [Gal et al, 2005; Mitchell et al, 2004; Slevin et al, 1997; Kleberg et al,
2008], In our experience, the use of pacifiers during ROP screening is difficult as the
infants tend to be screaming too much to suck the pacifier.
There is an urgent need to recognise that current analgesic regimes are inadequate
and to identify suitable alternatives. One way is to try and change the examination
technique. We are now using an eyelid speculum with smaller blades that do not
stretch the eyelids as widely apart. We have not formally assessed the infants' pain
responses but generally feel they seem less distressed than they were during our
study. The brightness of the light is likely to be another cause of distress and perhaps
a reduction in this may be beneficial for the infants. Another way is try different
systemic analgesia. One small uncontrolled study used remifentanil (very short
acting synthetic opioid) intravenously to effectively reduce the pain from laser
photocoagulation [Sammartino et al, 2003]. This may be a possibility for routine eye
screening although intravenous access would be required. An opioid intranasal spray
would be an attractive option to avoid intravenous cannulation in the well infants.
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These differing approaches could be used in conjunction with comfort care to reduce
neonatal pain. Further research in this area is needed in order to enable the
development of evidence-based clinical practice guidelines on the management of
pain during ROP screening.
7.4 Conclusion
Retinopathy of prematurity is a leading cause of childhood blindness. Advances in
obstetric and neonatal care within the developed world over the last two decades are
likely responsible for the increased survival of premature infants and the overall
decreasing incidence of ROP seen in Lothian. Current treatment for ROP with laser
photocoagulation prevents blindness but is destructive and treated children still suffer
visual morbidity in childhood. A preventative therapy is highly desirable. This
research has demonstrated that body growth and IGF-1 are important in the
pathogenesis of ROP. We have highlighted that SGA infants are particularly at risk.
Nutritional therapies may help by improving normal retinal blood vessel
development and thereby preventing local tissue hypoxia. Clinical trials of nutritional
therapies are needed as these offer real potential to reduce the incidence of sight-
threatening ROP. Our work has helped pave the way for future clinical trials.
WFDRI is a useful examination technique for ROP eye screening but has some
technical limitations which need to be improved. Further work is required to
implement adequate analgesia regimes for ROP screening. These published trials will
help form the basis for future clinical intervention studies. The WINROP algorithm
could potentially lead to a reduction in the number of infants undergoing stressful





Adamis AP, Miller JW, Bernal MT et al. Increased vascular endothelial growth
factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
Am.J.Ophthalmol. 1994;118:445-50.
Adamis AP, Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth
factor prevents retinal ischemia-associated iris neovascularization in a nonhuman
primate. Arch.Ophthalmol. 1996;114:66-71.
Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular
fluid of patients with diabetic retinopathy and other retinal disorders. N.Engl.J.Med.
1994;331:1480-7.
Aiello LP, Northrup JM, Keyt BA et al. Hypoxic regulation of vascular endothelial
growth factor in retinal cells. Arch.Ophthalmol. 1995;113:1538-44.
Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in
vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble
VEGF-receptor chimeric proteins. Proc.Natl.Acad.Sci.U.S.A 1995;92:10457-61.
Allegaert K, Vanhole C, Casteels I et al. Perinatal growth characteristics and
associated risk of developing threshold retinopathy of prematurity. J AAPOS.
2003;7:34-7.
American Academy of Pediatrics. Prevention and management of pain and stress in
the neonate. Committee on Fetus and Newborn. Committee on Drugs. Section on
Anesthesiology. Section on Surgery. Canadian Paediatric Society. Fetus and
Newborn Committee. Pediatrics 2000;105:454-61.
Anand KJ, Coskun V, Thrivikraman KV et al. Long-term behavioral effects of
repetitive pain in neonatal rat pups. Physiol Behav. 1999;66:627-37.
Anand KJ, Scalzo FM. Can adverse neonatal experiences alter brain development
and subsequent behavior? Biol.Neonate 2000;77:69-82.
Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity and pulse
oximetry: a national survey of recent practices. J.Perinatol. 2004;24:164-8.
Aralikatti AK, Mitra A, Denniston AK et al. Is ethnicity a risk factor for severe
retinopathy of prematurity? Arch.Dis. Child Fetal Neonatal Ed 2010;95(3):F174-176.
Arosio M, Cortelazzi D, Persani L et al. Circulating levels of growth hormone,
insulin-like growth factor-I and prolactin in normal, growth retarded and
anencephalic human fetuses. J Endocrinol.Invest 1995;18:346-53.
Arroe M, Peitersen B. Retinopathy of prematurity: review of a seven-year period in a
Danish neonatal intensive care unit. Acta Paediatr. 1994;83:501-5.
109
Askie LM, Henderson-Smart DJ, Irwig L et al. Oxygen-saturation targets and
outcomes in extremely preterm infants. N.Engl.J Med 2003;349:959-67.
Aslam T, Fleck B, Patton N et al. Digital image analysis of plus disease in
retinopathy of prematurity. Acta Ophthalmol. 2009;87:368-77.
Avery ME. Recent increase in mortality from hyaline membrane disease. J.Pediatr.
1960;57:553-9.
Bardin C, Zelkowitz P, Papageorgiou A. Outcome of small-for-gestational age and
appropriate-for-gestational age infants born before 27 weeks of gestation. Pediatrics
1997;100:E4.
Barker DJ, Eriksson JG, Forsen T et al. Fetal origins of adult disease: strength of
effects and biological basis. Int. J.Epidemiol. 2002;31:1235-9.
Barker DJ. The fetal and infant origins of adult disease. BMJ 1990;301:1111.
Beeby PJ. Risk of death for small for gestational age very preterm infants. Pediatrics
1998;102:1497-8.
Belda S, Pallas CR, De la CJ et al. Screening for retinopathy of prematurity: is it
painful? Biol.Neonate 2004;86:195-200.
Ben S, I, Nissenkorn I, Kremer I. Retinopathy of prematurity. Sum.Ophthalmol.
1988;33:1-16.
Benediktsson R, Lindsay RS, Noble J et al. Glucocorticoid exposure in utero: new
model for adult hypertension. Lancet 1993;341:339-41.
Bernstein IM, Horbar JD, Badger GJ et al. Morbidity and mortality among very-low-
birth-weight neonates with intrauterine growth restriction. The Vermont Oxford
Network. Am J Obstet.Gynecol. 2000;182:198-206.
Bharwani SK,.Dhanireddy R. Systemic fungal infection is associated with the
development of retinopathy of prematurity in very low birth weight infants: a meta-
review. J.Perinatol. 2008;28:61-6.
Boyle EM, Freer Y, Khan-Orakzai Z et al. Sucrose and non-nutritive sucking for the
relief of pain in screening for retinopathy of prematurity: a randomised controlled
trial. Arch Dis.Child Fetal Neonatal Ed 2006;91:F166-F168.
Bullard SR, Donahue SP, Feman SS et al. The decreasing incidence and severity of
retinopathy of prematurity. J AAPOS. 1999;3:46-52.
Cairns, JE. Normal development of the hyaloid and retinal vessels in the rat.
Br.J.Ophthalmol. 1959;43:385-93.
110
Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasias
clinical approach. 1951. Med J Aust 2, 48-50.
Carlo WA, Finer NN, Walsh MC et al. Target ranges of oxygen saturation in
extremely preterm infants. N.Engl.J.Med. 2010;362:1959-69.
Castillo-Riquelme MC, Lord J, Moseley MJ et al. Cost-effectiveness of digital
photographic screening for retinopathy of prematurity in the United Kingdom.
Int.J. Technol.Assess.Health Care 2004;20:201-13.
Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division.
Evidence that 'physiological hypoxia' is the stimulus for normal retinal
vasculogenesis. Invest Ophthalmol Vis.Sci. 1995;36:1201-14.
Chan-Ling T. Glial, vascular, and neuronal cytogenesis in whole-mounted cat retina.
Microsc.Res. Tech. 1997 ;36:1-16.
Chaudhari S, Patwardhan V, Vaidya U et al. Retinopathy of prematurity in a tertiary
care center—incidence, risk factors and outcome. Indian Pediatr. 2009;46:219-24.
Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-40.
Chiang MF, Arons RR, Flynn JT et al. Incidence of retinopathy of prematurity from
1996 to 2000: analysis of a comprehensive New York state patient database.
Ophthalmology 2004;111:1317-25.
Chiang MF, Gelman R, Williams SL et al. Plus disease in retinopathy of prematurity:
development of composite images by quantification of expert opinion. Invest
Ophthalmol. Vis.Sci. 2008;49:4064-70.
Chiang MF, Jiang L, Gelman R et al. Interexpert agreement of plus disease diagnosis
in retinopathy of prematurity. Arch.Ophthalmol. 2007;125:875-80.
Chiang MF, Wang L, Busuioc M et al. Telemedical retinopathy of prematurity
diagnosis: accuracy, reliability, and image quality. Arch.Ophthalmol.
2007;125:1531-8.
Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the
incidence of severe retinopathy of prematurity in very low birth weight infants?
Pediatrics 2003;111:339-45.
Chu Y, Hughes S, Chan-Ling T. Differentiation and migration of astrocyte precursor
cells and astrocytes in human fetal retina: relevance to optic nerve coloboma. FASEB
J 2001;15:2013-5.
Chung EJ, Kim JH, Ahn HS et al. Combination of laser photocoagulation and
intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
Graefes Arch. Clin.Exp.Ophthalmol. 2007;245:1727-30.
Ill
Clarke WN, Hodges E, Noel LP et al. The oculocardiac reflex during
ophthalmoscopy in premature infants. Am J Ophthalmol 1985;99:649-51.
Cole CH, Wright KW, Tarnow-Mordi W et al. Resolving our uncertainty about
oxygen therapy. Pediatrics 2003;112:1415-9.
Connolly BP, Ng EY, McNamara JA et al. A comparison of laser photocoagulation
with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2.
Refractive outcome. Ophthalmology 2002;109:936-41.
Cooke RJ, Ainsworth SB, Fenton AC. Postnatal growth retardation: a universal
problem in preterm infants. Arch Dis. Child Fetal Neonatal Ed 2004;89:F428-F430.
Cooke RW, Clark D, Hickey-Dwyer M et al. The apparent role of blood transfusions
in the development of retinopathy of prematurity. Eur.J.Pediatr. 1993;152:833-6.
Cooke RW. Preterm mortality and morbidity over 25 years. Arch Dis.Child Fetal
Neonatal Ed 2006;91:F293-F294.
Crawford MA, Golfetto I, Ghebremeskel K et al. The potential role for arachidonic
and docosahexaenoic acids in protection against some central nervous system
injuries in preterm infants. Lipids 2003;38:303-15.
Cryotherapy for ROP cooperative group. Multicenter trial of cryotherapy for
retinopathy of prematurity. Arch Ophthalmol 1988;106, 471-479.
Cunningham S, Fleck BW, Elton RA et al. Transcutaneous oxygen levels in
retinopathy of prematurity. Lancet 1995;346:1464-5.
Cunningham S, McColm JR, Wade J et al. A novel model of retinopathy of
prematurity simulating preterm oxygen variability in the rat. Invest Ophthalmol
Vis.Sci. 2000;41:4275-80.
Darlow BA, Cust AE, Donoghue DA. Improved outcomes for very low birthweight
infants: evidence from New Zealand national population based data. Arch Dis.Child
Fetal Neonatal Ed 2003;88:F23-F28.
Darlow BA, Elder MJ, Horwood LJ et al. Does observer bias contribute to variations
in the rate of retinopathy of prematurity between centres?
Clin.Experiment.Ophthalmol. 2008;36:43-6.
Darlow BA, Hutchinson JL, Simpson JM et al. Variation in rates of severe
retinopathy of prematurity among neonatal intensive care units in the Australian and
New Zealand Neonatal Network. Br.J.Ophthalmol. 2005;89:1592-6.
Darlow BA. Incidence of retinopathy of prematurity in New Zealand. Arch Dis.Child
1988;63:1083-6.
112
Davenport ML, D'Ercole AJ, Underwood LE. Effect of maternal fasting on fetal
growth, serum insulin-like growth factors (IGFs), and tissue IGF messenger
ribonucleic acids. Endocrinology 1990;126:2062-7.
de Grauw TJ, Myers RE, Scott WJ. Fetal growth retardation in rats from different
levels of hypoxia. Biol.Neonate 1986;49:85-9.
Denne SC. Protein and energy requirements in preterm infants. Semin.Neonatol.
2001;6:377-82.
Deulofeut R, Critz A, ms-Chapman I et al. Avoiding hyperoxia in infants < or =
1250 g is associated with improved short- and long-term outcomes. J Perinatol.
2006;26:700-5.
Dhaliwal C, Fleck B, Wright E et al. Incidence of retinopathy of prematurity in
Lothian, Scotland, from 1990 to 2004. Arch Dis.Child Fetal Neonatal Ed
2008;93:F422-F426.
Dhaliwal CA, Fleck BW, Wright E et al. Retinopathy of prematurity in small-for-
gestational age infants compared to appropriate-for-gestational age infants. Arch
Dis.Child Fetal Neonatal Ed 2009;94(3):F193-195.
Dhillon B, Wright E, Fleck BW. Screening for retinopathy of prematurity: are a lid
speculum and scleral indentation necessary? J Pediatr. Ophthalmol Strabismus
1993;30:377-81.
Donahue ML, Phelps DL, Watkins RH et al. Retinal vascular endothelial growth
factor (VEGF) mRNA expression is altered in relation to neovascularization in
oxygen induced retinopathy. Curr.Eye Res. 1996;15:175-84.
Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by
endothelial filopodia, a preexisting astrocytic template and specific R-cadherin
adhesion. Invest Ophthalmol Vis.Sci. 2002;43:3500-10.
Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised
indications for the treatment of retinopathy of prematurity: results of the early
treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol
2003;121:1684-94.
Ells AL, Holmes JM, Astle WF et al. Telemedicine approach to screening for severe
retinopathy of prematurity: a pilot study. Ophthalmology 2003;110:2113-7.
Embleton NE, Pang N, Cooke RJ. Postnatal malnutrition and growth retardation: an
inevitable consequence of current recommendations in preterm infants? Pediatrics
2001;107:270-3.
113
Eriksson JG, Forsen T, Tuomilehto J et al. Early growth and coronary heart disease
in later life: longitudinal study. BMJ 2001;322:949-53.
Eriksson JG, Forsen TJ, Kajantie E et al. Childhood growth and hypertension in later
life. Hypertension 2007;49:1415-21.
Eriksson JG, Forsen TJ, Osmond C et al. Pathways of infant and childhood growth
that lead to type 2 diabetes. Diabetes Care 2003;26:3006-10.
Eriksson JG, Osmond C, Kajantie E et al. Patterns of growth among children who
later develop type 2 diabetes or its risk factors. Diabetologia 2006;49:2853-8.
Ertl T, Gyarmati J, Gaal V et al. Relationship between hyperglycemia and
retinopathy of prematurity in very low birth weight infants. Biol.Neonate
2006;89:56-9.
Field MJ. Telemedicine: a guide to assessing telecommunications in healthcare.
J.Digit.Imaging 1997; 10:28.
Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell
proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4).
J.Pharmacol.Exp. Ther. 2002;300:385-92.
Fitzgerald M, Beggs S. The neurobiology of pain: developmental aspects.
Neuroscientist. 2001;7:246-57.
Fleck BW, Dangata Y. Causes of visual handicap in the Royal Blind School,
Edinburgh, 1991-2. Br.J Ophthalmol 1994;78:421.
Fleck BW, Mcintosh N. Pathogenesis of retinopathy of prematurity and possible
preventive strategies. Early Hum.Dev. 2008;84:83-8.
Floyd BN, Leske DA, Wren SM et al. Differences between rat strains in models of
retinopathy of prematurity. Mol.Vis. 2005;11:524-30.
Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial growth
factor gene transcription by hypoxia-inducible factor 1. Mol.Cell Biol. 1996;16:4604-
13.
Fruttiger M. Development of the retinal vasculature. Angiogenesis. 2007;10:77-88.
Gal P, Kissling GE, Young WO et al. Efficacy of sucrose to reduce pain in
premature infants during eye examinations for retinopathy of prematurity.
Ann.Pharmacother. 2005;39:1029-33.
Gariano RF, Iruela-Arispe ME, Hendrickson AE. Vascular development in primate
retina: comparison of laminar plexus formation in monkey and human. Invest
Ophthalmol Vis.Sci. 1994;35:3442-55.
114
Gibson AT, Carney S, Wright NP et al. Measurement and the newborn infant.
Horm.Res. 2003;59 Suppl 1:119-28.
Gibson DL, Sheps SB, Schechter MT et al. Retinopathy of prematurity: a new
epidemic? Pediatrics 1989;83:486-92.
Gibson DL, Sheps SB, Uh SH et al. Retinopathy of prematurity-induced blindness:
birth weight-specific survival and the new epidemic. Pediatrics 1990:86:405-12.
Gilbert C, Fielder A, Gordillo L et al. Characteristics of infants with severe
retinopathy of prematurity in countries with low, moderate, and high levels of
development: implications for screening programs. Pediatrics 2005;115:e518-e525.
Gilbert C, Rahi J, Eckstein M et al. Retinopathy of prematurity in middle-income
countries. Lancet 1997;350:12-4.
Gilbert C, Foster A. Childhood blindness in the context of VISION 2020-the right to
sight. Bull. World Health Organ 2001 ;79:227-32.
Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics,
population of babies at risk and implications for control. Early Hum.Dev.
2008;84:77-82.
Goggin M, O'Keefe M. Childhood blindness in the Republic of Ireland: a national
survey. Br.J Ophthalmol 1991;75:425-9.
Gortner L, Wauer RR, Stock GJ et al. Neonatal outcome in small for gestational age
infants: do they really better? J.Perinat.Med. 1999;27:484-9.
Granata R, Trovato L, Garbarino G et al. Dual effects of IGFBP-3 on endothelial cell
apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB
J. 2004;18:1456-8.
Grigsby J, Sanders JH. Telemedicine: where it is and where it's going.
Ann.Intern.Med. 1998;129:123-7.
Grunau RE, Oberlander TF, Whitfield MF et al. Demographic and therapeutic
determinants of pain reactivity in very low birth weight neonates at 32 Weeks'
postconceptional Age. Pediatrics 2001;107:105-12.
Haines L, Fielder AR, Baker H et al. UK population based study of severe
retinopathy of prematurity: screening, treatment, and outcome. Arch.Dis.Child Fetal
Neonatal Ed 2005;90:F240-F244.
Hales CN, Barker DJ, Clark PM et al. Fetal and infant growth and impaired glucose
tolerance at age 64. BMJ 1991 ;303:1019-22.
115
Hall JG, Freedman SF, Kylstra JA. Clinical course and systemic correlates of
retinopathy of prematurity in quintuplets. Am J Ophthalmol 1995;119:658-60.
Halsey CL, Collin MF, Anderson CL. Extremely low birth weight children and their
peers: a comparison of preschool performance. Pediatrics 1993;91:807-11.
Hameed B, Shyamanur K, Kotecha S et al. Trends in the incidence of severe
retinopathy of prematurity in a geographically defined population over a 10-year
period. Pediatrics 2004; 113:1653-7.
Hatfield EM. Blindness in infants and young children. Sight Sav Rev. 1972;42:69-89.
Hellstrom A, Dahlgren J, Marsal K et al. Abnormal retinal vascular morphology in
young adults following intrauterine growth restriction. Pediatrics 2004;113:e77-e80.
Hellstrom A, Engstrom E, Hard AL et al. Postnatal serum insulin-like growth factor I
deficiency is associated with retinopathy of prematurity and other complications of
premature birth. Pediatrics 2003;112:1016-20.
Hellstrom A, Hard AL, Engstrom E et al. Early weight gain predicts retinopathy in
preterm infants: new, simple, efficient approach to screening. Pediatrics
2009;123:e638-e645.
Hellstrom A, Perruzzi C, Ju M et al. Low IGF-I suppresses VEGF-survival signaling
in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity.
Proc.Natl.Acad.Sci.U.S.A 2001;98:5804-8.
Henkind P. Radial peripapillary capillaries of the retina. I. Anatomy: human and
comparative. Br.J.Ophthalmol. 1967;51:115-23.
Hesse L, Eberl W, Schlaud M et al. Blood transfusion. Iron load and retinopathy of
prematurity. Eur.J.Pediatr. 1997;156:465-70.
Hikino S, Ihara K, Yamamoto J et al. Physical growth and retinopathy in preterm
infants: involvement of IGF-I and GH. Pediatr.Res. 2001;50:732-6.
Hirabayashi H, Honda S, Morioka I et al. Inhibitory effects of maternal smoking on
the development of severe ROP. Eye 2010;24:1024-7.
Hiraoka M, Berinstein DM, Trese MT et al. Insertion and deletion mutations in the
dinucleotide repeat region of the Norrie disease gene in patients with advanced
retinopathy of prematurity. J.Hum.Genet. 2001;46:178-81.
Hohmann M, Kunzel W. Dihydroergotamine causes fetal growth retardation in
guinea pigs. Arch. Gynecol.Obstet. 1992;251:187-92.
116
Hok-Wikstrand M, Hard AL, Niklasson A et al. Early postnatal growth variables are
related to morphologic and functional ophthalmologic outcome in children born
preterm. Acta Paediatr. 2010;99:658-64.
Holemans K, Aerts L, Van Assche FA. Fetal growth and long-term consequences in
animal models of growth retardation. Eur.J.Obstet.Gynecol.Reprod.Biol.
1998;81:149-56.
Holly J, Perks C. The role of insulin-like growth factor binding proteins.
Neuroendocrinology 2006;83:154-60.
Holmes JM, Zhang S, Leske DA et al. Metabolic acidosis-induced retinopathy in the
neonatal rat. Invest Ophthalmol. Vis.Sci. 1999;40:804-9.
Holmes JM, Duffner LA. The effect of postnatal growth retardation on abnormal
neovascularization in the oxygen exposed neonatal rat. Curr.Eye Res. 1996;15:403-9.
Holmes R, Montemagno R, Jones J. et al. Fetal and maternal plasma insulin-like
growth factors and binding proteins in pregnancies with appropriate or retarded fetal
growth. Early Hum.Dev. 1997;49:7-17.
Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the
introduction of surfactant therapy: an observational study of neonates weighing 601
to 1300 grams at birth. The Members of the National Institute of Child Health and
Human Development Neonatal Research Network. Pediatrics 1993;92:191-6.
Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of
vasculogenesis and angiogenesis. Invest Ophthalmol Vis.Sci. 2000;41:1217-28.
Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity,
1989-1997. Pediatrics 1999;104:e26.
Jackson KM, Scott KE, Graff ZJ et al. Cost-utility analysis of telemedicine and
ophthalmoscopy for retinopathy of prematurity management. Arch Ophthalmol
2008;126:493-9.
Johnson KS, Mills MD, Karp KA et al. Quantitative analysis of retinal vessel
diameter reduction after photocoagulation treatment for retinopathy of prematurity.
Am.J.Ophthalmol. 2007;143:1030-2.
Johnson KS, Mills MD, Karp KA et al. Semiautomated analysis of retinal vessel
diameter in retinopathy of prematurity patients with and without plus disease.
Am.J.Ophthalmol. 2007;143:723-5.
Johnson L, Bowen FW, Jr., Abbasi S et al. Relationship of prolonged pharmacologic
serum levels of vitamin E to incidence of sepsis and necrotizing enterocolitis in
infants with birth weight 1,500 grams or less. Pediatrics 1985;75:619-38.
117
Keith CG, Doyle LW. Retinopathy of prematurity in extremely low birth weight
infants. Pediatrics 1995;95:42-5.
Kelly FJ. Free radical disorders of preterm infants. Br.Med.Bull. 1993;49:668-78.
Kemper AR, Wallace DK, Quinn GE. Systematic review of digital imaging
screening strategies for retinopathy of prematurity. Pediatrics 2008;122:825-30.
Kermorvant-Duchemin E, Sennlaub F et al. Trans-arachidonic acids generated
during nitrative stress induces a thrombospondin-1-dependent microvascular
degeneration. Nat.Med. 2005;11:1339-45.
Kinsey VE. Retrolental fibroplasia; cooperative study of retrolental fibroplasia and
the use of oxygen. AMA.Arch. Ophthalmol. 1956;56:481-543.
Kirchner L, Jeitler V, Pollak A et al. Must screening examinations for retinopathy of
prematurity necessarily be painful? Retina 2009;29:586-91.
Kleberg A, Warren I, Norman E et al. Lower stress responses after Newborn
Individualized Developmental Care and Assessment Program care during eye
screening examinations for retinopathy of prematurity: a randomized study.
Pediatrics 2008;121:el267-el278.
Kok JH, den Ouden AL, Verloove-Vanhorick SP et al. Outcome of very preterm
small for gestational age infants: the first nine years of life. Br.J Obstet.Gynaecol.
1998;105:162-8.
Kondo T, Vicent D, Suzuma K et al. Knockout of insulin and IGF-1 receptors on
vascular endothelial cells protects against retinal neovascularization. J Clin.Invest
2003;111:1835-42.
Krupinski E, Nypaver M, Poropatich R et al. Telemedicine/telehealth: an
international perspective. Clinical applications in telemedicine/telehealth.
Telemed.J.E.Health 2002;8:13-34.
Kusaka S, Shima C, Wada K et al. Efficacy of intravitreal injection of bevacizumab
for severe retinopathy of prematurity: a pilot study. Br.J.Ophthalmol. 2008;92:1450-
5.
Lad EM, Nguyen TC, Morton JM et al. Retinopathy of prematurity in the United
States. Br.J.Ophthalmol. 2008;92:320-5.
Lalwani GA, Berrocal AM, Murray TG et al. Off-label use of intravitreal
bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of
prematurity. Retina 2008;28:S13-S18.
118
Langford K, Nicolaides K, Miell JP. Maternal and fetal insulin-like growth factors
and their binding proteins in the second and third trimesters of human pregnancy.
Hum.Reprod. 1998;13:1389-93.
Langley-Evans SC, Phillips GJ, Jackson AA. In utero exposure to maternal low
protein diets induces hypertension in weanling rats, independently of maternal blood
pressure changes. Clin.Nutr. 1994;13:319-24.
Langley-Evans SC, Nwagwu M. Impaired growth and increased glucocorticoid-
sensitive enzyme activities in tissues of rat fetuses exposed to maternal low protein
diets. Life Sci. 1998;63:605-15.
Larsson E, Carle-Petrelius B, Cernerud G et al. Incidence of ROP in two consecutive
Swedish population based studies. Br.J Ophthalmol 2002;86:1122-6.
Larsson E, Martin L, Holmstrom G. Peripheral and central visual fields in 11-year-
old children who had been born prematurely and at term.
J.Pediatr.Ophthalmol.Strabismus 2004;41:39-45.
Larsson EK, Rydberg AC, Holmstrom GE. A population-based study of the
refractive outcome in 10-year-old preterm and full-term children. Arch.Ophthalmol.
2003;121:1430-6.
Larsson EK, Rydberg AC, Holmstrom GE. A population-based study on the visual
outcome in 10-year-old preterm and full-term children. Arch. Ophthalmol.
2005;123:825-32.
Larsson EK, Holmstrom GE. Development of astigmatism and anisometropia in
preterm children during the first 10 years of life: a population-based study.
Arch.Ophthalmol. 2006; 124:1608-14.
Laws DE, Morton C, Weindling M et al. Systemic effects of screening for
retinopathy of prematurity. Br.J Ophthalmol 1996;80:425-8.
Lee SK, McMillan DD, Ohlsson A et al. Variations in practice and outcomes in the
Canadian NICU network: 1996-1997. Pediatrics 2000;106:1070-9.
Leung DW, Cachianes G, Kuang WJ et al. Vascular endothelial growth factor is a
secreted angiogenic mitogen. Science 1989;246:1306-9.
Ley D, Wide-Swensson D, Lindroth M et al. Respiratory distress syndrome in infants
with impaired intrauterine growth. Acta Paediatr. 1997;86:1090-6.
119
Liechty EA, Boyle DW, Moorehead H et al. Glucose and amino acid kinetic
response to graded infusion of rhIGF-I in the late gestation ovine fetus. Am.J.Physiol
1999;277:E537-E543.
Ling TL, Stone J. The development of astrocytes in the cat retina: evidence of
migration from the optic nerve. Brain Res.Dev.Brain Res. 1988;44:73-85.
Liu PM, Fang PC, Huang CB et al. Risk factors of retinopathy of prematurity in
premature infants weighing less than 1600 g. Am.J.Perinatol. 2005;22:115-20.
Lofqvist C, Andersson E, Sigurdsson J et al. Longitudinal postnatal weight and
insulin-like growth factor I measurements in the prediction of retinopathy of
prematurity. Arch.Ophthalmol. 2006:124:1711-8.
Lofqvist C, Chen J, Connor KM et al. IGFBP3 suppresses retinopathy through
suppression of oxygen-induced vessel loss and promotion of vascular regrowth.
Proc.Natl.Acad.Sci.U.S.A 2007;104:10589-94.
Lofqvist C, Hansen-Pupp I, Andersson E et al. Validation of a new retinopathy of
prematurity screening method monitoring longitudinal postnatal weight and
insulinlike growth factor I. Arch.Ophthalmol. 2009;127:622-7.
Lorenz B, Bock M, Muller HM et al. Telemedicine based screening of infants at risk
for retinopathy of prematurity. Stud.Health Technol.Inform. 1999;64:155-63.
Lorenz B, Spasovska K, Elflein H et al. Wide-field digital imaging based
telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year
results of a multicentre field study. Graefes Arch. Clin. Exp.Ophthalmol.
2009;247:1251-62.
Lucas A. Long-term programming effects of early nutrition — implications for the
preterm infant. J.Perinatol. 2005;25 SuppI 2:S2-S6.
Lundqvist P, Kallen K, Hallstrom I et al. Trends in outcomes for very preterm infants
in the southern region of Sweden over a 10-year period. Acta Paediatr. 2009;98:648-
53.
Mactier, H and Weaver, LT. Vitamin A and preterm infants: what we know, what we
don't know and what we need to know. Arch.Dis.Child Fetal Neonatal Ed.
2005;90:F103-108.
Maroney DI. Recognizing the potential effect of stress and trauma on premature
infants in the NICU: how are outcomes affected? J.Perinatol. 2003;23:679-83.
120
Marsh VA, Young WO, Dunaway KK et al. Efficacy of topical anesthetics to reduce
pain in premature infants during eye examinations for retinopathy of prematurity.
Ann.Pharmacother. 2005;39:829-33.
Mathews LS, Hammer RE, Behringer RR et al. Growth enhancement of transgenic
mice expressing human insulin-like growth factor I. Endocrinology 1988;123:2827-
33.
McColm JR, Cunningham S, Sedowofia SK et al. Induction of retinopathy in
newborn rats using a clinically relevant oxygen profile. Early Hum. Dev. 2000;58:75-
6.
McColm JR, Cunningham S, Wade J et al. Hypoxic oxygen fluctuations produce less
severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of
prematurity. Pediatr.Res. 2004;55:107-13.
McDonald AD. Cerebral palsy in children of very low birth weight. Arch Dis.Child
1963;38:579-88.
Mehta M, Adams GG, Bunce C et al. Pilot study of the systemic effects of three
different screening methods used for retinopathy of prematurity. Early Hum. Dev.
2005;81:355-60.
Mets MB. Childhood blindness and visual loss: an assessment at two institutions
including a "new" cause. Trans.Am.Ophthalmol.Soc. 1999;97:653-96.
Miller JW, Adamis AP, Shima DT et al. Vascular endothelial growth factor/vascular
permeability factor is temporally and spatially correlated with ocular angiogenesis in
a primate model. Am.J.Pathol. 1994;145:574-84.
Mintz-Hittner HA, Kuffel RR, Jr. Intravitreal injection of bevacizumab (avastin) for
treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina
2008;28:831-8.
Misra A, Heckford E, Curley A et al. Do current retinopathy of prematurity
screening guidelines miss the early development of pre-threshold type 1 ROP in
small for gestational age neonates? Eye (Lond) 2008;22:825-9.
Mitchell A, Stevens B, Mungan N et al. Analgesic effects of oral sucrose and pacifier
during eye examinations for retinopathy of prematurity. Pain Manag.Nurs.
2004;5:160-8.
Msall ME, Phelps DL, Hardy RJ et al. Educational and social competencies at 8
years in children with threshold retinopathy of prematurity in the CRYO-ROP
multicenter study. Pediatrics 2004;113:790-9.
121
Mukheijee AN, Watts P, Al-Madfai H et al. Impact of retinopathy of prematurity
screening examination on cardiorespiratory indices: a comparison of indirect
ophthalmoscopy and retcam imaging. Ophthalmology 2006;113:1547-52.
Murakami Y, Silva RA, Jain A et al. Stanford University Network for Diagnosis of
Retinopathy of Prematurity (SUNDROP): 24-month experience with telemedicine
screening. Acta Ophthalmol. 2009. [epub ahead of print]
National Perinatal Epidemiology Unit. BOOST-II UK. 2009.
Neu J. Gastrointestinal development and meeting the nutritional needs of premature
infants. Am.J.Clin.Nutr. 2007;85:629S-34S.
Ng EY, Connolly BP, McNamara JA et al. A comparison of laser photocoagulation
with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual
function and structural outcome. Ophthalmology 2002;109:928-34.
Ng YK, Fielder AR, Shaw DE et al. Epidemiology of retinopathy of prematurity.
Lancet 1988;2:1235-8.
Nodgaard H, Andreasen H, Hansen H et al. Risk factors associated with retinopathy
of prematurity (ROP) in northern Jutland, Denmark 1990-1993. Acta Ophthalmol
Scand. 1996;74:306-10.
Oberlander TF, Grunau RE, Whitfield MF et al. Biobehavioral pain responses in
former extremely low birth weight infants at four months' corrected age. Pediatrics
2000;105:e6.
O'Connor AR, Stephenson T, Johnson A et al. Long-term ophthalmic outcome of
low birth weight children with and without retinopathy of prematurity. Pediatrics
2002;109:12-8.
O'Connor MT, Vohr BR, Tucker R et al. Is retinopathy of prematurity increasing
among infants less than 1250 g birth weight? J Perinatol. 2003;23:673-8.
Osmond C, Kajantie E, Forsen TJ et al. Infant growth and stroke in adult life: the
Helsinki birth cohort study. Stroke 2007;38:264-70.
Park KH, Hwang JM, Choi MY et al. Retinal detachment of regressed retinopathy of
prematurity in children aged 2 to 15 years. Retina 2004;24:368-75.
Patz A. The role of oxygen in retrolental fibroplasia. Sinai Hosp.J.(Balt.) 1954;3:6-
20.
Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia
causes severe proliferative retinopathy in the newborn rat. Pediatr.Res. 1994;36:724-
31.
122
Penn JS, Johnson BD. Fluorescein angiography as a means of assessing retinal
vascular pathology in oxygen-exposed newborn rats. Curr.Eye Res. 1993;12:561-70.
Penn JS, Thum LA. The rat as an animal model for retinopathy of prematurity.
Prog. Clin.Biol.Res. 1989;314:623-42.
Peters JW, Koot HM, de Boer JB et al. Major surgery within the first 3 months of
life and subsequent biobehavioral pain responses to immunization at later age: a case
comparison study. Pediatrics 2003;111:129-35.
Phelps DL. The Early Treatment for Retinopathy of Prematurity study: better
outcomes, changing strategy. Pediatrics 2004;114:490-1.
Pierce EA, Avery RL, Foley ED et al. Vascular endothelial growth factor/vascular
permeability factor expression in a mouse model of retinal neovascularization.
Proc.Natl.Acad.Sci. U.S.A 1995;92:905-9.
Pirazzoli P, Cacciari E, De IR et al. Developmental pattern of fetal growth hormone,
insulin-like growth factor I, growth hormone binding protein and insulin-like growth
factor binding protein-3. Arch Dis.Child Fetal Neonatal Ed 1997;77:F100-F104.
Plate KH, Warnke PC. Vascular endothelial growth factor. J Neurooncol.
1997;35:365-72.
Porter FL, Grunau RE, Anand KJ. Long-term effects of pain in infants.
J. Dev.Behav.Pediatr. 1999;20:253-61.
Provis JM, Leech J, Diaz CM et al. Development of the human retinal vasculature:
cellular relations and VEGF expression. Exp.Eye Res. 1997;65:555-68.
Provis JM. Development of the primate retinal vasculature. Prog.Retin.Eye Res.
2001;20:799-821.
Quinn GE, Dobson V, Saigal S et al. Health-related quality of life at age 10 years in
very low-birth-weight children with and without threshold retinopathy of
prematurity. Arch.Ophthalmol. 2004;122:1659-66.
Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML et al.
Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.
Retina 2008;28:S19-S25.
Rahi JS, Cable N. Severe visual impairment and blindness in children in the UK.
Lancet 2003;362:1359-65.
Rahi JS, Dezateux C. Epidemiology of visual impairment in Britain. Arch Dis.Child
1998;78:381-6.
123
Raju TN, Langenberg P, Bhutani V et al. Vitamin E prophylaxis to reduce
retinopathy of prematurity: a reappraisal of published trials. J.Pediatr. 1997; 131:844-
50.
Reece EA, Wiznitzer A, Le E et al. The relation between human fetal growth and
fetal blood levels of insulin-like growth factors I and II, their binding proteins, and
receptors. Obstet.Gynecol. 1994;84:88-95.
Regev RH, Lusky A, Dolfin T et al. Excess mortality and morbidity among small-
for-gestational-age premature infants: a population-based study. J Pediatr.
2003;143:186-91.
Regev RH, Reichman B. Prematurity and intrauterine growth retardation-double
jeopardy? Clin.Perinatol. 2004;31:453-73.
Reynolds JD, Hardy RJ, Kennedy KA et al. Lack of efficacy of light reduction in
preventing retinopathy of prematurity. Light Reduction in Retinopathy of
Prematurity (LIGHT-ROP) Cooperative Group. N.Engl.J.Med. 1998;338:1572-6.
Ricci B, Calogero G. Oxygen-induced retinopathy in newborn rats: effects of
prolonged normobaric and hyperbaric oxygen supplementation. Pediatrics
1988;82:193-8.
Richardson DK, Gray JE, Gortmaker SL et al. Declining severity adjusted mortality:
evidence of improving neonatal intensive care. Pediatrics 1998;102:893-9.
Robinson GS, Pierce EA, Rook SL et al. Oligodeoxynucleotides inhibit retinal
neovascularization in a murine model of proliferative retinopathy.
Proc.Natl.Acad.Sci. U.S.A 1996;93:4851-6.
Romagnoli C. Risk factors and growth factors in ROP. Early Hum.Dev.
2009;85:S79-S82.
Roth DB, Morales D, Feuer WJ et al. Screening for retinopathy of prematurity
employing the retcam 120: sensitivity and specificity. Arch Ophthalmol
2001;119:268-72.
Rowlands E, Ionides AC, Chinn S et al. Reduced incidence of retinopathy of
prematurity. Br.J Ophthalmol 2001 ;85:933-5.
Royal College of Paediatrics and Child Health, Royal College of Ophthalmologists,
British Association of Perinatal Medicine and BLISS. Guideline for Screening and
Treatment of Retinopathy of Prematurity. 2008.
Ruda MA, Ling QD, Hohmann AG et al. Altered nociceptive neuronal circuits after
neonatal peripheral inflammation. Science 2000;289:628-31.
124
Rush R, Rush S, Nicolau J et al. Systemic manifestations in response to mydriasis
and physical examination during screening for retinopathy of prematurity. Retina
2004;24:242-5.
Salonen MK, Kajantie E, Osmond C et al. Childhood growth and future risk of the
metabolic syndrome in normal-weight men and women. Diabetes Metab
2009;35:143-50.
Sammartino M, Bocci MG, Ferro G et al. Efficacy and safety of continuous
intravenous infusion of remifentanil in preterm infants undergoing laser therapy in
retinopathy of prematurity: clinical experience. Paediatr.Anaesth. 2003;13:596-602.
Saugstad OD. Update on oxygen radical disease in neonatology.
Curr.Opin.Obstet.Gynecol. 2001;13:147-53.
Saunders RA, Bluestein EC, Sinatra RB et al. The predictive value of posterior pole
vessels in retinopathy of prematurity. J Pediatr.Ophthalmol Strabismus 1995;32:82-
5.
Saunders RA, Miller KW, Hunt HH. Topical anesthesia during infant eye
examinations: does it reduce stress? Ann.Ophthalmol. 1993;25:436-9.
Schaffer DB, Palmer EA, Plotsky DF et al. Prognostic factors in the natural course
of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Ophthalmology 1993;100:230-7.
Schalij-Delfos NE, Cats BP. Retinopathy of prematurity: the continuing threat to
vision in preterm infants. Dutch survey from 1986 to 1994. Acta Ophthalmol Scand.
1997;75:72-5.
Schiariti V, Matsuba C, Hoube JS et al. Severe retinopathy of prematurity and visual
outcomes in British Columbia: a 10-year analysis. J Perinatol. 2008;28:566-72.
Schulenburg WE, Tsanaktsidis G. Variations in the morphology of retinopathy of
prematurity in extremely low birthweight infants. Br.J Ophthalmol 2004;88:1500-3.
Scott KE, Kim DY, Wang L et al. Telemedical diagnosis of retinopathy of
prematurity intraphysician agreement between ophthalmoscopic examination and
image-based interpretation. Ophthalmology 2008;115:1222-8.
Sears JE, Pietz J, Sonnie C et al. A change in oxygen supplementation can decrease
the incidence of retinopathy of prematurity. Ophthalmology 2009(3);513-518.
Seiberth V, Linderkamp O. Risk factors in retinopathy of prematurity, a multivariate
statistical analysis. Ophthalmologica 2000;214:131-5.
Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability
factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
125
Shah PK, Narendran V, Kalpana N et al. Anatomical and visual outcome of stages 4
and 5 retinopathy of prematurity. Eye (Lond) 2009;23:176-80.
Shah PK, Narendran V, Saravanan VR et al. Screening for retinopathy of
prematurity—a comparison between binocular indirect ophthalmoscopy and RetCam
120. Indian J Ophthalmol 2006;54:35-8.
Shastry BS, Pendergast SD, Hartzer MK et al. Identification of missense mutations
in the Norrie disease gene associated with advanced retinopathy of prematurity.
A rch.Ophthalmol. 1997;115:651-5.
Shohat M, Reisner SH, Krikler R et al. Retinopathy of prematurity: incidence and
risk factors. Pediatrics 1983;72:159-63.
Silverman WA. A cautionary tale about supplemental oxygen: the albatross of
neonatal medicine. Pediatrics 2004;113:394-6.
Simpson JM, Evans N, Gibberd RW et al. Analysing differences in clinical outcomes
between hospitals. Qual.SafHealth Care 2003;12:257-62.
Slevin M, Murphy JF, Daly L et al. Retinopathy of prematurity screening, stress
related responses, the role of nesting. Br.J Ophthalmol 1997;81:762-4.
Smith LE, Shen W, Perruzzi C et al. Regulation of vascular endothelial growth
factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.
Nat.Med 1999;5:1390-5.
Smith LE, Wesolowski E, McLellan A et al. Oxygen-induced retinopathy in the
mouse. Invest Ophthalmol. Vis.Sci. 1994;35:101-11.
Smith LE. IGF-1 and retinopathy of prematurity in the preterm infant. Biol.Neonate
2005;88:237-44.
Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm.IGF.Res.
2004;14 Suppl A:S140-S144.
Smith WJ, Underwood LE, Keyes L et al. Use of insulin-like growth factor I (IGF-I)
and IGF-binding protein measurements to monitor feeding of premature infants.
J. Clin.Endocrinol.Metab 1997 ;82:3982-8.
Snoeck A, Remacle C, Reusens B et al. Effect of a low protein diet during pregnancy
on the fetal rat endocrine pancreas. Biol.Neonate 1990;57:107-18.
Sola A, Rogido MR, Deulofeut R. Oxygen as a neonatal health hazard: call for
detente in clinical practice. Acta Paediatr. 2007;96:801-12.
Steinkuller PG, Du L, Gilbert C et al. Childhood blindness. J AAPOS. 1999;3:26-32.
126
Stevens B, Johnston C, Petryshen P et al. Premature Infant Pain Profile: development
and initial validation. Clin.J Pain 1996;12:13-22.
Stone J, Chan-Ling T, Pe'er J et al. Roles of vascular endothelial growth factor and
astrocyte degeneration in the genesis of retinopathy of prematurity. Invest
Ophthalmol. Vis.Sci. 1996;37:290-9.
Stone J, Itin A, Alon T, Pe'er J et al. Development of retinal vasculature is mediated
by hypoxia-induced vascular endothelial growth factor (VEGF) expression by
neuroglia. JNeurosci. 1995;15:4738-47.
Sun X, Lemyre B, Barrowman N et al. Pain management during eye examinations
for retinopathy of prematurity in preterm infants: a systematic review. Acta Paediatr.
2010;99:329-34.
Sung IK, Vohr B, Oh W. Growth and neurodevelopmental outcome of very low birth
weight infants with intrauterine growth retardation: comparison with control subjects
matched by birth weight and gestational age. J.Pediatr. 1993;123:618-24.
Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity
(STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics
2000;105:295-310.
Tamai H, Majima A. Implications of the severity of retinopathy of prematurity on
childhood development. Jpn.J.Ophthalmol. 1996;40:371-6.
Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular
sheath behind each crystalline lens. Am J Ophthalmol 25; 1942:203-206.
The Committee for the Classification of Retinopathy of Prematurity. An international
classification of retinopathy of prematurity. Arch Ophthalmol 1984;102:1130-1134.
The General Register Office for Scotland. Scotland 2001 Census. 2007.
The International Classification of Retinopathy of Prematurity revisited. Arch
Ophthalmol 2005;123:991-9.
The photographic screening for retinopathy of prematurity study (photo-ROP).
Primary outcomes. Retina 2008;28:S47-S54.
Tin W, Milligan DW, Pennefather P et al. Pulse oximetry, severe retinopathy, and
outcome at one year in babies of less than 28 weeks gestation. Arch Dis.Child Fetal
Neonatal Ed 2001;84:F106-F110.
Todd D, Kennedy J, Roberts V et al. Risk factors in progression beyond stage 2
retinopathy of prematurity. Aust N.Z.J Ophthalmol 1990;18:57-60.
127
Todd DA, Wright A, Smith J. Severe retinopathy of prematurity in infants <30
weeks' gestation in New South Wales and the Australian Capital Territory from 1992
to 2002. Arch Dis.Child Fetal Neonatal Ed 2007;92:F251-F254.
Tokuhiro Y, Yoshida T, Nakabayashi Y et al. Reduced oxygen protocol decreases
the incidence of threshold retinopathy of prematurity (ROP) in infants of less than 33
weeks gestation. Pediatr.Int. 2009;51:804-6.
Treins C, Giorgetti-Peraldi S, Murdaca J et al. Regulation of hypoxia-inducible
factor (HIF)-l activity and expression of HIF hydroxylases in response to insulin-like
growth factor I. Mol.Endocrinol. 2005;19:1304-17.
Tyson JE, Kennedy K, Broyles S, et al. The small for gestational age infant:
accelerated or delayed pulmonary maturation? Increased or decreased survival?
Pediatrics 1995;95:534-8.
Valentine PH, Jackson JC, Kalina RE et al. Increased survival of low birth weight
infants: impact on the incidence of retinopathy of prematurity. Pediatrics
1989;84:442-5.
van Kleffens M, Groffen C, Lindenbergh-Kortleve DJ et al. The IGF system during
fetal-placental development of the mouse. Mol.Cell Endocrinol. 1998;140:129-35.
Vanderveen DK, Mansfield TA, Eichenwald EC. Lower oxygen saturation alarm
limits decrease the severity of retinopathy of prematurity. J AAPOS. 2006;10:445-8.
Vanhaesebrouck S, Daniels H, Moons L et al. Oxygen-induced retinopathy in mice:
amplification by neonatal IGF-I deficit and attenuation by IGF-I administration.
Pediatries. 2009;65:307-10.
Vasu V, Modi N. Assessing the impact of preterm nutrition. Early Hum.Dev.
2007;83:813-8.
Vento G, Matassa PG, Ameglio F et al. HFOV in premature neonates: effects on
pulmonary mechanics and epithelial lining fluid cytokines. A randomized controlled
trial. Intensive Care Med 2005;31:463-70.
Ventresca MR, Gonder JR, Tanswell AK. Oxygen-induced proliferative retinopathy
in the newborn rat. Can.J.Ophthalmol. 1990;25:186-9.
Vohr BR, Wright LL, Dusick AM et al. Center differences and outcomes of
extremely low birth weight infants. Pediatrics 2004;113:781-9.
Vyas J, Field D, Draper ES et al. Severe retinopathy of prematurity and its
association with different rates of survival in infants of less than 1251 g birth weight.
Arch.Dis.Child Fetal Neonatal Ed 2000;82:F145-F149.
128
Wallace DK, Kylstra JA, Phillips SJ et al. Poor postnatal weight gain: a risk factor
for severe retinopathy of prematurity. J AAPOS. 2000;4:343-7.
Wallace DK, Quinn GE, Freedman SF et al. Agreement among pediatric
ophthalmologists in diagnosing plus and pre-plus disease in retinopathy of
prematurity. J.AAPOS. 2008;12:352-6.
Wallace DK, Veness-Meehan KA, Miller WC. Incidence of severe retinopathy of
prematurity before and after a modest reduction in target oxygen saturation levels. J
AAPOS. 2007;11:170-4.
Wigglesworth JS. Experimental growth retardation in the foetal rat.
J.Pathol.Bacteriol. 1964;88:1-13.
Woodall SM, Breier BH, Johnston BM et al. A model of intrauterine growth
retardation caused by chronic maternal undernutrition in the rat: effects on the
somatotrophic axis and postnatal growth. J.Endocrinol. 1996;150:231-42.
Wright KW, Sami D, Thompson F et al. A physiologic reduced oxygen protocol
decreases the incidence of threshold retinopathy of prematurity. Trans.Am
Ophthalmol Soc. 2006;104:78-84.
Wu C, Petersen RA, Vanderveen DK. RetCam imaging for retinopathy of
prematurity screening. J AAPOS. 2006;10:107-11.
Wu C, Vanderveen DK, Hellstrom A et al. Fongitudinal postnatal weight
measurements for the prediction of retinopathy of prematurity. Arch.Ophthalmol.
2010;128:443-7.
Yen KG, Hess D, Burke B et al. Telephotoscreening to detect retinopathy of
prematurity: preliminary study of the optimum time to employ digital fundus camera
imaging to detect ROP. J AAPOS. 2002;6:64-70.
Young TF, Anthony DC, Pierce E et al. Histopathology and vascular endothelial
growth factor in untreated and diode laser-treated retinopathy of prematurity.
J.AAPOS. 1997;1:105-10.
Yu VY, Upadhyay A. Neonatal management of the growth-restricted infant.
Semin.Fetal Neonatal Med. 2004;9:403-9.
Zhang S, Leske DA, Holmes JM. Neovascularization grading methods in a rat model
of retinopathy of prematurity. Invest Ophthalmol.Vis.Sci. 2000;41:887-91.
Zhang S, Feske DA, Fanier WF et al. Postnatal growth retardation exacerbates
acidosis-induced retinopathy in the neonatal rat. Curr.Eye Res. 2001;22:133-9.
Zhang Y, Stone J. Role of astrocytes in the control of developing retinal vessels.





1.2.1 Phosphate buffered saline (PBS)
To make 1 litre:- weigh out 7g NaCl, 3.4g Na2HPC>4, 0.8g KH2P04 [Sigma-Aldrich,
UK] and make up to 1 litre with distilled water. Check pH 7.3 using pH meter.
1.2.2 PX
1M buffered saline with 1% triton X.
To make lOOmls PX:- take 10ml of 10% triton X stock solution [BDH, UK] and
make up to lOOmls with 1M buffered saline.
1.2.3 Blocking buffer
5% swine serum [Vector Laboratories Ltd, UK], 0.1% bovine serum albumin
[Sigma-Aldrich UK], 0.3% triton X [BDH UK],
To make lOOmls blocking buffer:- take 5mls swine serum, 0.lg bovine serum
albumin, 0.3mls triton X and make up to lOOmls with 1M buffered saline
1.2.4 Mowiol Mounting Medium
Add 2.4g Mowiol [Calbiochem, Merck, UK] to 6g of glycerol [Sigma-Aldrich, UK].
Add 12mls distilled water and leave at room temperature overnight. Add 12mls 0.2M
Tris [Sigma-Aldrich, UK] and heat to 50°C for 1-2 hours until Mowiol dissolved.
Centrifuge at 2000rpm for 15 minutes. Add 0.72g of 1,4-DABCO [Sigma-Aldrich,
UK], Aliquot and store at -20°C.
1.3 Rat diets
The diet compositions tabulated on the following page were kindly supplied by Dr
Simon Langley-Evans, University of Nottingham. The diets were made to these
compositions and supplied to us by Special Diets Services, Edinburgh. The crude






Casein (dry acid free) 180 90




Vitamins 1 5 5
Minerals 1 20 20
Choline chloride 2 2
D,L-Methionine 5 5
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ABSTRACT
Background: To report the trends in incidence of
retinopathy of prematurity (ROP) within Lothian, a
geographically defined region in southeast Scotland over a
15-year period from 1990 to 2004.
Methods: This was a prospective observational study of
all infants born with gestational age <32 weeks and/or
birth weight <1500 g who were born to mothers
resident in Lothian between 1 January 1990 and 31
December 2004. Eligible infants underwent eye screening
by two experienced paediatric ophthalmologists (BF and
EW). Lothian population data were obtained from the
Scottish Health Service. The trends in survival rates,
incidence and treatment of ROP were analysed from 1990
to 1994, 1995 to 1999 and 2000 to 2004.
Results: Lothian population data showed a steady
decline in the number of live births from 1990 to 2004.
The proportion of babies born with birth weight <1500 g
and/or gestational age <32 weeks remained constant
(p = 0.271 using x2 test), although the proportion of
these babies surviving to 42 weeks corrected gestation
increased from 1990 to 2004 (p<0.001 using x2 test for
trend). There was a statistically significant linear trend
towards a reduction in the number of babies undergoing
treatment for ROP throughout the study period (p<0.01
using x2 test for trend). A reduction in the incidence of
any degree of ROP and severe (stage 3 or greater) ROP
was also observed although this did not reach statistical
significance.
Conclusions: There was a significant increase in survival
of infants with birth weight <1500 g and/or gestational
age <32 weeks together with a significant reduction in
the number of infants treated for ROP in the Lothian
region of southeast Scotland from 1990 to 2004.
What is already known on this topic
Many centres are now reporting a reduction in
the incidence of retinopathy of prematurity
(ROP).
However very few population-based studies
have been published which accurately report the
longer-term trends in ROP incidence.
Retinopathy of prematurity (ROP) is a disorder of
retinal vascular development in premature infants.
It is a major cause of childhood blindness world¬
wide.1 The trends in incidence of ROP over time
have been the subject of much debate. Since ROP
was first described in 1942,2 there have been two
notable epidemics within the developed world.3"6
The first was seen in the early 1950s and was
associated with exposure to high oxygen concen¬
trations for prolonged periods of time.3 The second
epidemic developed in the 1980s and was related to
increased survival of very low birth weight
(BW<1500 g) infants associated with advances in
neonatal medicine.4"7 Many centres have reported a
decline in the incidence of ROP in the 1990s and
early 2000s.s" Since then, there has been an
increasing body of evidence demonstrating that a
modest reduction in target oxygen saturation levels
is associated with a reduction in the incidence of
severe ROP.12"15 There has, however, been a marked
What this study adds
This 15-year population-based study shows a
significant increase in survival of infants with
birth weight <1500g and/or gestational age
<32weeks together with a significant reduction
in the number of infants undergoing treatment
for ROP.
There was also a trend towards a reduced
number of infants with any stage of ROP and
severe (stage 3 or greater) ROP.
lack of population-based studies, which will report
the longer term trends in incidence of ROP most
accurately.16"21
We report the trends in incidence of ROP within
Lothian, a geographically defined region in south¬




This was a prospective observational cohort study.
The population of the study consisted of all infants
eligible for eye screening who were born to
mothers' resident within the Lothian region of
southeast Scotland during the study period of 1
January 1990 - 31 December 2004. All infants born
with gestational age <32 weeks and/or birth
weight <1500 g who survived until eye screening
commenced were eligible. Eligible Lothian babies
born outside Lothian and transferred back into
Lothian during eye screening were included.
The total population of Lothian increased
steadily from approximately 745 000 in 1990 to
790 000 in 2004. There were approximately 9800
livebirths in 1990 which decreased over the years to
8300 in 2004. During the study period infants were
born at one of three hospitals:
► The Simpson Memorial Maternity Pavilion/the
New Royal Infirmary, Edinburgh: Level 3
South East Scotland Regional Neonatal Unit
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with over 6000 live births per year. Approximately 520
infants admitted to neonatal unit each year. Hospital moved
to the site of the New Royal Infirmary, Edinburgh in
summer 2002.
► The Eastern General Hospital, Edinburgh: Level 2 neonatal
unit with approximately 2200 live births and 250 babies
admitted to the neonatal unit each year. This hospital closed
in April 1998.
St Johns Hospital, Livingston: Level 2 neonatal unit with
approximately 2400 live births and 170 admissions to the
neonatal unit each year.
Nursing staff in these hospitals referred all eligible babies to
the ophthalmology team. Ophthalmologists recorded the date
of birth, sex, gestational age, birth weight and maximum
severity of ROP reached in any one eye for every baby
examined. This information was prospectively stored on a
database. Each hospital throughout the period of study used
oxygen saturation monitor thresholds of 86-94%.
Lothian population epidemiological data
Epidemiological data was obtained from the Information
Services Division (ISD) of the Scottish Health Service, which
accessed the Scottish Morbidity Record (SMR02). Their figures
differ from our Lothian hospital data and our results are based
on both sources. Unfortunately, we could not cross-check our
data with ISD due to patient confidentiality and data protection
legislation, thus a small discrepancy remains.
Eye examination schedule
Screening and treatment (if required) was carried out by two
dedicated paediatric ophthalmologists (BF and EW). Eligible
infants were first examined at 4-6 weeks chronological age, or
34 weeks corrected age, whichever was earlier. Screening was
continued fortnightly until full retinal vascularisation.
Examinations were performed weekly if "prethreshold" disease
was found (see below for definition).
Eye examination technique
Pupils were dilated with topical phenylephrine 2.5% and
tropicamide 0.5% applied 60 min and 30 min prior to eye
examination. Indirect ophthalmoscopy was performed using a
binocular indirect ophthalmoscope and 28 Dioptre lens. A lid
speculum and scleral indenter were routinely used. The entire
retina was examined, including the periphery throughout 360°.
Retinopathy was graded according to the International
Classification of ROP.22 The stage of ROP (1-5), zone of
vascularisation, number of clock hours of ROP and presence or
absence of "plus" disease was documented in both the eye
logbook and patient medical notes. "Plus" disease represented
significant dilatation and tortuosity of posterior pole blood
vessels.22 "Threshold" ROP referred to five or more contiguous
or eight or more cumulative clock hours of stage 3 ROP in zones
1 or 2 in the presence of "plus" disease.22 "Prethreshold" disease
consisted of any stage 3 disease less extensive than threshold, or
stage 2 disease in the presence of "plus".22 All eyes examined
with "threshold" ROP were treated with cryotherapy in 1990-
1991 and with diode laser therapy from 1992 onwards. From
January 2005 new treatment criteria were used following the
publication of the Early Treatment For Retinopathy Of
Prematurity (ETROP) study.23 The study was therefore termi¬
nated at the end of 2004.
Statistical analysis
For analysis, the maximum severity of ROP in either eye for an
individual infant was recorded. The 15-year study period was
divided into three 5-year epochs: 1990-4, 1995-9 and 2000-4.
Statistical analysis was performed using the GraphPad
InStat programme (GraphPad Software, California, USA).
Contingency tables were analysed using the y2 test (y2) and x2
test for trend (y2 trend). As birth weights and gestational ages
did not appear to follow a normal distribution, the Mann-
Whitney test was used to compare the missing eligible babies
with those of the study population. The Kruskal—Wallis test
was used to compare the birth weights and gestational ages of
the study population in each of the three epochs. In all cases a p
value <0.05 was taken to indicate statistical significance.
The Lothian Research Ethics Committee were contacted and
it was declared that no ethical approval was required for this
research.
RESULTS
Lothian population epidemiological data—supplied by ISD
(table 1)
The proportion of babies born with birth weight <1500 g and/
or gestational age <32 weeks who survived to 42 weeks'
corrected gestational age (CGA) has increased from 1990 to
2004 (p<0.001 using y2 trend). This increase in survival is
evident despite the proportion of these babies being born
remaining unchanged (p = 0.271 using y2).
Study population—from Lothian hospitals data
During the study period, there were 1450 eligible babies
registered for eye screening; 77 (5%) were discharged home
prior to eye screening, or failed to attend outpatient eye
screening. There were insufficient medical records from 10
(0.7%) babies. Thus complete data were available on 1363
infants (1363/1450, 94% of eligible population). ISD reported a
total of 1636 babies from 1990 to 2004 with birth weight
<1500 g and/or gestational age <32 weeks where the baby
survived to CGA 42 weeks or more (table 1). Therefore, a
discrepancy of 186 babies remains between our hospital data
and ISD data. We could not access details on these babies due to
Table 1 Lothian population epidemiological data (supplied by ISD Scotland)
Time periods Livebirths
Livebirths BW <1500 g and/
or GA <32 weeks (% of
livebirths)
Livebirths BW <1500 g and/or
GA <32 weeks admitted to
Lothian neonatal units
Livebirths BW <1500 g and/or GA <32 weeks
surviving to CGA 42 weeks (% of livebirth BW
<1500 g and/or GA <32 weeks)*
1990-4 47 937 701 (1.5) 637 586 (84)
1995-9 44 410 596 (1.3) 547 518 (87)
2000-4 40 833 587 (1.4) 564 532 (91)
Total 133 180 1884 (1.4) 1748 1636 (87)
*X2 trend shows evidence towards increased survival 1990-2004 (p<0.001).
BW, birth weight; CGA, corrected gestational age; GA, gestational age.
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Table 2 Incidence of retinopathy of prematurity (ROP) in Lothian hospitals study population (1363 babies)
Time period Total number of babies
Number of babies with any degree
of ROP (% of total number)*
Number of babies with severe
ROP (% of total numberjt
Number of babies treated for
ROP (% of total number)):
1990-4 442 96 (22) 53 (12) 41 (9)
1995-9 447 94 (21) 39 (9) 21 (5)
2000-4 474 81 (17) 45 (9) 24 (5)
Severe ROP = stage 3 or greater ROP.
*No evidence of a statistically significant difference (x2 = 3.628, p = 0.16; x2 trend = 3.13, p = 0.08).
iNo evidence of a statistically significant difference (x2 = 2.872, p = 0.24; xz trend = 1.52, p = 0.22).
^Evidence of a statistically significant difference (x2 = 9.789, p<0.01; x2 trend = 6.686, p<0.01).
patient confidentiality and data protection legislation and
therefore could not cross-check our hospital records with ISD.
The median gestational age for the Lothian hospitals study
population (1363) was 29 weeks, (interquartile range 28-31),
median birth weight was 1240 g (interquartile range 965-1490).
The study population comprised 54% boys. The median
gestational age of the missing eligible babies (enough data only
from 77 discharged babies) was 31 weeks (interquartile range
30-32) and median birth weight was 1467 g (interquartile range
1340-1675). Using the Mann-Whitney test we found that the
77 babies had a significantly higher gestational age (p<0.001)
and also a higher birth weight (p<0.001). These baseline
characteristics were expected as only the more mature and
heavier babies would have been discharged prior to commence¬
ment of eye screening.
The baseline characteristics of infants in the three time
epochs, 1990-4, 1995-9 and 2000-4, were also calculated. There
was no evidence of statistically significant differences in birth
weight (Kruskal-Wallis, p = 0.48) or gestational age at birth
(Kruskal-Wallis, p = 0.09) between the three cohorts.
Incidence and severity of ROP in Lothian hospitals study
population (table 2)
One baby in 1999 developed stage 4 ROP after laser treatment.
No babies developed stage 5 ROP during the study period. The
heaviest baby treated weighed 1190 g at birth and the most
mature baby treated was 30 weeks' gestation at birth.
Incidence and severity of ROP in Lothian hospitals study
population for birth weight categories (tables 3 and 4)
From Lothian hospitals study population data, a total of 1032
babies with birth weight <1500 g underwent eye screening
from 1990 to 2004. The remaining 331 babies had gestational
ages <32 weeks but birth weights >1500 g and were not
included in this analysis. A trend towards a greater proportion
of babies with birth weight <750 g having no ROP (p = 0.03)
was observed, and a reduced proportion of these babies required
treatment (p<0.01). The incidence of severe ROP in babies with
birth weight 1000-1249 g and 1250-1499 g was consistently
low and there was a trend towards fewer 1250-1499 g birth
weight babies having any ROP (p = 0.04). No statistically
significant trends from 1990 to 2004 were observed for babies
with birth weight 750-999 g and 1000-1249 g.
Incidence and severity of ROP in Lothian hospitals study
population for gestational age categories
Similar trends were observed when considering the babies in
gestational age categories (see data supplement online).
DISCUSSION
The changing trends in the incidence of ROP have been the
cause of much debate. Improved survival rates for premature
infants led to the concern that the incidence of ROP
might increase.6 24 Conversely, improved neonatal care led to a
reported decrease in the incidence of ROP in some centres.8 "~15
Table 3 Incidence of retinopathy of prematurity (ROP) in Lothian hospitals study population with birth weight <750 g and 750-999 g
Babies with stage 3 ROP, Babies with stage 3 ROP,
Total babies screened in Babies with no ROP (% of Babies with stages 1,2 ROP untreated (% of babies treated (% of babies
Birth weight (g)
Lothian babies screened) (% of babies screened) screened) screened)
<750 750-999 <750* 750-999 <750 750-999 <750 750-999 <750t 750-999
1990-4 35 92 6 (17) 50 (54) 6(17) 16 (17) 4 (11) 7 (8) 19 (54) 19 (21)
1995-9 50 61 9 (18) 37 (61) 15 (30) 15 (25) 11 (22) 4(7) 15 (30) 5(8)
2000-4 48 83 18 (38) 51 (61) ^ (15) 16 (19) 11 (23) 6 (7) 12 (25) 10 (12)
"Linear trend towards increased proportion of babies with no ROP (x2 = 6.489, p = 0.04; x2 trend = 5.050, p = 0.03).
tLinear trend towards reduced proportion of babies treated (x2 = 8.418, p = 0.01; x2 trend = 7.148, p<0.01).
Table 4 Incidence of retinopathy of prematurity (ROP) in Lothian hospitals study population with birth weight 1000-1249 g and 1250-1499 g
Babies with stage 3 R0P-
Total babies screened in Babies with no ROP (% of Babies with stages 1,2 ROP untreated (% of babies Babies with stage 3 ROP-
Lothian babies screened) (% of babies screened) screened) treated (% of babies screened)
Birth weight
(g) 1000-1249 1250-1499 1000-1249 1250-1499* 1000-1249 1250-1499 1000-1249 1250-1499 1000-1249 1250
1990-1994 97 101 81 (84) 95 (94) 13 (13) 5 (5) 0 (0) 1 (D 3 (3) 0(0)
1995-1999 104 126 83 (80) 121 (96) 17 (16) 5 (4) 3 (3) 0 (0) 1 (D 0(0)
2000-2004 118 117 106 (90) 116 (99) 7 (6) 0(0) 3 (3) 1 ID 2 (2) 0 (0)
•Linear trend towards increased proportion of babies with no ROP (x2 = 4.301, p = 0.12; x2 trend = 4.224, p = 0.04).
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Our prospective population based study has found a significant
reduction in the number of babies treated for ROP from 1990 to
2004. A reduction in the overall incidence of any degree of ROP
and severe ROP was also observed. We have also seen an
increase in overall survival in babies with birth weight <1500 g
or gestational age <32 weeks.
Our observed changes are based on a complete population
rather than single hospital data and therefore referral and
inclusion bias should be eliminated. Interobserver variation
should be minimal for detection of severe ROP as only two
examiners examined the population over the 15 year period and
both were experienced paediatric ophthalmologists. The meth¬
ods of ophthalmoscopic examination for ROP and the classifica¬
tion system used were the same for the whole study period. We
have not, however, analysed our incidence of mild (stage 1 or 2)
ROP, as these data are less robust due to likely inherent observer
error in scoring these lesser grades. There may have been an
under-reporting of "any degree of ROP" and a related over-
reporting of "no ROP" as a consequence of failure to detect
minor degrees of ROP. The context of this prospective data
acquisition was as a clinical service rather than a precisely
defined epidemiological project as in other studies.17 We did not
formally record ethnicity but results from the 2001 census in
Scotland report the Scottish population as being 98%
Caucasian, 1.4% Asian and 0.6% African Caribbean and other
ethnic background.25 There was minimal movement of babies
between different centres. Oxygen saturation monitors were
introduced in the late 1990s and the target limits have always
been 86-94%. Arterial catheters were infrequently used
throughout the study period with the target partial pressure
of oxygen being 6-10 kPa.
Recent population studies report differing trends in the
incidence of ROP. Chiang et aI report a 20.3% incidence of any
ROP in infants with birth weight <1500 g born in New York
State between 1996 and 2000 which is a similar incidence to the
present Lothian study.20 Larsson et al compared ROP rates
during 1988-90 and 1998-2000 in Sweden and found no change
in incidence of any ROP and no change in severe ROP in infants
with birth weight <1500 g.26 Todd et al studied the incidence
and treatment of severe ROP in New South Wales and the
Australian Capital Territory from 1992 to 2002." They found a
considerable increase in severe ROP in infants <24 weeks'
gestation (42% to 54%) together with an increase in treatment
for severe ROP (19% to 24%). In infants of 25-26 weeks'
gestation there was a marked decrease in severe ROP (26% to
19%) and there was no change in infants with gestational age
27-29 weeks. In the most recent population-based study to be
carried out in the UK, Hameed et al2i reported on severe ROP in
Leicestershire from 1990 to 1999 in infants with birth weight
<1250 g. They found an increase in severe ROP from 4% in
1990-4 to 12% in 1995-9. This increase in severe ROP was also
observed in infants with birth weight <750 g. This is very
different from our findings as we observed a reduction in the
incidence of severe ROP in babies <750 g. The reason for the
different outcomes is unknown but the incidence of severe ROP
may be influenced by relatively minor changes in neonatal care
policies and practice.
The papers discussed above are all population studies
although most incidence papers published have observed the
trends in either a single hospital or a group of hospitals. These
findings can be difficult to relate to the population as a whole
due to local regional differences in survival rates, neonatal
management and ethnicity, but large hospital-based studies
over long periods of time still provide useful information.
Rowlands at al found a significant reduction in the incidence of
severe ROP from 1989 to 1998 in a level 2 neonatal unit in
London.9 Hussain et al reported on a similar time period (1989—
97) from a level 3 neonatal unit in the USA and found an
incidence of 21% for any stage ROP and 5% for severe ROP.8
These are very similar to our findings.
In the past decade, several publications have highlighted the
role of oxygen free radicals in several neonatal disease processes,
as well as ROP.27"29 As a result, many neonatal units have
implemented new oxygen saturation policies to reduce the
amount of supplemental oxygen given to premature babies.
Several large centres have reported a significant decrease in the
incidence of severe ROP following introduction of lower oxygen
saturation targets.12 14 15 We did not change our oxygen
saturation policy throughout the period of the study.
In summary, we have seen an increase in survival of preterm
infants, a reduction in the incidence of any degree of ROP,
severe ROP and a marked reduction in treatment for ROP in
Lothian from 1990 to 2004. The past 20 years have seen
dramatic advances in obstetric and neonatal care with routine
administration of antenatal corticosteroids for premature
labour, use of surfactant therapy, new methods of neonatal
mechanical ventilation, introduction of continuous pulse
oximetry, use of computerised monitoring systems and
advances in neonatal nutritional support. It is highly probable
that these advances are responsible for the overall decreasing
incidence of ROP.
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Retinopathy of prematurity in small-for-gestational
age infants compared with those of appropriate size
for gestational age
C A Dhaliwal,1 B W Fleck,2 E Wright,3 C Graham,4 N Mcintosh5
ABSTRACT
Aim: To compare the incidence of retinopathy of
prematurity (ROP) in small-for-gestational age (SGA)
infants compared with appropriate-for-gestational age
(AGA) infants undergoing eye screening in the Lothian
region of south east Scotland 1990-2004.
Methods: All infants in Lothian born with birth weight
<1500 g and/or gestational age <32 weeks underwent
eye screening by two experienced paediatric ophthal¬
mologists. The presence of any stage of ROP (1-5),
severe (stage 3 or greater) ROP and treated ROP was
compared between the SGA and AGA infants using x2 or
Fisher exact tests. SGA was defined as birth weight
below the 10th centile for gestational age.
Results: A total of 1413 babies with birth weights
<1500 g and/or gestational age <32 weeks underwent
eye screening; 329 (23%) were SGA. SGA infants born at
gestational ages 26-31 weeks were more likely to
develop any stage of ROP (p<0.01) than their AGA peers.
SGA infants were also more likely to develop severe ROP
(gestational age 26-27 weeks, p<0.01; 28-29 weeks,
p = 0.01; 30-31 weeks, p = 0.01).
Conclusions: SGA infants who underwent eye screening
in the Lothian region of south east Scotland from 1990 to
2004 were significantly more likely to develop ROP and
more severe disease than AGA infants.
Retinopathy of prematurity (ROP) is a vasoproli-
ferative disorder of the eye affecting premature
neonates. It is a major cause of childhood blindness
in both the developed and developing worlds.1 The
pathogenesis of ROP is multifactorial, although the
most recognised risk factors are low birth weight
and low gestational age.2 Small-for-gestational age
(SGA) infants are a vulnerable population. They
have a greater than average risk of morbidity and
mortality from many neonatal disorders and have
been reported to be at increased risk of developing
ROP.3"7 They are also at increased risk of develop¬
ing cardiovascular disease and type 2 diabetes in
later life.8 9 Research into the mechanisms of
perinatal growth is of major interest in order to
try to minimise these risks and optimise the care of
these infants. We report and compare the incidence
of ROP in SGA and appropriate-for-gestational age
(AGA) infants who underwent eye screening in the
Lothian region of south east Scotland over a 15-
year period from 1990 to 2004.
MATERIALS AND METHODS
Study population
In the Lothian region of south east Scotland, all
infants born at gestational age (GA) <32 weeks
What is already known on this topic
Small-for-gestational age (SGA) infants are at
higher than average risk of morbidity and mortality
from many neonatal disorders, including retinopathy
of prematurity (ROP).
What this study adds
In this large cohort of 1413 infants, SGA infants
born at 26-31 weeks' gestation were
more likely to develop any stage of ROP or severe
ROP.
and/or birth weight <1500 g have their eyes
screened for ROP. GA was determined by early
ultrasound examination. Infants were screened at
one of three hospitals:
1. The Simpsons Memorial Maternity Pavilion/
The New Royal Infirmary, Edinburgh: level 3
south east Scotland Regional Neonatal Unit.
Hospital moved to the site of the New Royal
Infirmary, Edinburgh in summer 2002.
2. The Eastern General Hospital, Edinburgh: level
2 neonatal unit. Hospital closed in April 1998.
3. St Johns Hospital, Livingston: level 2 neonatal
unit.
Eligible babies in these hospitals were referred to
the ophthalmology team by nursing staff.
Eye examination schedule
Two dedicated paediatric ophthalmologists (BWF
and EW) carried out all eye screening in Lothian.
Infants were first examined at 4-6 weeks' chron¬
ological age, or 34 weeks' corrected age, whichever
was earlier. Screening was repeated fortnightly
until full retinal vascularisation. If "prethreshold"
disease was found (see below for definition),
screening was carried out weekly. Eye examina¬
tions continued after discharge from hospital if the
vasculature was still immature when the infants
left.
Eye examination technique
Pupils were dilated with topical 2.5% phenylephr¬
ine and 0.5% tropicamide. Drops were applied
60 min and 30 min before the eye examination.
Indirect ophthalmoscopy was performed using a
binocular indirect ophthalmoscope and 28 dioptre
lens. A lid speculum and scleral indenter were
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routinely used. Retinopathy was graded according to the
international classification of ROP.10 The zone of vascularisa-
tion, presence or absence of "plus" disease, number of clock
hours of ROP, and the stage of ROP (1-5) were recorded. Plus
disease represented significant dilatation and tortuosity of
posterior pole blood vessels.10 "Threshold" disease referred to
five or more contiguous, or eight or more cumulative, clock
hours of stage 3 ROP in zones 1 or 2 in the presence of plus
disease.11 "Prethreshold" ROP consisted of any stage 3 disease
less extensive than threshold, or stage 2 disease in the presence
of plus.11 If threshold ROP was present, eyes were treated with
cryotherapy in 1990-1991 and laser therapy from 1992 onwards.
Data collection
After every eye examination, the ophthalmologists recorded the
date of birth, sex, GA, birth weight and maximum severity of
ROP reached in any one eye for every baby examined. This
information was stored on a database. The study included any
baby born between 1 January 1990and 31 December 2004. The
database was not analysed after 2004 because new treatment
criteria were used from January 2005 following the publication
of the ETROP study.12 For every baby, the birth weight was
plotted on a sex-specific growth chart.13 An infant was defined
as being SGA if their birth weight was below the 10th centile for
GA.
Statistical analysis
For analysis, the maximum severity of ROP in either eye for an
individual infant was recorded. Statistical analysis was per¬
formed using SPSS and the GraphPad Instat program. As birth
weights and GAs did not follow a normal distribution, Mann-
Whitney tests were used to compare the baseline characteristics
of the SGA and AGA babies. Contingency tables were analysed
in GA categories using x~ test with Yate's continuity correction.
The Fisher exact test was used when numbers were small. In all
cases, a two-sided p value of <0.05 was taken to indicate
significance.
The Lothian research ethics committee declared that ethical
approval was not required for this research.
RESULTS
Study population
In Lothian, from 1990 to 2004 there were 1748 live births with
birth weight <1500 g and/or GA <32 weeks admitted to
Lothian neonatal units.14 Of these infants, 1668 were registered
for eye screening. The difference between the number of live
births and the number registered for screening was due to 80
babies dying before reaching screening age. Of the infants
registered, 168 (10%) were transferred to a neonatal unit
outwith Lothian before eye screening, 77 (5%) were discharged
home before eye screening or failed to attend outpatient eye
screening, and there were insufficient medical records for 10
(<1%). Thus complete data were available for 1413 infants. Just
under a quarter (329/1413; 23%) of the study population were
SGA. Table 1 shows the baseline characteristics.
The SGA infants had a higher median birth weight and GA
than the AGA infants (Mann-Whitney p<0.0001 for both).
There were more female infants than male infants in the SGA
cohort.
Prevalence and severity of ROP
Table 2 presents eye findings. One AGA baby in 1999 developed
stage 4 ROP after laser treatment. No babies developed stage 5
ROP during the study period. The numbers of AGA and SGA
infants with any stage of ROP (1-5), severe (stage 3 or greater)
ROP and treated ROP were compared using the x2 test, or the
Fisher exact test when cell numbers were small. Table 2 gives
the findings. SGA infants born at GA 26-31 weeks were more
likely to develop any stage of ROP (p<0.01) than their AGA
peers. They were also more likely to develop severe ROP (GA
26-27 weeks, p<0.01; GA 28-29 weeks, p = 0.01; GA 30-
31 weeks, p = 0.01).
DISCUSSION
Our ROP eye screening data gathered over 15 years show that
SGA infants (GA 26-31 weeks) are more likely to develop any
stage of ROP and severe ROP than their AGA peers. We did not
find this association to be significant in infants of GA
<25 weeks. This may have been because of the small numbers
at this gestation, but also because these infants are at a high risk
of ROP irrespective of whether they are SGA or AGA. We also
did not find a significant difference in SGA and AGA infants of
GA >32 weeks and this is almost certainly due to the low
incidence and low risk of developing ROP at this GA. When the
numbers of SGA and AGA infants treated for ROP were
compared with the numbers of those with ROP but not treated,
SGA infants were no more likely to require laser treatment for
severe ROP. Again, this finding can probably be explained by
the small numbers with treated ROP.
Our study is useful, as our findings are based on a large cohort
of babies over a long period of time with two consistent
observers and methodical documentation of eye examinations.
The two specialised ophthalmologists (EW and BF) have worked
together using indirect ophthalmoscopy to perform all the ROP
eye screening examinations in the Lothian region since 1990. In
2007, for the purposes of another study, the examiners
undertook interobserver agreement studies by independently
and blindly grading 80 clinical ROP screening Retcam images.
They showed 95% agreement for the presence or absence of plus
disease, 94% agreement for stage of ROP, and 97% agreement
for zone of ROP. We are therefore confident that interobserver
variation was minimal. The methods of ophthalmoscopic
examination for ROP and the classification system used were
the same over the whole study period. Ethnicity was not
formally recorded, but the 2001 census in Scotland reported the
population as being 98% Caucasian, 1.4% Asian and 0.6% Afro-
Caribbean and other ethnic background.15 As both level 2 and 3
Table 1 Baseline characteristics of the study population
Number (male:female) Birth weight (g)* GA (weeks)* Number nf GA s=32 weeks
AGA infants 1084 (617:438)t 890(585-1170) 27(26-31) 25
SGA infants 329(130:194)1 1035(825-1235) 31(29-32) 125
•Median (interquartile range).
tSex not recorded for 29 babies.
JSex not recorded for five babies.
AGA, appropriate-for-gestational age; GA, gestational age; SGA, small-for-gestational age.
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Table 2 Maximum severity of retinopathy of prematurity (ROP) in appropriate-for-gestational age (AGA) and
small-for-gestational age (SGA) babies (and the significance of differences)
<25 weeks 26-27 weeks 28-29 weeks 30-31 weeks 3=32 weeks
Without ROP (AGA:SGA) 27:0 112:6 265:51 429:83 25:123
Stages 1,2 ROP (AGA:SGA) 31:3 39:10 25:10 15:11 0:1
Stage 3 ROP untreated (AGA:SGA) 19:0 12:11 4:5 0:1 0:1
Stage 3 ROP treated (AGA:SGA) 51:3 28:8 2:1 0:1 0:0
p Value of difference*
Any stage of ROP 0.46 <0.01 <0.01 <0.01 LOOt
Severe (stage 3-5) ROP 1.00t <0.01 0.01 0.03t LOOt
Treated ROP 1.00t 0.59 LOOt 0.46t -
*p Values relate to comparison of numbers of AGA and SGA infants using x2 test; p values not corrected for the multiple
comparisons, p Values in bold indicate significant difference.
tFisher exact test used because of small numbers.
units were involved, llieie may have been some variations in
neonatal care. However, there were no changes in our target
oxygen saturation policies during the study period.
SGA infants are a vulnerable population at higher risk of
perinatal morbidity and mortality than their appropriately sized
peers.3-6 Other studies have also reported on the incidence of
ROP in SGA and AGA infants with similar findings to ours.4 6 7
Gortner et al6 reported the incidence of ROP in SGA infants to
be more than double that in AGA infants (37% vs 15%),
although there was no difference in prevalence of stage 3 disease
between the two groups Rardin et aI" compared two historical
cohorts of SGA and AGA infants born at 24-26 weeks'
gestation. Like us, they found SGA infants to be at increased
risk of developing any stage of ROP (90% vs 58%) and severe
ROP (65% vs 12%). Allegaert et al7 showed that SGA infants
were 3.7 times more likely to develop threshold ROP than their
AGA peers. They went on to document perinatal growth and
found that, even when growth-restricted (birth weight <25th
centile) infants displayed normal postnatal growth (ie, the same
g/kg/day as AGA infants), they still had a higher risk of
developing threshold ROP.7 Experiments in rat models of ROP
also support these clinical findings. Rats raised in expanded
litters undergo postnatal growth restriction. These growth-
restricted rats have been found to have more abnormal retinal
neovascularisation in two well-established models of ROP.1617
There are many possible explanations for why SGA infants
have an increased incidence of ROP. Most SGA infants are small
as a result of intrauterine growth restriction. Such infants are
exposed to changes in organ development because of fetal
hypoxaemia, nutrient restriction and an altered endocrine
environment.18 These developmental changes may be linked to
the increase in ROP. SGA infants are often sicker than their
AGA peers, requiring more intensive and more prolonged
hospital care.19 They are therefore more likely to require
supplemental oxygen, which is a well-documented risk factor
for ROP.20 SGA infants have lower serum concentrations of
insulin-like growth factor 1, and there is evidence for a role for
this growth factor and vascular endothelial growth factor in the
pathogenesis of ROP.21
In conclusion, SGA infants born in Lothian from 1990 to 2004
were significantly more likely to develop any stage of ROP and
more severe ROP than AGA infants.
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Aim: To compare the diagnostic accuracy of wide-field
digital retinal imaging (WFDRI) with the current "gold
standard" of binocular indirect ophthalmoscopy (BIO) for
retinopathy of prematurity (ROP) screening examinations.
Methods: A consecutive series of premature infants
undergoing ROP screening at Edinburgh Royal Infirmary
were eligible for recruitment into this prospective,
randomised, comparative study. Infants were screened
using both WFDRI (Retcam II with neonatal lens) and BIO
by two paediatric ophthalmologists who were randomised
to the examination technique. Both examiners documen¬
ted their clinical findings and management plans in a
masked fashion. WFDRI eye findings were compared with
those of BIO.
Results: A total of 81 infants were recruited, and
information from 245 eye examinations was analysed. The
sensitivity of WFDRI in detecting any stage of ROP, stage
3 ROP and "plus" disease was 60%, 57% and 80%,
respectively, and specificity 91%, 98% and 98%,
respectively. The proportional agreement between WFDRI
and BIO was 0.96 for detecting stage 3 disease and 0.97
for detecting "plus" disease. There was very good
agreement on management decisions (kappa 0.85).
Conclusion: When used in a routine ROP screening
setting, a randomised comparison of WFDRI and BIO,
WFDRI showed relatively poor sensitivity in detecting mild
forms of ROP in the retinal periphery. This resulted in
difficulty in making decisions to discharge infants from the
screening programme. Sensitivity was better for more
severe forms of ROP, but at present WFDRI should be
regarded as an adjunct to, rather than a replacement for,
BIO in routine ROP screening.
Retinopathy of prematurity (ROP) is a vasoproli-
ferative disorder of the eye affecting premature
infants and is an important cause of childhood
blindness.1 Early detection and treatment of Type 1
ROP as defined by the Early Treatment of ROP
(ETROP) study has been shown to significantly
reduce the incidence of severe visual loss.2
Screening guidelines have been developed in
many countries with the aim of identifying
premature infants with potentially sight-threaten¬
ing disease. The conventional gold standard screen¬
ing technique is binocular indirect ophthalmoscopy
(BIO) with scleral indentation. Current screening
for ROP by this technique is difficult, as it requires
a specialised paediatric ophthalmologist, and ade¬
quate ophthalmic expertise is often confined to
larger regional centres. Provision of satisfactory
ophthalmology services for these babies is challen¬
ging in developed countries,3 and even more
difficult in "middle income" countries.1
A wide-field digital camera system (Retcam II,
Clarity Medical Systems, Pleasanton, California)
has been developed that can image the retina of
premature infants.4-9 Store and forward telemedi-
cine using this method potentially enables local
ophthalmologists, neonatologists or neonatal
nurses to capture images at a remote location for
transmission and interpretation by a regional or
international expert.5-7 9-14
A number of studies have compared the perfor¬
mance of wide-field digital retinal imaging
(WFDRI) and binocular indirect ophthalmoscopy
(BIO) in ROP screening.5 6 8 9 14-18 All these studies
have a similar methodology whereby the same or
different examiners perform WFDRI and BIO
imaging on an infant. The stored WFDRI images
are then cleared of any patient identifiable data
and interpreted at a later date by either the study
examiner or an independent expert.
We have carried out a masked, double-observer
prospective randomised comparison ofWFDRI and
BIO in a consecutive series of ROP screening
examinations in one nursery. We used two expert
examiners who were randomised to WFDRI or BIO
examination technique and remained masked to
each other's findings throughout the study.
Clinical findings and management decisions were
made at the time of clinical examination.
METHODS
This was a prospective, randomised, comparative
study. The Local Research Ethics Committee
(LREC) reviewed and approved the study. All
parents gave informed consent.
Study population
Consecutive infants undergoing routine ROP
screening at Edinburgh Royal Infirmary Neonatal
Intensive Care Unit were eligible for inclusion in
the study. At this centre, all babies bom with
gestational age less than 32 weeks or birth weight
less than 1500 g have their eyes screened for ROP.
Patients were recruited from June 2004 to May
2007.
Examination schedule
Screening was carried out by two experienced
paediatric ophthalmologists (BWF and EW).
Infants were first examined at a chronological age
Br J Ophthalmol 2009;93:355-359. doi:10.1136/bjo.2008.148908 355
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of 4-6 weeks or corrected age of 34 weeks, whichever was
earlier. Screening was continued fortnightly if no R.OP was
present and weekly if any ROP was seen. Screening continued
until the retina was normally vaoculariocd into zone 3, the
infant required treatment or until the infant was transferred to
an outlying hospital. On each screening occasion, study infants
had both eyes examined by both WFDRI and BIO. The study
coordinator (CD) randomised both examiners to screening using
either WrDRI oi BIO and also randomised the uidei in which
the examinations were to be carried out. Randomisation was
carried out for each examination, using sealed envelopes.
Examination technique
Pupils were dilated with topical phenylephrine 2.5% and
tropicamide 0.5% applied 60 min and 30 min prior to the eye
examination. One drop of oxybuprocaine 0.4% was applied to
each eye immediately prior to examination. BIO was performed
using a 28 dioptre lens. A lid speculum and scleral indenter were
used. WFDRI images were recorded with the Retcam II Digital
Retinal Camera (Clarity Medical Systems) with the neonatal
nose-cone. A lid speculum was used, and polyacrylic acid gel
was applied to the anaesthetised cornea before capturing the
images. The study coordinator timed how long each eye
examination took from the insertion of the eyelid speculum to
its removal at the end of the examination.
All examinations were performed with cardiac and oxygen
saturation monitoring. The examinations were interrupted if an
infant's heart rate or oxygen saturation decreased to an
unacceptably low level and recommenced once these had
stabilised.
Clinical findings
Both examiners graded retinopathy according to The
International Classification of ROP.19 The stage of ROP, zone
of vascularisation, number of clock hours of ROP and presence
or absence of "plus" disease were documented. "Plus" disease
represented significant dilatation and tortuosity of posterior
pole blood vessels meeting or exceeding that of a standard
photograph.19 "Threshold" ROP, as defined in the CRYO-ROP
trial, referred to stage 3 ROP in zone 1 or 2, of five or more
contiguous or eight or more cumulative clock hours in the
presence of "plus" disease.20 All eyes with "threshold" ROP
were treated with diode laser therapy from June 2004 to
December 2004. From January 2005, new treatment criteria
were used, following the publication of the ETROP study. Eyes
with type 1 ROP were treated.2 Type 1 ROP was defined as any
stage of ROP with plus disease in zone 1; stage 3 ROP without
plus disease in zone 1; or stage 2 or 3 ROP with plus disease in
zone 2.2 Both eyes were treated, even when one eye did not fully
meet treatment criteria.
Cable 1 Diagnostic comparison ot the two examiners
Examiner 1 Examiner 2 Examiner 1 Examiner 2
BIO BIO WFDRI WFDRI
Plus disease (eyes) 5 5 7 4
Stage 3 ROP (eyes) 7 7 6 7
Any ROP (eyes) 26 19 25 21
Treat (infants) 3 3 4 3
Discharge (infants) 35 34 31 31
Examination documentation and management plans
Each examiner documented their findings in separate books and
remained masked to the other examiner's findings, and to their
own findings from previous weeks. Based on their findings, each
examiner documented a management plan, which was to
discharge the infant, treat the infant or examine the infant
again in either 1 or 2 weeks' time. The study coordinator (CD)
read each examiner's management plans. If there was any
difference in management plan then the infant was seen again
the following week. This continued until both management
plans were the same. If a decision to treat was reached using
BIO but not using WFDRI then the infant was seen the
following week. If the infant still warranted treatment the
following week as judged by BIO then the infant was treated
even if a discrepancy remained with the WFDRI management
plan. The study coordinator was present at all examinations to
ensure that examiners remained masked to each other's
findings.
Standardisation of examiners
The two specialised paediatric ophthalmologists (BF and EW)
have worked together using BIO to perform all ROP eye
screening examinations in the Lothian region since 1990. In
order to measure interobserver agreement, the examiners
independently analysed Retcam images from 81 clinical ROP
screening examinations from the study. The stage of ROP seen,
the presence or absence of plus disease and the location of the
disease were documented.
Data interpretation and statistical method
For each eye examined by BIO and WFDRI, the highest stage of
ROP, the presence or absence of plus disease and the manage¬
ment plan were recorded and used for analysis. The WFDRI
findings were compared with those of the current "gold
standard" of BIO, and the sensitivity and specificity, together
with 95% confidence intervals, were calculated. The WFDRI
management plan reached for each infant after both eyes were
examined was compared with the plan from the "gold
standard" BIO by calculating the kappa value as a marker of
technique agreement.
RESULTS
Patients and study examinations
A total of 81 infants were recruited from May 2004 to June
2007. The median gestational age at birth of study infants was
29 weeks (interquartile range 27 to 31), and a median birth
weight was 1225 g (interquartile range 878 to 1492). A total of
123 eye examinations on both eyes were carried out (246 eyes
examined in total). On one occasion it was not possible to
obtain adequate quality images from one eye using WFDRI.
Findings from 245 eyes were therefore analysed. Fifty-four
infants contributed one examination, 20 infants contributed
two examinations, three infants contributed three examina¬
tions, two infants contributed four examinations, one infant
contributed five examinations, and one infant contributed
Table 2 Detection of any stage of retinopathy of prematurity (ROP)
BIO ROP present BIO no ROP
WFDRI ROP present 27 19
WFDRI no ROP 18 181
BIO, binocular indirect ophthalmoscopy; ROP, retinopathy of prematurity; WFDRI,
wide-field digital retinal imaging.
Sensitivity = 60% (44-74%). Specificity = 91% (86-94%).
BIO, binocular indirect ophthalmoscopy; ROP, retinopathy of prematurity; WFDRI,
wide-field digital retinal imaging.
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Table 3 Detection of stage 3 disease Table 4 Detection of "plus" disease
BIO stage 3 present BIO no stage 3 disease BIO plus present BIO no plus
WFDRI stage 3 present 8 5 WFDRI plus present 8 5
WFDRI no stage 3 disease 6 226 WFDRI no plus 2 230
Sensitivity = 57% (29-82%). Specificity = 98% (95-99%).
BIO, binocular indirect ophthalmoscopy; WFDRI, wide-field digital retinal imaging.
seven examinations on both eyes. Not every examination of
every infant was included, as study examinations could not be
performed when one examiner was unavailable. Almost all
examinations were performed at postconceptual age 32-
36 weeks. In this cohort, BIO detected 24 infants who
developed ROP (24/81, 30%) and five infants (5/81, 6%) that
required treatment. On 63/123 examinations, BWF used
WFDRI, and EW used BIO.
Standardisation of examiners
The two examiners demonstrated 95% agreement (95%
confidence intervals 91 to 98) on the presence or absence of
plus disease, 94% agreement on the stage of ROP (95%
confidence intervals 91 to 98) and 97% agreement (95%
confidence intervals 95 to 99) on the zone of ROP following
the independent, masked scoring of 81 Retcam examinations. In
addition, the study data were analysed for systematic bias
between the two examiners in each diagnostic category, for BIO
and for WFDRI. There were no significant systematic differ¬
ences in any diagnostic category, using the Fisher exact test
(table 1).
Detection of disease
The detection of any stage of ROP, stage 3 disease and plus
disease is shown in tables 2-4.
Proportional agreement
The proportional agreement of the two examination methods is
shown in table 5.
Patient management decisions
Following the eye examination, each examiner decided a
management plan for the infant choosing one out of three
possible outcomes—treat the infant, discharge the infant or
review the infant in 1 or 2 weeks' time. The kappa value for
agreement on management decisions between WFDRI and BIO
was 0.85, which is very good agreement. Details of decisions to
treat are given in table 6, and to discharge in table 7.
On two occasions the WFDRI examination decision was to
treat the infant while the BIO examination decision was not to
treat. One infant was re-examined the following week, and
both WFDRI and BIO agreed that treatment was required. The
second infant was re-examined the following week using BIO
only (one examiner was absent) and was not treated.
On one occasion the BIO decision was to treat the infant,
while the WFDRI decision was not to treat. The documented
clinical findings for this individual case showed that the infant
was borderline for treatment. When this case was re-examined
1 week later both BIO examination and WFDRI examination
findings agreed that treatment was required.
On five occasions the WFDRI decision was to discharge the
infant, and the BIO was to perform a further examination. On
re-examination the following week there was agreement
between the WFDRI and BIO in two cases. The remaining
three infants had left the study due to transfer back to local
Sensitivity = 80% (44—97%). Specificity = 98% (95-99%).
BIO, binocular indirect ophthalmoscopy; WFDRI, wide-field digital
retinal imaging.
hospitals, and detailed retinal examination findings were
unknown. However, it was known that no infant subsequently
required treatment. On 14 occasions, the BIO decision was to
discharge the infant and the WFDRI not to discharge. There
was agreement on management plan within 1 week in seven
cases and 2 weeks in one case, and we do not have information
on five infants who left the study due to transfer back to local
hospitals. It was known that none of these infants subsequently
required treatment.
Time taken to complete an examination
The median time taken for WFDRI examination of both eyes
was 110 s (interquartile range 80 to 133). The median time
taken for BIO examination of both eyes was 90 s (interquartile
range 65 to 120). Examinations using BIO were significantly
quicker (Mann-Whitney p = 0.005).
DISCUSSION
We compared the ability of WFDRI to detect ROP and guide
patient management decisions compared with the current gold
standard of BIO. We found the sensitivity of WFDRI in
detecting any ROP, stage 3 ROP and plus disease to be 60%,
57% and 80%, respectively, with a specificity of 91%, 98% and
98%, respectively. There was excellent proportional agreement
between the two screening methods for detecting stage 3 ROP
and plus disease (0.96 and 0.97) and very good agreement on
management decisions (kappa value 0.85).
A number of previous studies have compared the performance
of WFDRI and BIO in ROP screening." 8 91416 Roth et a! found
82% sensitivity and 94% specificity of WFDRI compared with
BIO for detecting any stage of ROP.8 Shah et al found 86%
sensitivity and 92% specificity ofWFDRI compared with BIO in
detecting any stage of ROP, and no case of threshold ROP was
missed with WFDRI.16 Yen et al used WFDRI to attempt to
predict which eyes would develop threshold disease by
evaluating WFDRI images at two distinct gestational time
points. Low sensitivities and high specificities were recorded for
detecting various stages of ROP.14 The authors of these three
studies thought their lower sensitivities were due in part to the
technical difficulties encountered using a standard child lens
attachment for the screening examinations. Visualisation of the
peripheral retina was particularly poor. This technical limitation
of camera size has now been partly overcome, and a specialised
smaller neonatal nose cone has been developed, which we used
in our study. However, we found difficulty in visualising the
peripheral retina with this lens.
Table 5 Proportional agreement of the two examination methods
Outcome Proportional agreement
Detection of any stage of retinopathy of prematurity 0.85
Detection of stage 3 disease 0.96
Detection of "plus" disease 0.97
The proportional agreement is represented by the number of times that BIO and
WFDRI concur divided by the total number of examinations.
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Table 6 Decision to treat (based on examination of a
baby: 123 examinations in total)
BIO treated BIO not treated
WFDRI treat 5 2
WFDRI not treat 1 115
BIO, binocular indirect ophthalmoscopy; WFDRI, wide-field digital
retinal imaging.
We found that the peripheral retina could be visualised much
more easily with the BIO than with WFDRI. As we studied a
consecutive series of infants in our nursery, a relatively high
proportion of our cases had mild or no ROP. Our series therefore
included a higher proportion of cases that were relatively more
difficult to diagnose with WFDRI, and this may partly explain
the relatively low sensitivity results for any stage of ROP in our
study.
Our results of low sensitivity for stage 3 disease and plus
disease, normally visualised in the more posterior part of the
retina, were lower than those reported in a number of other
studies.5 8 9 13 15-18 Ells et al reported a sensitivity of 100% and
specificity of 96% in the detection of "referral warranted" ROP
(any zone 1 disease, or any plus disease or stage 3 disease).6
Chiang et al reported 100% sensitivity for the detection of ROP
that required treatment.5 The recently reported SUNDROP
study found a sensitivity of 100% and specificity of 99% for the
detection of ROP that required treatment.17 Similarly, the
multicentre Photo-ROP study reported a sensitivity of 92% and
specificity of 37% for the detection of "clinically significant"
ROP, and a sensitivity of 92% and specificity of 67% for the
detection of ETROP study Type 1 ROP.15
In our study, all cases judged to require treatment following
BIO examination were identified with WFDRI examination.
One infant, with borderline findings, was thought to require
treatment following indirect ophthalmoscopy examination but
not following WFDRI examination. However, 1 week later a
decision to treat was made by both observers. In our study the
sensitivity of WFDRI examination in making treatment
decisions was therefore 100%, allowing for a repeat examination
after 1 week. Interestingly, the WFDRI examination manage¬
ment decision on two occasions was to treat the infant a week
before BIO examination resulted in a decision to treat. Ells et aI
found that severe ROP was diagnosed by WFDRI at least
1 week before BIO in 43% of eye examinations.6
We found that the peripheral retina could be visualised much
more easily with BIO than WFDRI. This resulted in a higher
rate of decisions to discontinue screening examinations when
using BIO, as visualisation of normal vascularisation into Zone
3 was much more readily achieved. Our study suggests that BIO
is superior to WFDRI examination in making decisions to
discharge infants from ROP screening. In nurseries where both
methods are available, it may be more efficient to perform the
anticipated final "discharge" examination of an infant using the
BIO, even when the WFDRI is used for earlier examinations. In
nurseries where BIO screening is not available, uncertainty
about the end point of screening with the WFDRI requires a
more prolonged screening programme for each infant.
The outcome of the ETROP study has shifted the emphasis of
diagnostic decisions about treatment towards the detection of
dilatation and tortuosity of the posterior retinal blood vessels
(plus disease).2 The emphasis in ROP screening has therefore
moved to examination on the posterior retinal blood vessels.
WFDRI is particularly effective in imaging the posterior retina.
We found a 80% sensitivity and 98% specificity of WFDRI
Table 7 Decision to discharge (based on examination of
a baby: 123 examinations in total)
BIO discharge BIO not discharge
WFDRI discharge 56 5
WFDRI not discharge 14 48
The term "not discharge" refers to treat, or follow up.
BIO, binocular indirect ophthalmoscopy; WFDRI, wide-field digital
retinal imaging.
examination compared with BIO examination in the detection
of plus disease. Other studies have found a very high sensitivity
of WFDRI examination compared with BIO examination in the
detection of plus disease.61518
The interobserver agreement for the presence or absence of
plus disease was high in our study, with 98% agreement.
However, few cases with plus disease were included, and this
figure may therefore be unreliably high. The interobserver
agreement on the presence or absence of plus disease has been
surprisingly low in some studies.21-23 This may partly explain the
variation in reported rates of treatment-requiring ROP in
different hospitals.24 The standard photograph originally used
to define plus disease was a single, narrow-field photograph.19
The updated classification of ROP25 includes a wide-field
standard photograph. A number of representative wide-field
photographs, which have a severity of plus disease equivalent to
the current standard narrow field photograph, would be helpful
in educating users of wide-field images in the diagnosis of plus
disease. The development of image analysis software that can
quantify features of plus disease may remove subjectivity from
this important area of decision-making.26
We have carried out a masked, double-observer prospective
randomised comparison to determine the sensitivity and
specificity of WFDRI in making diagnostic decisions in the
nursery, compared with the current gold standard of BIO. The
WFDRI showed relatively poor sensitivity in detecting mild
forms of ROP. In nurseries where both methods are available, it
may be more efficient to perform the anticipated final
"discharge" examination of a infant using the BIO. Sensitivity
was better for more severe forms of ROP, and no infants who
required treatment were missed by WFDRI examination.
However, at present WFDRI should be regarded as an adjunct
to, rather than a replacement for, BIO in routine ROP screening.
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ISIS 1
Pain in neonates during screening for retinopathy of
prematurity using binocular indirect ophthalmoscopy
and wide-field digital retinal imaging: a randomised
comparison
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ABSTRACT
Objective To compare the pain experienced by
premature infants undergoing wide-field digital retinal
imaging (WFDRI) and binocular indirect ophthalmoscopy
(BIO) for retinopathy of prematurity (ROP) screening.
Methods Infants were recruited at Edinburgh Royal
Infirmary Neonatal Unit, Edinburgh, UK. Eyes were
examined by WFDRI and BIO with eyelid speculum by
two experienced paediatric ophthalmologists in random
order. A pain score (Premature Infant Pain Profile (PIPP))
for WFDRI and BIO was generated.
Results A total of 76 infants were recruited. The
(mean, SD) PIPP score for WFDRI was 15.0, 2.1 and for
BIO was 15.2, 2.4 (paired t test p=0.47). The authors
observed that infants 3tartcd crying with corresponding
physiological changes as soon as the eyelid speculum
was inserted and crying stopped on speculum removal.
Conclusion WFDRI and BIO with eyelid speculum are
similarly painful for infants. The authors speculate that
the eyelid speculum rather than the examination method
may contribute most to the pain experienced.
What is already known on this topic
Wide-field digital retinal imaging and
binocular indirect ophthalmoscopy are both
used for routine retinopathy of prematurity
eye screening.
We have limited information about the pain
experienced by neonates undergoing both
techniques.
INTRODUCTION
Premature infants need regular screening for the
early detection of retinopathy of prematurity
(ROP) and the successful prevention of its blinding
end stage.1 The mainstay of screening is binocular
indirect ophthalmoscopy (BIO), with eyelid spec¬
ulum and scleral indentation. This technique must
be carried out by an expert ophthalmologist. It is
recognised as being painful, and analgesia should
be used routinely for the procedure.1
The use of the digital retinal camera for wide-
field digital retinal imaging (WFDRI) has been
suggested as a replacement for BIO. WFDRI can
be carried out by less specialist staff with the
help of experts for interpretation using telemedi-
cine. It has been suggested that WFDRI may be
less painful than BIO.2 We recently carried out a
masked, double-observer prospective randomised
comparison of the diagnostic accuracy ofWFDRI
with BIO.3 We designed, as part of our investiga¬
tion, a study to compare the pain effects of BIO
and WFDRI screening processes and this report
describes the findings.
METHODS
This was a prospective, randomised, compara¬
tive study. Ethical approval was granted by the
Lothian Research Ethics Committee, and all par¬
ents gave written consent.
What this study adds
Both screening methods are painful for
infants but the pain experienced is of a similar
severity for both techniques.
We propose that the eyelid speculum, rather
than the examination method contributes
most to the pain experienced.
Subjects and study design
All infants recruited required routine ROP screen¬
ing at Edinburgh Royal Infirmary Neonatal
Intensive Care Unit between June 2004 and May
2007. Infants were excluded if they were requir¬
ing mechanical ventilation or analgesic medica¬
tion or if they had moderate/severe neurological
impairment (grade 3/4 intraventricular haemor¬
rhage or periventricular leukomalacia) as it was
felt that these infants would respond differently
to painful stimuli. Infants were examined by
two experienced paediatric ophthalmologists (BF
and EW). Only the first screening examination
for each baby was included in this study. Infants
had both eyes examined byWFDRI and BIO. The
study coordinator (CD) randomised (via sealed
brown envelopes) both examiners to screening
using either WFDRI or BIO and also randomised
the order in which the examinations were to be
carried out.
Eye examinations
Infants had their pupils dilated with topical phen¬
ylephrine 2.5% and tropicamide 0.5% applied
60 min and 30 min prior to eye examination.
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Infants were then handled minimally and were not exposed
to painful procedures unless medically indicated. One drop
of oxybuprocaine 0.4% was applied to each eye immediately
prior to each eye examination. Infants were examined on a cot
blanket. They were unswaddled and non-nested. The study
coordinator held the infants arms gently across their chests
and steadied their heads during both examinations. Pacifiers
were not used and oral sucrose was not given. A lid speculum
(Barraquer Oosterhuis child speculum) and scleral indenter
(Schokett-style paediatric scleral depressor) was routinely used
during BIO. WFDRI images were taken using the digital reti¬
nal camera (RetCam II; Clarity Medical Systems, Pleasanton,
California, USA) with the neonatal nose cone. The same
type of lid speculum was used but scleral indentation was not
routinely performed. After the first examination by the first
examiner, the infant was handled minimally and allowed to
recover for at least 30 min, to allow physiological variables to
return to baseline prior to undergoing the second eye exami¬
nation. All infants had constant cardiac and oxygen saturation
monitoring.
Pain monitoring and data interpretation
The Premature Infant Pain Profile (PIPP) scoring system was
used.4 Baseline observations were recorded and during the
first minute of BIO and WFDRI, the maximum and mini¬
mum heart rate (FIR) and minimum oxygen saturation of the
infants were documented. The facial features of every infant
were video recorded and videotapes were later reviewed by
an independent observer (KD) who scored the facial features
during the first minute of BIO and WFDRI according to the
PIPP. KD could not be blinded to the type of examination. The
PIPP scores, heart rates and oxygen saturations for WFDRI
and BIO were compared using paired t tests generated from
the GraphPad InStat program (GraphPad, La Jolla, California,
USA). Fisher's exact test was used to compare the occurrence
of marked bradycardias and desaturations. A p value <0.05
was taken to indicate statistical significance.
RESULTS
A total of 81 infants were recruited to ourWFDRI/BIO diagnos¬
tic comparative trial.3 Inadequate quality video recordings were
obtained for four babies and one baby was excluded as he had
a periventricular leukomalacia. Therefore, a total of 76 infants
were included in this study. In all, 39 infants received BIO first,
and 37 WFDRI first. The baseline characteristics of the study
population are shown in table 1. There were 40 boy infants and
36 girls. A total of 50 babies were breathing room air, 13 babies
had nasal prong oxygen and 13 babies were having nasal contin¬
uous positive airway pressure (CPAP) with oxygen.
Table 2 shows details of the infants' heart rates and oxy¬
gen saturation levels before and during both eye examinations.
There were no differences in baseline levels between the two
groups. The mean PIPP score forWFDRI was 15.0 (SD 2.1) and
the mean PIPP score for BIO was 15.2 (SD 2.4). There was no
statistically significant difference in PIPP scores (paired t test
p=0.47).
We observed a significantly greater increase in HR during
WFDRI than during BIO (p-0.03). There was no statistically
significant difference in occurrence of marked bradycardias
((HR <100 bpm); Fisher's exact test p=1.00) or marked desatu¬
rations ((min O, sat <80%); Fisher's exact test p=0.52) during
the two examination techniques.
;Shor0e0di(
Table 1 Baseline characteristics of the study population
Mean (range)
Gestational age, weeks 28.6(24-35)
Corrected gestational age at retinopathy of 34.1 (30-40)
prematurity examination, weeks
Birth weight, g 1208(610-1970)
Number of days intubated and ventilated 4.6(0-45)
Number of days of morphine 0.2 (0-5)




Baseline heart rate. 148(13) 147(14)
bpm
Minimum heart rate 134(25) 133(28)
during examination
Maximum heart rate 168(18)* 172(17)*
during examination
Baseline oxygen 96(4) 96(4)
saturation, %
Minimum oxygen 87 (12) 88(10)
saturation during
examination
'Statistically significant difference comparing BIO and
WFDRI maximum heart rates (paired t test p=0.03).
BIO, binocular indirect ophthalmoscopy; WFDRI, wide-field
digital retinal imaging.
DISCUSSION
This study, where infants received BIO and WFDRI but in a
random order, demonstrates that ROP eye screening is painful,
but the pain experienced is similar for both techniques.
The PIPPwas chosen as it is a well validated method for mea¬
suring procedural pain in preterm infants and uses contextual
indicators (gestational age and behavioural state), physiological
indicators (heart rate and oxygen saturation) and behavioural
indicators (brow bulge, eye squeeze and nasolabial furrow) in
its calculation.4 The major drawback of using the PIPP score
in this setting is that it only takes into account an increase in
heart rate, and bradycardia during eye screening can occur due
to the oculocardiac reflex. We therefore additionally recorded
the minimum heart rates during all examinations but there
was no significant difference in these between the two screen¬
ing methods.
While carrying out this study we observed that infants
immediately started crying with corresponding physiological
changes as soon as the eyelid speculum was inserted and cry¬
ing stopped on speculum removal. As WFDRI and BIO both
require speculum use to obtain optimal retinal views, we pro¬
pose that the speculum, rather than the examination method,
may contribute most to the pain experienced. Other groups
have reported marked physiological responses associated
with speculum usage.5 Perhaps more investigation should be
directed to examination techniques that do not require the use
of a speculum, or to improved speculum design and insertion
technique. We are currently investigating the use of a small,
relatively malleable Barraquer style single use neonatal spec
ulum that can bo slightly bent prior to use in order to set the
blades closer together or wider apart in order to accommodate
differing palpebral aperture sizes (Malosa Medical 7.00 mm
closed blade, 0.8 mm wire; Malosa, Sowerby Bridge, UK).
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There is currently much debate about whether WFDRI
can be introduced to replace BIO screening examinations.
Premature neonates are exposed daily to many painful stimuli
and we have shown that WFDRI and BIO with eyelid specu¬
lum are similarly painful. Further work is required to imple¬
ment adequate analgesia regimes for ROP screening.
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